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Summary 
Scope 
The scope can be found here: Scope. 
The aim of this report was to assess the effectiveness and safety of repetitive 
transcranial magnetic stimulation (rTMS) in treatment-resistant depression 
(TRD).  
 
Introduction 
Health problem 
The target condition in the scope of the assessment is treatment-resistant 
major depressive disorder (TRD), which often refers to major depressive dis-
order (MDD) that does not respond satisfactorily to at least two trials of an-
tidepressant monotherapy. However, the definition has not been standardized 
yet. Defining treatment resistant depression is also complicated due to the 
lack of consensus in describing acute antidepressant responses. In many stud-
ies, response is classified as ≥ 50 percent improvement from baseline on the 
depression rating scale. Remission is defined as a depression rating scale score 
less than or equal to a specific cut-off that defines the normal range (score on 
the HRSD-17 or on the MASD ≤ 7) [1] (A0002). 
The prevalence of unipolar TRD is not clear due to the lack of international-
ly acknowledged and standardized definition. However, there are reasonable 
estimates available. If response is used as outcome, according to the defini-
tion of response, the prevalence rate for Stage 2 TRD (failure to achieve re-
sponse after two courses of adequate treatment) is estimated to be 15-35% [5, 
6, 44] (A0023). 
MDD is currently diagnosed by using the Diagnostic Criteria for Major De-
pressive Disorder and Depressive Episodes (DSM-IV-TR) (details in Appen-
dix 4). Because of differences in treatment, the diagnosis of unipolar MDD 
should be confirmed and other diagnosis, such as bipolar depression or dys-
thymic disorder, ruled out. The treatment history of patients who may be treat-
ment resistant is usually assessed through a clinical interview as well as a re-
view of the medical record [1] (A0024). 
Description of technology and comparators 
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neu-
rostimulation and neuromodulation technique, which is delivered as a series 
of pulses i.e. a train. The most typical technical parameters of rTMS are the 
frequency (high-frequency: stimulation delivered >1 pulse per second, but 
generally ≥ 5 Hz is applied as HF [5, 7], or low-frequency: stimulation de-
livered at ≤ 1 pulse per second), intensity (expressed as a percentage of the 
resting motor threshold, generally set at 100-120%), train duration, intertrain 
interval, number of trains per session, and number of pulses per session [7, 8]. 
There are various treatment protocols, but the FDA-based standard parame-
ters are most widely used and for the acute treatment they include: 10 mag-
netic pulses per second (Hz), 3000 pulses per session, 100 to 120 percent of 
motor threshold and train duration of 4 s with intertrain interval of 26 s [9]. 
However, the stimulation parameters required to optimize the efficacy of 
rTMS treatment are not well known. 
aim 
target population: 
patients with TRD 
unclear prevalence  
diagnosis:  
DSM-IV-TR criteria 
rTMS: non-invasive 
neurostimulation 
Technical parameters:  
 frequency 
 intensity 
 train duration 
 intertrain interval 
 number of trains  
per session 
 number of pulses  
per session 
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The use of the rTMS is prohibited for patients with metal implants in the 
head area, implanted medical devices during pregnancy, increased intracra-
nial pressure, a history of epileptic seizures, increased cerebral susceptibility 
to epileptic seizures through medication and unstable general medical disor-
ders [7, 8, 10] (A0001). 
rTMS is indicated for patients with unipolar major depression who have failed 
to achieve satisfactory improvement from prior antidepressant medication in 
the current episode (A0020). The claimed benefit of rTMS is that it is non-in-
vasive, the patient remains awake and alert throughout the process, no post-
session recovery is needed, hence the patient can resume normal activities 
immediately and no cognitive side-effects have been reported with rTMS.  
Comparators 
Sham stimulation is delivered with a sham coil.  
Electroconvulsive therapy (ECT) involves the induction of a seizure by the ap-
plication of electrical current to the brain. It is delivered under general an-
aesthesia and application of a muscle relaxant. Treatment parameters include 
electrode position, electrical intensity, pulse width and duration [11]. ECT is 
a complex intervention and its efficacy and safety are affected by a number 
of parameters including the placement of electrodes, dosage and waveform of 
the electrical stimulus, and the frequency with which ECT is administered 
[12]. As regards to mortality, ECT is a safe procedure with a very low mortality 
rate (1 death per 73,440 treatments) [11] (A0001). However, cognitive effects 
including transient disorientation when recovering from ECT sessions, retro-
grade and anterograde amnesia, mild, short-term impairment in memory and 
other cognitive domains during and after treatment with ECT might occur. 
[4, 11] (B0002). 
 
Methods 
The systematic literature search and analysis of the studies was performed in 
two phases: secondary studies (i.e. HTA reports and systematic reviews/SRs) 
were screened as a first step and evaluated on the basis of their scope, inclu-
sion and exclusion criteria, and quality. The AMSTAR tool was used for quali-
ty assessment of SRs, and as a result, the Health Quality Ontario (HQO) re-
port [13] was selected for update.  
As a second step, to identify further, more recent, primary studies fulfilling 
the inclusion criteria of the present assessment, a literature search for ran-
domized controlled trials (RCTs) published since the literature search of the 
chosen HQO report [13] was performed. 2 studies [14, 15] were selected that 
fulfilled our inclusion criteria and included within the present assessment. 
The 2 studies compare HF-rTMS to the left DLPFC with sham. No studies 
were found that compared active stimulation with ECT. The Cochrane risk 
of bias assessment approach was used to assess the quality of RCTs. For the 
assessment of the strength of evidence, the Grading of Recommendations, 
Assessment, Development and Evaluation approach was used. 
Clinical effectiveness 
The critical endpoints in assessing clinical effectiveness were response and 
remission rates. The mean difference in depression scores was considered im-
portant, but not critical endpoint.  
contraindications  
benefits: non-invasive, 
no cognitive side-effects, 
no general anaesthesia 
needed, no post-session 
recovery needed 
comparators: sham 
stimulation  
(with a sham coil) … 
 
… and ECT 
(neuromodulation 
under general 
anaesthesia,  
induction of a seizure  
to the brain) 
2-step systematic 
literature search:  
1.  SRs and HTAs 
2.  RCTs 
HQO report selected  
for update 
Inclusion of additional  
2 RCTs 
 
Cochrane risk of bias 
tool to assess quality 
GRADE approach to 
assess the strength of 
evidence 
critical endpoints: 
response and remission 
Summary 
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Safety 
The critical endpoint in assessing safety was cognitive impairment, whereas 
the number of seizures was considered important endpoint. 
 
Results 
Available evidence 
rTMS vs sham 
23 studies met the inclusion criteria in the HQO report. We found two addi-
tional RCTs [14, 15] that are included in the present analysis. One of them 
[15] is the 6 month follow-up of a study included in the HQO report [16]. A 
total of 1180 patients were analysed in the studies, 615 in the rTMS arm and 
565 in the sham arm.  
The inclusion criteria of the studies varied as follows: 
 Baseline values on HDRS-17 
 In 11 studies: >25 (severe depression)  
 In 6 studies: 19-24 (moderate depression) 
 TRD definition 
 In 16 studies: two or more failed antidepressant trials 
 In 9 studies: one or more failed antidepressant trial  
 rTMS as add-on or monotherapy 
 In 17 studies: add-on therapy 
 In 8 studies: monotherapy 
The stimulation parameters varied: the frequency ranged from 5 to 20 Hz, 
the intensity from 80 to 120% of patients’ MT, the number of trains per ses-
sion from 15 to 75, the train duration from 2 to 10 seconds (s), the intertrain 
interval from 22 to 58 s, the number of pulses per session from 800 to 3,000, 
and the total number of pulses during rTMS treatment from 8,000 to 90,000. 
All studies used the figure 8 coil.  
rTMS vs ECT 
The HQO report included six studies that compared rTMS with ECT. Most 
of the studies were conducted in the early 2000s. The total number of patients 
was 266, 133 in each arm. Two of the studies reported 6 month follow-up da-
ta as well [17, 18].  
The inclusion criteria of the studies varied as follows: 
 Baseline values on HDRS-17 
 In the rTMS group: 24-26  
 In the ECT group: 25-28 
 TRD definition 
 In 2 studies: two or more failed antidepressant trials 
 In 1 study: one or more failed antidepressant trial 
 In 2 studies the number of failed antidepressant trials was not re-
ported, only the number of failed ECT trials 
 In 1 study only the number of failed antidepressants in the cur-
rent episode was reported 
critical endpoint: 
cognitive impairment 
25 included studies with 
1180 patients 
inclusion criteria  
varying stimulation 
parameters 
6 included studies with 
266 patients 
inclusion criteria 
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 rTMS as add-on or monotherapy 
 In 2 studies: add-on therapy 
 In 2 studies: monotherapy 
 In 2 studies: only lorazepam or clonazepam were allowed 
The characteristics of the intervention varied also, one study used 20 Hz fre-
quency stimulation, four studies used 10 Hz and one study did not report on 
the frequency used. The intensity of the stimulation ranged from 90 to 110% 
of the MT, the number of trains from 20 to 30-35, the train duration from 2 
to 10 s, the intertrain interval from 20 to 55 s, the pulses per session from 408 
to 2500 and the number of sessions from 10 to 20. Hence the total number of 
pulses delivered also ranged from 4,080 to 50,000. All studies reported that 
they used a figure 8 coil.  
Clinical effectiveness 
rTMS vs sham 
The pooled risk ratio for response rate across 19 studies was 1.82 (95% CI 1.18-
2.82; p=.0068). There was a moderate degree of heterogeneity among studies 
(I2=50%, p=.01). This pooled estimate suggests that patients may be twice 
more likely to experience treatment response with rTMS than with sham.  
The pooled risk ratio for remission rate across 12 studies was 2.16 (95% CI 
1.42-3.29; p=.0003). This pooled estimate suggests that patients may be twice 
more likely to experience remission with rTMS than with sham. No hetero-
geneity was observed among the studies (I2=0.0%; p=.7164).  
On average, rTMS reduced depression scores by about 2.31 points more than 
sham (95% CI 1.19-3.43; p<.001), which is below the mean value that was 
deemed a priori clinically important (threshold of 3.5 points).  
There was a statistically significant improvement favouring rTMS on the gen-
eral health and mental health SF-36 subscales at 4- and 6-week follow-up. 
Statistically significant improvement favouring rTMS was also seen in the Q-
LES-Q total score at 4-and 6-week follow-up [15] (D0012, D0013). 
rTMS vs ECT 
The pooled risk ratio for response at the end of treatment was 1.72 (95% CI 
0.95-3.11, p=.072) favouring ECT. There was a high degree of heterogeneity 
among studies (I2=60.6%, p=.079). While the effect is not statistically signif-
icant, this pooled estimate would suggest a higher response with ECT than 
with rTMS (D0006). 
The pooled risk ratio for remission was 1.44 (95% CI 0.64-3.23, p=.375) at 
the end of treatment, favouring ECT, however, these results are not signifi-
cant. There was a high degree of heterogeneity among studies (I2=69.1%, 
p=.039).  
The weighted mean difference of depression scores from baseline to the end 
of treatment was -5.97 points (95% CI -11.00 to-0.94, p=.020) in favour of ECT, 
which is higher than the mean value that was defined a priori as clinically 
important. The degree of heterogeneity among studies was high (I2=72.2%, 
p=.013) (D0005).  
One study [19] reported data on suicide scores or suicidal ideations. The su-
icide score decreased from 1.5 (0.8) to 1.2 (0.9) as measured by BDI and from 
1.9 (1.3) to 1.4 (1.2) as measured by HDRS in the rTMS group. In the ECT 
varying stimulation 
parameters 
RR for response:  
1.82 favouring rTMS 
RR for remission:  
2.16 favouring rTMS 
MD 2.31 points 
favouring rTMS 
significant improvement 
favouring rTMS in 
general health, mental 
health, and Q-LES-Q 
RR for response:  
1.72 favouring ECT,  
but statistically not 
significant 
RR for remission:  
1.44 favouring ECT,  
but statistically not 
significant 
MD 5.97 points 
favouring ECT 
decrease in suicide 
scores greater in the 
ECT group  
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group the decrease was significantly greater: from baseline 1.4 (1.0) to 0.5 
(0.7) as measured by BDI and 2.3 (1.1) to 0.3 (0.5) as measured by HDRS 
(p<.001). The results suggest that ECT decreases suicidal scores more than 
rTMS.  
Safety 
rTMS vs sham 
The most common side-effect presented in the studies was headache. The rate 
of headache ranged from 0 to 60% in the rTMS group and from 0 to 50% in 
the sham group. Seizures did not occur in any of the studies and transient 
impairment of working memory occurred in five patients (16.7%) in the rTMS 
group and in one patient (4.3%) in the sham group (C0008). 
rTMS vs ECT 
No serious safety concerns were identified. The most common side-effect 
was headache in rTMS-treated patients. No adverse events occurred in ECT-
treated patients (C0008).  
Upcoming evidence 
There are four ongoing studies on rTMS compared to sham stimulation, no 
ongoing studies comparing rTMS with ECT. 
Reimbursement 
The technology is not reimbursed in the majority of the countries for which 
we have information available (A0021). The reason for its non-inclusion in 
the benefit catalogue is either that it has not been assessed or that the evi-
dence is insufficient to issue a recommendation.  
 
Discussion 
The overall quality of the body of evidence is very low for both sham and 
ECT comparison studies.  
The methodological limitations of the studies included in this assessment are 
likely to influence the robustness of our findings. These limitations include 
variable study parameters (rTMS treatment protocols, the definition of re-
mission, the level of treatment resistance, and if rTMS was used as mono- or 
add-on therapy), risk of bias (high risk of bias in the blinding domain in ECT 
controlled studies), small sample sizes (in both the sham and ECT controlled 
trials).  
Ideally, outcomes such as quality of life and function would be primary out-
comes that determine the impact of the intervention, but this was not re-
ported in the included studies, except for one. A major limitation in the out-
comes is that they are not measuring directly the improvement in the pa-
tients’ quality of life and that there is only short-term data available. Patient 
satisfaction was also not measured by any dedicated tool. 
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Conclusion 
The body of evidence indicates that rTMS is generally safe and well-tolerated. 
rTMS had a small short-term effect for improving depression in comparison 
with sham, but follow-up studies did not show that the small effect will con-
tinue for longer periods. It remains unresolved if rTMS is as effective as 
ECT, since no significant differences in remission and response rates where 
found, and studies showed high heterogeneity at a low total sample size. How-
ever, rTMS patients had less, and not clinically relevant decreases in depres-
sion scores as compared to ECT patients.  
Due to the low quality of evidence, new study results would potentially in-
fluence the effect estimate considerably. Additional research is needed to 
support the finidings with high-quality evidence. 
 
  
rTMS is safe and  
well-tolerated, more 
effective than sham, 
unclear effectiveness 
compared to ECT 
further research  
needed 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Der Fokus dieses Berichts liegt in der Bewertung der transkraniellen Mag-
netstimulation zur Behandlung therapieresistenter Depression (TRD). Der 
Bericht ging der Frage nach, ob repetitive transkranielle Magnetstimulation 
(rTMS) im Vergleich zu einer Scheinintervention und im Vergleich zur Stan-
dardintervention der Elektrokonvulsionstherapie gleich wirksam bzw. wirk-
samer und gleich sicher, bzw. sicherer ist bei der Behandlung der TRD. 
Unter TRD wird eine schwere Form der Depression verstanden (im Engli-
schen Major Depression Disorder, MDD), bei nach mindestens zwei Versuchen 
verschiedener Antidepressiver Therapie (AD) sich keine Verbesserung ein-
stellt. Eine allgemeingültige Definition gibt es zurzeit jedoch noch nicht. Die 
genaue Definition ab wann eine schwere Depression therapieresistent ist, ist 
auch deshalb schwierig, da es keine Einigung gibt was als Therapieansprechen 
gilt. In vielen Studien wird Therapieansprechen als eine mehr als 50 prozen-
tige Verbesserung auf der Depression Skala eingestuft [1]. 
MDD wird derzeit mit den Diagnostic Criteria for Major Depressive Disorder 
and Depressive Episods (DSM-IV-TR) diagnostiziert (Details in Appendix 4). 
Alternative Verdachtsdiagnosen, wie bipolare Depression oder dysthymische 
Störung, sollten aufgrund der unterschiedlichen Behandlungsmöglichkeiten 
ausgeschlossen werden. Therapieresistente PatientInnen werden durch Anam-
nese und Krankengeschichte identifiziert.  
Die Prävalenz der unipolaren TRD ist aufgrund der fehlenden international 
anerkannter Definition nicht klar. Schätzungen zufolge sprechen 30-40 % 
oder 50 % der PatientInnen – abhängig von der gewählten Definition des The-
rapieansprechens – nicht auf eine AD-Therapie an [3, 5, 44]. In Österreich 
werden 120.000 bis 140.000 Patienten pro Jahr mit Depressionen diagnosti-
ziert, von denen nur 24.000 bis 36.000 ausreichend behandelt und Remission 
erreicht wird [48]. Von den restlichen 84.000 bis 116.000 Patienten, werden 
geschätzte 10-15 % (8.400 bis 17.400 Personen) nicht auf eine Therapie an-
sprechen. 
Beschreibung der Technologie 
Die repetitive transkranielle magnetische Stimulation (rTMS) ist eine nicht-
invasive Neurostimulation, die als eine Reihe Einzelimpulsen über eine Mag-
netspule auf den Kortex übertragen wird. Die typischsten technischen Daten 
eines Einzelstimulus sind die Frequenzen (Hochfrequenz-Stimulation >1Hz 
[5, 7] oder Niederfrequenz-Stimulation bei ≤ 1 Hz), Intensität, Stimulations-
dauer, Intervall zwischen den einzelnen Stimuli, und die Anzahl der Stimuli 
pro Sitzung [7, 8]. 
Es gibt verschiedene Behandlungsprotokolle, wobei die FDA-basierten Stan-
dardparameter am weitesten verbreitet sind und für diesen Bericht berück-
sichtigt wurden: 10 magnetische Impulse pro Sekunde (Hz), 3.000 Impulse 
pro Sitzung, 100 bis 120 % Intensität, Stimulationsdauer von 4 s mit stimula-
tionsfreiem Intervall von 26 s [9]. Die optimalen Einstellungen für die Wirk-
samkeit der rTMS sind allerdings nicht belegt.  
Fragestellung 
Definition TRD:  
schwere Depression, 
keine Verbesserung 
durch verschiedene  
AD Therapie  
MDD = schwere 
Depression,  
nach DSM-IV TR 
diagnostiziert 
Prävalenz: nicht klar, 
geschätzt: bis zu 50 % 
der PatientInnen kein 
Therapieansprechen  
auf AD-Therapie 
 
in Österreich:  
140.000 PatientInnen 
mit Depression,  
circa 15 % TRD 
rTMS: nicht-invasive 
kranielle Stimulation 
 
verschiedene Arten und 
Intensitäten (niedrig 
und hochfrequent 
rTMS) 
unterschiedliche 
Behandlungsprotokolle, 
meist:  
FDA-Standardparameter 
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rTMS ist für PatientInnen mit unipolarer, schwerer Depression (MDD) in-
diziert, die keine zufriedenstellende Verbesserung durch vorangegangene AD 
Therapie hatten. Der erwartete Vorteil der rTMS gegenüber der Vergleich 
Intervention der elektrokonvulsiven Therapie (ECT) ist die geringe Invasi-
vität, die ambulante Anwendung ohne Notwendigkeit einer Anästhesie und 
Aufwachphase. Die PatientInnen können ihrer Tätigkeit im Anschluss der 
Intervention ohne Einschränkungen nachgehen. Es wurden des Weiteren kei-
ne kognitiven Einschränkungen bei der Behandlung mit rTMS berichtet. Bei 
ECT Sitzungen hingegen, können vorübergehende kognitive Einschränkun-
gen vorkommen, und umfassen Desorientierung beim Aufwachen, Amnesie, 
Beeinträchtigung des Gedächtnisses während und nach der Behandlung mit 
ECT. Allerdings sind diese Nebenwirkungen üblicherweise nur vorüberge-
hend mit Wiederherstellung der vollen kognitiven Funktionen innerhalb von 
Wochen oder Monaten [4, 11]. 
Kontraindikationen für die Anwendung von rTMS sind PatientInnen mit Me-
tallimplantaten im Kopfbereich, implantierte Medizinprodukte (Cochlea-Im-
plantat, Herzschrittmacher, etc.), Schwangerschaft, erhöhter intrakranieller 
Druck, Epilepsie bzw. erhöhte zerebrale Anfälligkeit für epileptische Anfäl-
le und allgemeine instabile Komorbiditäten [7, 8, 10]. 
 
Methoden 
Zur Beantwortung der Forschungsfrage wurde eine systematische Literatur-
suche und -analyse in zwei Phasen durchgeführt: als erster Schritt wurden 
Sekundärstudien (z. B. HTA-Berichte und systematische Reviews/SRs) an-
hand ihrer Qualität, und ihrer Einschluss- und Ausschlusskriterien bewer-
tet. Zur Qualitätsbewertung der SRs wurde AMSTAR-Tool verwendet. Aus 
insgesamt 20 vorliegenden SR wurde der Health Quality Ontario (HQO Be-
richt) [13] ausgewählt. In einem zweiten Schritt wurde eine ergänzende Suche 
nach Primärstudien durchgeführt, die seit der Literatursuche des gewählten 
HQO-Berichts [13] veröffentlicht wurden, und führte zum Einschluss zweier 
randomisierter, kontrollierter Studien (RCT) [14, 15]. Die Studien verglichen 
HF-rTMS mit der linken DLPFC mit einer Scheinintervention. Es wurden 
keine weiteren Primärstudien gefunden, die rTMS mit ECT verglichen ha-
ben. 
Klinische Wirksamkeit 
Die Endpunkte Therapieansprechrate und Remissionsrate wurden für die 
Beurteilung der Wirksamkeit als entscheidend definiert. Des Weiteren wur-
de eine durchschnittliche Verbesserung auf der Depressionsskala (HDRS) als 
wichtiger, jedoch nicht entscheidender Endpunkt herangezogen. 
Sicherheit 
Der entscheidende Endpunkt für die Beurteilung der Sicherheit war die kog-
nitive Einschränkung; wobei die Anzahl der Anfälle als wichtiger Endpunkt 
eingestuft wurde.  
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Ergebnisse 
Verfügbare Evidenz 
rTMS vs sham 
Im HQO Bericht erfüllten 23 Studien die Einschlusskriterien, die durch zwei 
zusätzliche RCTs aus der Primär Suche ergänzt wurden [14, 15]. Eines der 
beiden RCTs [15] ist eine 6-Monats-Follow-up Studie einer im HQO-Bericht 
bereits enthaltenen Studie [16]. Insgesamt wurden 1.180 Patienten in den Stu-
dien analysiert, 615 im aktiven rTMS-Arm und 565 im Scheinarm.  
Die Einschlusskriterien der Studien unterschieden sich folgendermaßen:  
 Ausgangwerte auf der HDRS-17 Skala:  
 11 Studien: >25 HDRS-17 (schwere Depression) 
 14 Studien: 19 bis 24 (moderate Depression)  
 AD- Einnahme:  
 16 Studien: vorangegangener AD-Therapieversuch  
mit zwei oder mehr AD 
 9 Studien: vorangegangener AD-Therapieversuch  
mit einem oder mehr AD 
 17 Studien: rTMS unter AD- Therapie  
 8 Studien: keine AD Therapie während rTMS 
 Stimulationsparameter:  
 Frequenz (5 bis 20 Hz), Intensität (80 bis 120 %), Anzahl der Sti-
mulationen pro Sitzung (15 bis 75), die Stimulationsdauer (2 bis 
10 Sekunden), Zwischenintervall (22 bis 58 Sekunden), Anzahl der 
Impulse pro Sitzung von (800 bis 3.000) Gesamtzahl der Impulse 
während der rTMS-Behandlung (8.000 bis 90.000).  
 Alle Studien verwendeten die Figur 8 Spulen. 
rTMS vs ECT 
Der HQO-Bericht enthielt sechs Studien, die rTMS mit ECT verglichen. Die 
meisten Studien wurden in den frühen 2000er Jahren durchgeführt. Die Ge-
samtzahl der Patienten betrug 266, 133 in jedem Arm.  
Die Einschlusskriterien der Studien unterschieden sich folgendermaßen:  
 Ausgangwerte auf der HDRS-17 Skala:  
 24 bis 26 in der rTMS-Gruppe 
 25 bis 28 in der ECT-Gruppe 
 AD- Einnahme:  
 2 Studien: vorangegangener AD-Therapieversuch  
mit zwei oder mehr AD 
 1 Studie: vorangegangener AD-Therapieversuch mit einem oder 
mehr AD, bzw. 1 Studie berichtete AD-Therapieversuche in der 
derzeitigen Episode 
 2 Studien: Einschluss von PatientInnen mit vorangegangener 
ECT Therapie (keine Information zur AD Therapie) 
 2 Studien: rTMS bzw. ECT unter AD Therapie 
 2 Studien: medikamentenfrei 
 2 Studien: Therapie mit Lorazepam oder Clonazepam  
verfügbare Evidenz:  
SR mit 23 Studien,  
2 RCTs 
unterschiedliche 
Einschlusskriterien der 
verschiedenen Studien 
in Bezug auf 
Ausgangswerte,  
AD-Einnahme und 
Stimulationsparameter 
verfügbare Evidenz:  
SR mit 6 Studien,  
266 PatientInnen,  
133 pro Arm 
unterschiedliche 
Einschlusskriterien der 
verschiedenen Studien 
in Bezug auf 
Ausgangswerte,  
AD-Einnahme und 
Stimulationsparameter 
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 Stimulationsparameter:  
 Frequenz (10Hz bzw 20 Hz), Intensität (90 bis 110 %), die Anzahl 
der Stimulationen (20 bis 30-35), die Stimulationsdauer (2 bis 10 s), 
Zwischeninterval (20 bis 55 s), die Impulse pro Sitzung (408 bis 
2.500), Anzahl der Sitzungen (10 bis 20). Gesamtzahl der geliefer-
ten Impulse (4.080 bis 50.000).  
 Alle Studien verwendeten die Figur 8 Spulen. 
Klinische Wirksamkeit 
rTMS vs sham 
Im Durchschnitt verringerte rTMS die Punktezahl auf der Depressionsskala 
um etwa 2.31 Punkte mehr als die Scheinintervention (95 % CI 1.19-3.43, p 
<.001). Dies liegt allerding unter dem klinisch relevanten Schwellenwert von 
3.5 Punkten.  
Das gepoolte Risikoverhältnis für die Remissionsrate über 12 Studien betrug 
2.16 (95 % CI 1.42-3.29, p = 0.0003). Das gepoolte Risiko-Verhältnis für die 
Ansprechrate über 19 Studien betrug 1.82 (95 % CI 1.18-2.82, p = 0.0068).  
In Bezug auf allgemeine und psychische Gesundheit, gemessen mit dem SF-
36 score, berichtete ein RCT [15] statistisch signifikanten Verbesserungen in 
der rTMS Gruppe. Auch in Hinblick auf QoL fand die Studie statistisch sig-
nifikante Verbesserung in der rTMS Gruppe, gemessen mit dem Q-LES-Q-
Score.  
rTMS vs ECT 
Die gewichtete mittlere Differenz der Depressionswerte von der Baseline bis 
zum Ende der Behandlung betrug -5.97 Punkte (95 % CI -11.00 – (-0.94), p = 
0.020) zugunsten von ECT, und damit höher der klinisch relevante Schwel-
lenwert. 
Das gepoolte Risikoverhältnis für die Remission betrug 1.44 (95 % CI 0.64-
3.23, p = 0.375) am Ende der Behandlung zu Gunsten von ECT. Diese Er-
gebnisse sind allerdings nicht signifikant und die Studien wiesen ein hohes 
Maß an Heterogenität auf (I2 = 69.1 %, p = 0.039).  
Das gepoolte Risikoverhältnis Therapieansprechrate betrug 1.72 (95 % CI 
0.95-3.11, p = 0.72). Wiederum waren diese Ergebnisse nicht signifikant, mit 
einem hohen Maß an Heterogenität der Studien (I2 = 60.6 %, p = 0.079).  
Die Selbstmordgedanken, gemessen sowohl mit BDI als auch HDRS Skala, 
sanken signifikant stärker in der ECT Gruppe als in der rTMS Gruppe.  
Sicherheit 
rTMs vs sham 
Die am häufigsten berichtete Nebenwirkung war Kopfschmerz. Die Rate der 
Kopfschmerzen reichte von 0 bis 60 % in der rTMS-Gruppe und 0 bis 50 % 
in der Scheingruppe. Krampfanfälle traten in keinen Studien auf, eine tran-
siente kognitive Beeinträchtigung trat bei fünf PatientInnen (16.7 %) in der 
rTMS-Gruppe und einem Patienten (4.3 %) in der Scheingruppe ein. 
rTMS vs ECT 
Es wurden keine schwerwiegenden Nebenwirkungen berichtet. Bei rTMS-
PatientInnen waren Kopfschmerzen die häufigsten Nebenwirkungen, ECT-
PatientInnen berichten keine unerwünschten Ereignisse. 
rTMS vs Sham 
 
Verbesserung in der 
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Remissionsrate: RR 2.16  
Ansprechrate: RR 1.82 
zugunsten von rTMS 
 
QoL: 1 RCT berichtete 
signifikante 
Verbesserungen 
Verbesserung in der 
Depressionsskala um 
5,97 Punkte in  
ECT Gruppe,  
klinisch relevant 
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Laufende Studien 
Es gibt vier laufende Studien zu rTMS im Vergleich zur Scheinstimulation, 
aber keine laufenden Studien, die rTMS mit ECT vergleichen. 
Kostenerstattung 
Die Technologie wird in der Mehrheit der Länder, für die wir Informationen 
zur Verfügung hatten, sowie in Österreich, nicht zurückerstattet.  
 
Diskussion 
Die Gesamtqualität des Beweismaterials ist sowohl für Schein- als auch für 
ECT-Vergleichsstudien sehr gering. 
Die methodischen Einschränkungen könnte die Empfehlung in Hinblick auf 
die Robustheit der Wirksamkeitsergebnisse erheblich beeinflussen. Diese Ein-
schränkungen beinhalten variable Studienparameter (rTMS-Behandlungspro-
tokolle, die Definition der Remission, die Definition der TRD, Verwendung 
als Mono- oder Add-On-Therapie), das Bias Risiko (ein hohes Risiko Bias dem 
ECT-kontrollierte Studien auf Grund fehlender Verblindung), kleine Patien-
tInnen Fallzahlen (sowohl im Schein- als auch in der ECT-kontrollierten Stu-
die). 
Lebensqualität und PatientInnen Zufriedenheit wären wünschenswerte pri-
mär Endpunkte für Studien an therapieresistenter Depression; diese wurden 
jedoch nur von einer Studie berichtet. Des Weiteren fehlen Langzeitdaten zu 
Wirkung von rTMS. 
 
Empfehlung 
Die Ergebnisse der Bewertung zeigen, dass rTMS im Allgemeinen sicher und 
gut verträglich ist. rTMS hatte einen kurzfristigen Effekt auf die Verbesse-
rung der Depression im Vergleich zur Scheinintervention, der allerdings kli-
nisch nicht relevant sein könnte. Follow-up Studien konnten keinen langan-
haltenden Effekt von rTMS finden.  
Die Wirksamkeit im Vergleich zu ECT zeigt einen Vorteil von ECT gegen-
über rTMS in Bezug auf die klinisch relevante Verbesserung auf der Depres-
sionsskala; jedoch gibt es keine signifikanten Unterschiede im Hinblick auf 
Ansprechrate und Remissionsrate. Die Qualität der Studien ist sehr niedrig, 
unter anderem bedingt durch die niedrige Fallzahl und hohe Heterogenität 
der Studien.  
Aufgrund dieser niedrigen Qualität der Evidenz könnten neue Studiener-
gebnisse die Effektschätzung erheblich beeinflussen. Weitere Studien, die 
Langzeitdaten zu rTMS untersuchen, sind notwendig, um die tatsächliche 
Wirksamkeit der Intervention zu bestätigen. 
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1 Scope 
1.1 PICO question 
Is repetitive transcranial magnetic stimulation (rTMS) in patients with treat-
ment-resistant major depression as effective as or more effective than and as 
safe as or safer than sham stimulation or electroconvulsive therapy (ECT)? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Description Project scope 
Population   Adult patients (>18 yrs) with major depressive disorder (MDD) as defined by DSM IV-
TR or ICD-10, which is treatment resistant (TRD) and characterized by: 
 syndrome of unipolar depression with or without psychotic features and  
 lack of clinically meaningful improvement despite the use of at least 2 antidepressant 
agents from different pharmacological classes with each antidepressant medication 
trial being adequate in terms of dose, duration, compliance, and tolerability 
 Intended use of technology: third- and subsequent-line treatment 
 MeSH terms: Major depressive disorder F03.600.300.375, Depressive disorder, 
treatment-resistant: F03.600.300.387 
 ICD-10 categories: F32 Depressive episode, F33 Recurrent depressive disorder 
 Rationale: population has been chosen based on information from the relevant published 
clinical guidelines [5, 7, 20-24] and amended following comments from external experts. 
Intervention   Repetitive transcranial magnetic stimulation (rTMS) as a therapeutic intervention  
in the acute phase 
 MeSH term: Transcranial Magnetic Stimulation E02.621.820 
 The following intervention will be considered:  
High-frequency (≥5 Hz) rTMS of the left dorsolateral prefrontal cortex (DLPFC)  
as monotherapy or add-on therapy 
 Products to be considered: 
 MagStim: Magstim Rapid2, Super Rapid2 and Super Rapid2 Plus1 
 Magventure: MagVita TMS Therapy system, Magpro X100 Stimulator,  
Magpro R30 Stimulator  
 Neurostar: NeuroStar TMS therapy system 
 Mag & More: PowerMAG, Different versions: PowerMAG Clinical 30,  
PowerMAG Clinical 100, PowerMAG Research 30, PowerMAG Research 100 
 Neurosoft: Neuro-MS, Neuro-MS/D 
Rationale: relevant published clinical guidelines [5, 21] issued level A recommendation  
for the use of high-frequency rTMS of the left DLPFC; for the use of low-frequency rTMS 
of the right DLPFC level B recommendation (probable effect) has been issued.  
 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Description Project scope 
Comparison  Sham stimulation (with antidepressant medication or no medication) 
 ECT 
Rationale: Comparator has been chosen based on information from EUnetHTA guidelines 
[25-27] and relevant published clinical guidelines [5, 7, 20-24], in which ECT is recommended 
for TRD patients after two treatment failures as a nonpharmacological treatment option. 
Other somatic therapies are not yet well established.  
Outcomes Clinical endpoints: 
Clinical effectiveness 
 Change in depression score (measured on one of the following scales: HDRS/HAMD, 
MADRS, BDI or QIDS) 
 Response rate (≥ 50% reduction in the depression scores) 
 Remission rate (HAMD score <7, MADRS score <7, QUIDS score <5) 
 Patient satisfaction  
 QoL  
 Relapse rate 
Safety: 
 Serious adverse device effect (SADE) 
 Seizure 
 Transient impairment of working memory 
 Induced currents in implanted devices 
 Adverse device effect (ADE):  
 Syncope (fainting) 
 Scalp discomfort or pain 
 Transient induction of hypomania 
 Transient hearing loss 
 Headache 
 Facial twitching 
 Vertigo 
 Device-related insomnia/drowsiness 
 Mild confusion 
 Other AEs 
Rationale: outcomes have been chosen based on information from relevant published 
clinical guidelines [5, 7, 20-24] and EUnetHTA guidelines [25-27]. 
Abbreviations: AEs adverse events, BDI Beck Depression Inventory, HDRS/HAMD Hamilton Depression Rating Scale, 
MADRS Montgomery-Asberg Depression Rating Scale, QIDS Quick Inventory of Depressive Symptomatology, QoL quality of life 
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2 Methods and evidence included  
2.1 Research questions 
Element ID Description and technical characteristics of the technology 
B0001 What are rTMS, sham stimulation and ECT? 
A0020 For which indications rTMS received marketing authorisation  
or CE marking? 
B0002 What is the claimed benefit of rTMS in relation to sham 
stimulation and ECT? 
B0003 What is the phase of development and implementation of rTMS 
and ECT? 
B0004 Who administers rTMS and ECT and in what context and level 
of care is it provided? 
B0008 What kind of special premises are needed to use rTMS and ECT? 
B0009 What equipment and supplies are needed to use rTMS and ECT? 
A0021 What is the reimbursement status of rTMS? 
 
Element ID Health problem and current use of the technology 
A0002 What is treatment-resistant major depressive disorder? 
A0003 What are the known risk factors for treatment-resistant major 
depressive disorder? 
A0004 What is the natural course of treatment-resistant major 
depressive disorder? 
A0005 What are the symptoms and the burden of treatment-resistant 
major depressive disorder for the patient? 
A0006 What are the consequences of treatment-resistant major 
depressive disorder for the society? 
A0024 How is treatment-resistant major depressive disorder currently 
diagnosed according to published guidelines and in practice? 
A0025 How is treatment-resistant major depressive disorder currently 
managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
A0011 How much is rTMS utilised? 
 
Element ID Clinical effectiveness 
D0001 What is the expected beneficial effect of rTMS on mortality? 
D0005 How does rTMS affect symptoms and findings (severity, 
frequency) of treatment-resistant major depressive disorder? 
D0006 How does rTMS affect progression (or recurrence) of 
treatment-resistant major depressive disorder? 
D0011 What is the effect of rTMS on patients’ body functions? 
D0016 How does the use of rTMS affect activities of daily living? 
D0012 What is the effect of rTMS on generic health-related quality of life? 
D0013 What is the effect of rTMS on disease-specific quality of life? 
D0017 Were patients satisfied with rTMS? 
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Element ID Safety  
C0008 How safe is rTMS in relation to sham stimulation and ECT? 
C0002 Are the harms related to dosage or frequency of applying rTMS? 
C0005 What are the susceptible patient groups that are more likely  
to be harmed through the use of rTMS? 
C0007 Are rTMS, sham stimulation and ECT associated with  
user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor 
the use of rTMS, sham stimulation and ECT? 
 
 
2.2 Source of assessment elements 
The selection of assessment elements is based on the HTA Core Model Ap-
plication for Rapid Relative Effectiveness (REA) Assessments (4.2). The se-
lected issues (generic questions) are translated into actual research questions 
(answerable questions). 
 
 
2.3 Search 
Detailed tables on search strategy are included in Appendix 1. 
Given the extensive body of evidence (randomized controlled trials/RCTs, sys-
tematic reviews/SRs and meta-analysis/MAs) the systematic literature search 
and analysis of the studies was performed in two phases: secondary studies 
(i.e. HTA reports and SRs) were screened as a first step and evaluated on the 
basis of their scope, inclusion and exclusion criteria, and quality. Primary 
studies were considered for inclusion in the second step. We did not apply 
any restrictions on language. 
The following sources of information were used in the first search: 
 Cochrane Library, 
 Centre for Research and Dissemination (CRD),  
 Embase,  
 Medline,  
 PsychInfo, 
 Handsearch (in reference list of relevant studies). 
Secondary studies were retrieved in full-text version. HTA reports and SRs 
were extracted and tabulated in ascending chronological order. Only the most 
recent reports (published in 2012-2016) were discussed qualitatively. SRs were 
assessed according to year of publication, time range, scope, and population 
to identify the most recent review that overlapped with the scope of the pre-
sent assessment. The AMSTAR tool was used for quality assessment of SRs. 
Details can be found in Table A-3 in Appendix 1. The Health Quality Ontar-
io (HQO) HTA report [13] was selected for update.  
Bericht folgt  
HTA Core Model für REA 
Literatursuche in  
2 Schritten:  
 
1. Suche nach sekundär 
Studien (HTA Berichte 
und SR) in  
5 Datenbanken 
HTA Berichte und SRs 
von 2012-2016  
 
qualitative Bewertung 
mittels AMSTAR 
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To identify further, more recent, primary studies fulfilling the inclusion cri-
teria of the present assessment, a literature search for RCTs published since 
the literature search of the chosen HTA report [13] was performed. The time 
period of the search was limited to November 2014 to January 2017. The fol-
lowing sources of information were used: 
 Cochrane Library, 
 Embase,  
 Medline,  
 PsychInfo, 
 Handsearch (in reference list of relevant studies) 
In addition, the following clinical trials databases were searched to identify 
ongoing studies on the rTMS in major depression:  
 ClincalTrials.gov  
 EU Clinical Trials Register  
 International Clinical Trials Registry Platform (ICTRP).  
Clinical Practice Guidelines (CPGs) were also searched in the UptoDate da-
tabase, through handsearch and consultation with clinical experts. 
 
  
2. Suche nach 
zusätzlichen primär 
Studien (RCTs) in  
4 Datenbanken 
Suche nach laufenden 
Studien zu rTMS 
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2.4 Study selection 
2.4.1 Selection of systematic reviews  
 
Figure 2-1: Flow chart for selection of systematic reviews 
 
The author (LBI-HTA) and the co-author (OSTEBA) screened and selected 
studies independently from each other. The author checked the discrepan-
cies. Any disagreements were resolved by consensus. 
The search yielded 669 records and after deduplication, 326 records re-
mained for screening. The reference list was screened by title and abstract to 
identify potentially relevant studies. A cross-reference search identified one 
further study.  
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(n = 327) 
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(n = 297) 
Full-text articles assessed  
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(n = 30) 
Full-text articles excluded, with 
reasons  
(n = 10) 
Exclusion criteria are e.g.: 
 Background literature (n=4) 
 Other population (n = 0) 
 Not available (n = 3) 
 Other intervention (deep rTMS) 
(n = 2) 
 Not reporting the outcomes  
of interest (n = 1) 
Studies included in qualitative synthesis  
(n = 20) 
rTMS vs sham SRs (n = 9) 
rTMS vs ECT SRs (n = 6) 
rTMS vs sham and ECT SRs (n = 5) 
Studies included in quantitative synthesis  
(n = 1) 
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A total of 20 SRs were selected that fulfilled our inclusion criteria. 14 studies 
had only one comparator each: nine compared rTMS with sham stimulation 
and six compared active stimulation with ECT. Five SRs included both com-
parators. Seven SRs included various types of rTMS (HF, LF, mixed frequen-
cies) applied to different sites. From these we considered only the HF-rTMS 
to the left DLPFC parts of the SR and extracted data regarding that (num-
ber of patients, studies included, scope of the assessment, inclusion criteria 
used). We assessed the quality of the SRs with the AMSTAR tool. The HQO 
report [13] was selected for update within the present assessment on the ba-
sis of the year of publication, time range, scope, population, intervention, out-
comes measured, comparators, and the AMSTAR score.  
 
2.4.2 Selection of primary studies 
 
Figure 2-2: Flow chart for selection of primary studies 
20 SRs von denen  
14 rTMS mit sham und  
6 rTMS mit ECT, und  
5 Studien beide 
Interventionen mit 
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(n = 521) 
Records screened  
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Records excluded  
(n = 505) 
Full-text articles assessed  
for eligibility  
(n = 16) 
Full-text articles excluded, with 
reasons  
(n = 14) 
Exclusion criteria are e.g.: 
 Other intervention 
(maintenance therapy or 
targeting other than the left 
site) (n = 2) 
 Publication before the search 
period of interest (n = 9) 
 Study design non-RCT (n = 2) 
 Only follow-up data (n = 1) 
Studies included in qualitative synthesis  
(n = 2) 
rTMS vs sham (n = 2) 
rTMS vs ECT (n= 0) 
Studies included in quantitative synthesis  
(n = 2) 
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Primary studies in the period November 2014 – January 2017 were screened 
to identify new evidence. The search yielded 849 records, after deduplication 
521 records remained for screening. A hand search identified no further stud-
ies. In total, two studies [14, 15] were selected that fulfilled our inclusion cri-
teria and included within the present assessment. The two studies compared 
HF-rTMS to the left DLPFC with sham. No studies were found that com-
pared active stimulation with ECT. Additionally, as the selected SR did not 
define QoL as an efficacy outcome and the included primary studies did not 
report on it, we also screened primary studies of the last 5 years (2012-2016). 
We tried to find those studies that might have been excluded from the selected 
SR in case they did not report on the primary outcomes defined in the SR.  
 
2.4.3 Selection of guidelines 
We identified guidelines via systematic search and hand search. The guide-
lines of the main scientific and professional organizations (APA, CANMAT, 
IFCN, RAZCP, and WSFBP) and the guidelines applicable by professional 
organizations of the author’s (Austria, DGPPN) and co-author’s (Spain, 
AVALIA-t) country of origin were selected to be included in the overview of 
available guidelines.  
 
 
2.5 Quality rating of studies 
AMSTAR was used to assess the quality of SRs and the Cochrane risk of bias 
assessment approach was used to assess RCTs (ACROBAT-NRSi tool), ac-
cording to the EUnetHTA Guidelines on Therapeutic medical devices [25]. 
For the assessment of the strength of evidence, the “Grading of Recommen-
dations, Assessment, Development and Evaluation” – GRADE approach was 
used. These steps were performed by the author independently from the co-
author(s). Any disagreements were resolved by consensus. The preliminary 
classification of the importance of the outcomes (GRADE specifies three cat-
egories of outcomes according to their importance for decision-making: cru-
cial, important, and of limited importance) was done in consensus by the au-
thors.  
For Description and Technical Characteristics of Technology (TEC) and 
Health Problem and Current Use of the Technology (CUR) domains, no qual-
ity assessment tool was used, but multiple sources were used in order to val-
idate individual, possibly biased, sources. Descriptive analysis of different 
information sources was performed. The completed EUnetHTA submission 
file from the manufacturers was used as a starting point. The AGREE II tool 
was used for the quality rating of guidelines. Two authors scored the guide-
lines independently from each other, disagreements were solved by consensus.  
 
 
insgesamt  
521 Primärstudien 
identifiziert 
Leitlinien relevanter 
Organisationen,  
im besonderen aus 
Österreich und Spanien 
AMSTAR zur Bewertung 
der Qualität der 
sekundär Studien 
 
 
Zusammenfassung der 
Ergebnisse mit GRADE 
AGREE II zur  
Bewertung der  
Qualität der Leitlinien  
Methods and evidence included 
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2.6 Statistical-analysis 
We conducted a meta-analysis of the pooled results in the R environment [28] 
using the package ‘‘meta’’ [29]. The HQO report used a random effects model 
for the meta-analysis; we also chose this model in our calculations. The degree 
of statistical heterogeneity among studies was assessed using the I-squared 
(I2) and tau-squared statistics.  
We calculated changes in depression scores measured by Hamilton Rating 
Scale for Depression from baseline to the end of treatment and conducted a 
meta-analysis on the mean changes in scores for the rTMS treatment and con-
trol groups. We calculated the effect size as the difference between the means 
of the two groups divided by the standard deviation (SD), a statistical meth-
od known as standardized mean difference (SMD) using Cohen’s method. 
We used Cohen’s conventional definition of small, medium, and large effect 
size as 0.2, 0.5, and 0.8, respectively. Pooled effect sizes for depression scores 
were calculated in the HQO report using weighted mean difference, the mean 
difference value of 3.5 points on the Hamilton Rating Scale for Depression 
was considered to be a clinically relevant treatment effect. 
For binary outcomes, we calculated remission and response rates, as well as 
the pooled risk ratios and risk differences as the summary effect estimates 
along with their corresponding 95% confidence intervals (CIs) around the 
point estimates.  
 
Metaanalyse der 
zusammengefassten 
Ergebnisse mittels 
random-effects Model 
Veränderungen im 
Depressionspotential 
mittels ‚Hamilton 
Rating’  
Ansprechrate, 
Unterschiede im Risiko, 
Risikoquote als Gesamt-
Effektschätzer mit 95 % 
Konfidenzintervallen 
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2.7 Description of the evidence 
Table 2-1: Main characteristics of the included systematic review for update 
Author, 
year 
Study  
type 
Number  
of patients,  
number of RCTs 
Aim  
of the study 
Intervention(s)  
vs Comparison(s) Main endpoints 
Inclusion criteria,  
exclusion criteria 
Included  
studies 
Period 
searched 
AMSTAR Score  
(# no,  
can’t answer, 
not applicable) 
HQO, 
2016 
[13] 
SR rTMS vs sham 
rTMS:  
1156 pts/ 
23 RCTs; 
rTMS vs ECT: 
266 pts/6 RCTs 
To examine the 
antidepressant 
efficacy of rTMS 
in patients with 
TRD. 
HF rTMS vs 
sham rTMS, 
HF rTMS vs ECT 
Standardized and 
weighted mean 
difference in 
depression scores, 
response, 
remission 
Inclusion: 
RCTs, 
age ≥ 18 yrs, 
HF rTMS for ≥ 10 sessions, 
only unipolar pts or  
max. 20% bipolar pts, 
≥ 80% of pts with TRD 
Exclusion: 
Nonrandomised trials 
stimulation site other than left 
DLPFC, frequencies outside the 
range for this review, bilateral 
or bilateral vs unilateral rTMS, 
sequential combined LF and 
HF rTMS, newer technologies 
(synchronized rTMS, pulsed 
rTMS, DTMS, rTMS with 
priming stimulation), 
studies with only cognitive 
functions outcome, 
population: depression due  
to specific conditions e.g. 
poststroke, postpartum. 
Avery 1999,  
Avery 2006,  
Bakim 2012, 
Berman 2000, 
Blumberger 2012, 
Bretlau 2008, 
Boutros 2002, 
Chen 2013, 
Fitzgerald 2003, 
Fitzgerald 2012, 
Garcia-Toro 2001, 
George 2010, 
Holtzheimer 2004, 
Hoppner 2003, 
Loo 1999, Loo 
2007, Mogg 2008, 
Mosimann 2004, 
O’Reardon 2007, 
Padberg 2002, 
Stern 2007,  
Su 2005,  
Triggs 2010 
1994-
2014 
9 
(#4,5 no) 
Abbreviations: AMSTAR A Measurement Tool to Assess Systematic Reviews, DLPFC dorsolateral prefrontal cortex, DTMS deep transcranial magnetic stimulation,  
ECT electroconvulsive therapy, HF high-frequency, HQO Health Quality Ontario, pts patients, RCT randomized controlled trial, rTMS repetitive transcranial magnetic stimulation,  
SR systematic review, TRD treatment-resistant depression, yrs years 
List of AMSTAR items: (1) Was an ‘a priori’ design provided? (2) Was there duplicate study selection and data extraction? (3) Was a comprehensive literature search performed?  
(4) Was the status of publication (i.e. grey literature) used as an inclusion criterion? (5) Was a list of studies (included and excluded) provided? (6) Were the characteristics of the included studies provided? 
(7) Was the scientific quality of the included studies assessed and documented? (8) Was the scientific quality of the included studies used appropriately in formulating conclusions?  
(9) Were the methods used to combine the findings of studies appropriate? (10) Was the likelihood of publication bias assessed? (11) Was the conflict of interest included 
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The HQO report [13] focused on the assessment of effectiveness and safety 
of rTMS in patients with treatment resistant depression. The review covered 
the time frame from January 1994 to November 2014. 23 RCTs compared 
rTMS with sham, and 6 RCTs compared rTMS with ECT. The inclusion cri-
teria and exclusion criteria are presented in Table 2-1. 
Two new comparative primary studies were identified by updating the HQO 
report [13]. For answering effectiveness domain questions, we considered all 
studies included in the HQO report and the two new studies identified in the 
search update. To answer safety questions, we only considered studies from 
the HQO report that contained safety data.  
We extracted the studies included in the HQO report as well, because we con-
sidered additional outcomes as compared to the HQO report. If stimulation 
site other than left DLPFC and frequency other than HF was a comparator 
besides sham and/or ECT, we disregarded the data and only extracted infor-
mation in relation to HF-rTMS and sham and/or ECT.  
Table 2-2: Main characteristics of primary studies included in the update: rTMS vs sham 
Author and year  
or study name 
Study 
type 
Number  
of patients Intervention(s) Main endpoints 
Included in clinical 
effectiveness and/or 
safety domain 
Solvason 2014 [15] RCT 301 HF-rTMS vs sham Quality of life  
(Q-LES-Q, SF-36) 
Clinical effectiveness 
Kang 2016 [14] RCT 24 HF-rTMS vs sham HAMD/HDRS score Clinical effectiveness 
Abbreviations: HAMD/HDRS Hamilton Depression Rating Scale, HF high frequency, RCT randomized controlled trial, 
rTMS repetitive transcranial magnetic stimulation, SF-36 Study-36 Item Short Form, Q-LES-Q Quality of Life Enjoyment 
and Satisfaction Questionnaire 
 
 
HQO Bericht zur 
Wirskamkeit und 
Sicherheit von rTMS 
2 zusätzliche 
Primärstudien zur 
Bewertung der 
Wirksamkeit 
nur Daten zu HF-rTMS 
und linker DLPFC 
extrahiert 
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3 Description and technical 
characteristics of technology (TEC) 
3.1 Results 
3.1.1 Features of the technology and comparators 
[B0001] – What are rTMS, sham stimulation and ECT? 
Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation 
and neuromodulation technique, based on the principle of electromagnetic in-
duction of an electric field (~100V/m) in the brain. The field can be of suf-
ficient magnitude and density to depolarize neurons and when TMS pulses 
are applied repetitively, they can modulate cortical excitability, decreasing or 
increasing it, depending on the parameters of stimulation [7, 10]. 
The equipment consists of a high current pulse generator which produces a 
discharge current that flows through a stimulating coil, generating a brief 
magnetic pulse (<1ms) with field strengths up to several Teslas (~4 Tesla) 
[5, 10]. 
TMS can be delivered either as a single pulse or as a series of pulses i.e. a train 
in which case it is called repetitive TMS (rTMS). The depth of the stimula-
tion is approximately 2-3 cm beneath the coil.  
The most typical technical parameters of rTMS are the following: 
 Frequency: number of magnetic pulses per second (Hz) 
 High (fast) frequency: stimulation delivered >1 pulse per second, 
but generally ≥ 5 Hz is applied as HF [5, 7] 
 Low (slow) frequency: stimulation delivered at ≤ 1 pulse  
per second. 
 Intensity: expressed as percentage of the resting motor threshold, which 
is established by stimulating the motor cortex and determining the 
minimum amount of energy that is required to evoke a motor response 
in a specific muscle group. The motor response is assessed visually or 
with electromyography (EEG). Intensity is generally set at 100 to 120 
percent of resting motor threshold.  
 Train duration (usually 2 s to 4 s) 
 Intertrain interval: time between successive trains (usually 8 s to 26 s) 
 Number of trains per session  
 Number of pulses per session: calculated from the frequency,  
train duration, and number of trains per session [7, 8]. 
There are various treatment protocols, but the FDA-based standard parame-
ters are most widely used and for the acute treatment they include: 10 mag-
netic pulses per second (Hz), 3000 pulses per session, 100 to 120 percent of 
motor threshold, train duration of 4 s with intertrain interval of 26 s [9]. How-
ever, the stimulation parameters required to optimize the efficacy of rTMS 
treatment are not well known. Thus the administration of the treatment is 
not standardized and the number of necessary treatments is also unclear [8]. 
Transkranielle 
Magnetstimulation: 
nicht-invasive 
Neurostimulation des 
Gehirns, die kortikale 
Erregbarkeit 
beeinflussen kann 
kann als einfache oder 
Serie von Stimulationen 
verabreicht werden 
typische Parameter: 
 Frequenz  
(hoch oder niedrig) 
 Intensität  
 Dauer der 
Stimulationen 
 Dauer zwischen  
den Stimulationen 
 Anzahl der 
Stimulationen  
 Anzahl der Pulse  
per Intervention 
unterschiedliche 
Protokolle, FDA- 
Standardparameter am 
häufigsten angewendet; 
effektivste 
Stimulationsparameter 
nicht bekannt 
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Figure 3-1: Mechanism of action of TMS; Source: submission file 
The type and orientation of the coil influences the effect of action. There are 
several types of coils in use. The large circular coils have a wide action radi-
us. The figure-of-eight coil is used for focal stimulation, when the stimulation 
zone should be only a few square centimetres large. The double cone angulated 
coil, consisting of two large circular coils forming an obtuse angle, can reach 
deeper targets. There are newer types of coils that allow a lesser rate of de-
crease of field of magnitude as a function of distance such as the Hesed-coil 
(H-coil) and the C-core coil, or circular-crown coil among others [30]. 
The use of rTMS is contraindicated for patients or test subjects with: 
 metal implants in the head area, e.g. shunts, clips (for patients with 
metallic implants or similar objects in the vicinity of the point of treat-
ment, the user must weigh the potential risk against the utility of the 
treatment),  
 implanted medical devices (cochlear implant, medication pump, 
pacemaker, intra-cardiac lines, etc.),  
 pregnancy (in this case the magnetic nerve root stimulation is of crit-
ical importance; the transcranial stimulation is less critical on the basis 
of the greater distance to the foetus),  
 increased intracranial pressure (e.g. after trauma or infection),  
 a history of epileptic seizures (only applies for the cortical use;  
if necessary, a risk/benefit analysis should be performed),  
 increased cerebral susceptibility to epileptic seizures through medica-
tion (e.g. wellbutrin, zoloft, adderall, fluoxetine, aripiprazole, lithium 
carbonate, clonazepam),  
 unstable general medical disorders [7, 8, 10]. 
A 13-item clinician-administered questionnaire (Screening 13-item Question-
naire for rTMS Candidates by the International Federation of Clinical Neu-
rophysiology) can be used to screen patients for the contraindications. Psy-
chotic features (delusions and hallucinations) are not a contraindication for 
treating MDD with rTMS, but most RCTs have excluded psychotic patients 
[8]. 
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Table 3-1: Features of the intervention  
Proprietary name Manufacturer Technical features Device class/UMDNS code 
Magnetic stimulator Neuro-MS 
Magnetic stimulator Neuro-MS/D 
Big ring coil RC-01-150 
Small ring coil RC-01-100 
Figure-of-eight coil FEC-01-100 
Neurosoft Magnetic stimulator Neuros-MS delivers 20 Hz stimulation with 100% intensity with a number of 
pulses generated during one session – up to 10 000. The magnetic field than reach up to 4 tesla. 
Magnetic stimulator Neuro-MS/D possesses a cooling unit that allows performing long-term 
therapeutic impacts (also TMS with high frequency and intensity) without quick coil overheating. 
It provides the possibility to increase the maximal effective stimulation frequency (the frequency 
when each stimulus in series has 100% intensity of MT for most people) twice (up to 20 Hz) owing 
to extra power supply unit. 
Class IIa/UMDNS 12-415 
Magstim Rapid2 
70mm Double Air Film Coil 
Magstim AFC Support Stand 
Magstim Trolley 
70mm Double Air Film Sham Coil 
Magstim Rapid² is a compact magnetic stimulator unit capable of repetitive rate output at high power 
levels. The system is highly versatile and is compatible with the full range of Magstim coils. The 
system can be interfaced with different EMG systems. Rapid² also features a unique temperature 
prediction algorithm that gives users a high degree of confidence that a protocol can be achieved. 
The D70mm Alpha coil utilizes a double figure of eight shape winding to achieve precise focal 
magnetic field allowing relatively accurate stimulation of cortical and peripheral structures as 
compared to circular coils. The profile of the coil allows easy access to most common areas of 
cortical stimulation and offers superior manoeuvrability. 
The Magstim AFC Support Stand is designed to aid the positioning of a stimulating coil in any 
desired orientation and can manoeuvre the coil around the subject. 
The Magstim trolley ensures the transport of the stimulators. 
The 70mm Double Air Film sham coil allows users to conduct research trials with a true sham 
condition. By stimulating the peripheral nerves of the face and scalp, the Air Film sham coil looks, 
sounds, and feels the same as an active coil, both to the subject and operator, but does not deliver 
active stimulation of deep nerves. 
Class II 
PowerMAG 100 clinical 
PowerMAG 30 clinical 
rTMS trolley 
Coil positioning arm 
Round coil PMR 110 
Double coil PMD 70 
Double coil PMD70-pCool-SHAM 
Treatment chair 
Mag&More PowerMAG 100 clinical is able to generate burst of pulses up to 100 Hz with constant intensities  
by recharging between pulses. It also has a maximum pulse frequency of 100 Hz at 70% intensity. 
The maximal frequency at 100% intensity is 30 Hz. Depending on the type of coil the magnetic 
induction can reach up to 4 tesla. 
PowerMAG 30 clinical features highly precise, single pulses. It can produce maximum intensity 
(100% output) in the whole frequency range (0 to 30Hz). 
Double coil PMD 70 is suitable for the selective stimulation of individual areas as well as cortical 
and spinal applications. 
Double coil PMD70-pCool-SHAM has a minimized magnetic field strength, thus enabling the coil  
to not stimulate the brain, and only stimulate the nearest area (such as scalp) that produces the 
twitching sensation. Moreover, the coil generates identical sounds compared to the active TMS 
coils and has a similar weight. 
Round coil PMR 110 has the largest stimulation spot within all coils. It also has a high penetration 
depth. The coil is designed for cortical, spinal, and peripheral applications. 
Class IIa 
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Proprietary name Manufacturer Technical features Device class/UMDNS code 
MagPro R30 
MagPro R20 
MagVita TMS Therapy® System 
Circular coils 
Butterfly coils 
Special coils 
MagVenture MagPro R30: 30 pps maximum rep. rate, 60 pps option available 
MagPro R20: stimulation rates up to 20 pps 
MagVita TMS Therapy System: 30 pps maximum rep. rate, chair, and vacuum pillow 
Circular coils: fairly large area of body tissue can be stimulated, usually serves well as a “general 
purpose coil”. C-100, MC-125, MMC-90, MMC-140, MMC-140-II, MCF-75, MCF-125, Cool-125. The 
various types differ in the diameter size and the pulses before warmup. 
Butterfly coils: more focused in comparison with the circular coils. The two windings are placed 
side-by-side, enabling the coil to stimulate structures with focus right under its centre. The 
butterfly coil is useful in focused stimulation.MC-B35, C-B60, D-B80, MC B65-HO, MC-B70, MCF-
B65, MCF-B70, Cool-B35, Cool-B65, Cool D-B80, Cool-B70. The various types differ in the diameter 
size and the pulses before warmup. 
Special coils: custom designed coils as well as modifications to existing coils, ranging from 
extending the coil cable, placebo coils, to a complete change of geometry of the coil. 
Class II 
Neurostar® MS System Neurostar/ 
Neuronetics 
%MT Range: 80% to 140%MT 
Pulses per second Range: 0.1-30 pps 
Stimulation Time Range (i.e. pulse train duration): 1-600 seconds for 1 pps, 1-20 seconds for >1 pps 
Inter-train Interval Range: 0-60 seconds for 1 pps, 10-60 seconds for > 1 pps 
Pulses per treatment session: Maximum: 5000, Nominal: 3000 
Coil type: ferromagnetic core 
Class II 
Abbreviations: MT motor threshold, pps pulses per second, UMDNS Universal Medical Device Nomenclature System 
Sources: product descriptions published on the websites of the manufacturers [31-36]. 
Class II and IIa medical devices are active therapeutic devices intended to administer or exchange energy. Devices classified by this rule are mostly electrical equipment used in surgery  
(such as lasers and surgical generators), devices for specialised treatment (such as radiation treatment), and stimulation devices, although not all of them can be considered delivering dangerous  
levels of energy considering the tissue involved [37].  
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Comparators 
Sham stimulation is defined as comparator in the scope of this assessment. 
Sham stimulation is delivered either with regular TMS coil that is tilted so 
that an edge remains in contact with the head or with a purpose-built sham 
TMS coils that resemble regular TMS coils but is equipped with a magnetic 
shield that attenuates the magnetic field. If a tilted regular coil is used, a sham 
TMS pulse produces a clicking sound that is very similar to an active TMS 
pulse and, depending on the geometry and orientation of the TMS coil, the 
magnetic field can still be sufficiently strong to result in somato-sensory ef-
fects. This variant was used in many clinical studies, but the current gold 
standard seems to be the purpose-built coil combined with surface electrodes 
for skin stimulation [38].  
The critical question is still whether blinding success can be achieved with 
the combined coil. Several very similar sham TMS setups were developed and 
their blinding success was evaluated. The general finding of these studies was 
that electrical stimulation of the skin resulted in somato-sensory effects that 
were very similar to active TMS if the stimulation intensity was individually 
calibrated. However, the skin sensation was more electric so that experienced 
participants might have been able to distinguish between active and sham 
TMS. Indeed, naïve participants have been found to mistake sham TMS for 
active TMS, whereas experienced participants can tell them apart. These re-
sults indicate that sham TMS approaches might suffice for clinical applica-
tions where patients are generally naïve to differences between active and 
sham TMS, in which case a blind research design is achieved (operator, the 
patient and the investigators are blinded). Nevertheless, the sham approach-
es require further developments and efficient blinding should be controlled 
for by systematically questioning the patients about their guess as to group al-
location [5, 38]. 
ECT involves the induction of a convulsion (seizure) by the application of 
electrical current to the brain. It is delivered under general anaesthesia and 
application of a muscle relaxant. The exact mechanism of action is still un-
clear and it is under investigation, but the most likely hypothesis includes 
seizure-induced changes in neurotransmitters, neuroplasticity, and functional 
connectivity. Treatment parameters include electrode position, electrical in-
tensity, pulse width, and duration. The most common electrode placements 
are bilateral, or right unilateral. The electrical intensity is based on the min-
imum intensity to produce a generalized seizure, called the seizure threshold. 
ECT usually uses brief pulse width (0.25 to 2 ms) and duration (0.5 to 8 or 
more seconds) [11]. ECT is a complex intervention and its efficacy and safe-
ty are affected by a number of parameters including the placement of elec-
trodes, dosage and waveform of the electrical stimulus, and the frequency 
with which ECT is administered [12]. 
As regards to mortality ECT is a safe procedure with a very low mortality rate 
(1 death per 73.440 treatments), approximating the risk of general anaesthe-
sia. The absolute contraindication for ECT is intracranial hypertension, how-
ever, patients with myocardial ischemia, cardiac arrhythmias, space-occupy-
ing cerebral lesion, increased intracranial pressure, recent cerebral haemor-
rhage, unstable vascular aneurysm or malformation, abdominal aortic aneu-
rysms, pheochromocytoma, and class 4 or 5 anaesthesia risk are also more 
likely to be harmed as they carry a higher morbidity and mortality risk [11].  
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ECT is frequently associated with cognitive impairment, including transient 
disorientation when recovering from ECT sessions, retrograde amnesia, and 
anterograde amnesia, and mild, short-term impairment in memory and other 
cognitive domains during and after treatment with ECT. However, these im-
pairments are normally transient and the cognitive functioning recovers with-
in weeks or months after the acute course of ECT [4, 11]. 
[A0020] – For which indications has rTMS received marketing 
authorisation or CE marking? 
TMS is indicated for patients with unipolar major depression who have failed 
to achieve satisfactory improvement from prior antidepressant medication in 
the current episode. Detailed information on the regulatory status of the in-
cluded products is included in Table A-11 in Appendix 2. 
[B0002] – What is the claimed benefit of rTMS in relation  
to sham stimulation and ECT? 
rTMS is a non-invasive procedure in which the patient remains awake and 
alert throughout. There is no post-session recovery needed, the patient can 
resume normal activities immediately. No cognitive side-effects have been 
reported with rTMS, unlike with ECT [4, 11].  
[B0003] – What is the phase of development  
and implementation of rTMS, sham stimulation and ECT?  
TMS was developed by Barker in 1985 in Scheffield, England. He created a 
focal electromagnetic device with sufficient power to induce currents in the 
spine. He also realized that the device was appropriate for the direct and non-
invasive stimulation of the brain. The device was first used in research and 
then became a therapeutic device [4]. The first device to gain FDA approval 
was NeuroStar TMS Therapy System in 2008 [39].  
Currently, the use of functional imaging (PET and resting fMRI) or neuro-
psychological techniques (EEG) is a new development to help in better pre-
dicting the response to rTMS treatment through evaluating the cortical excit-
ability. They permit direct quantification of evoked cortical activation gen-
erated by single TMS pulses. Therefore, it can be used as a marker of thera-
peutic response, it may help to optimize the treatment effects, to better un-
derstand the pathopsychology of the disorder and the mechanism of action 
of the technology [5, 7, 40].  
Another novelty currently tested is an oscillating weak TMS device, which 
aims to enable home delivery of TMS (under a doctor’s prescription) that is 
unlikely to cause seizures [30].  
There are several experimental techniques tested representing variations of 
rTMS, including the following: 
 Accelerated rTMs: instead of the one session with 3,000 pulses per day 
administration of rTMS, two sessions with 1,500 pulses each are ad-
ministered daily. 
 High-dose rTMS: more pulses than usual over the same treatment 
time frame (e.g. 6,000 pulses per session). 
 Theta burst rTMS: 50 Hz burst of rTMS delivered five times per second. 
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 Deep rTMS: brain structures are stimulated beneath the superficial 
prefrontal cortex using a magnetic coil (H-coil) that can induce a mag-
netic field with a deeper and wider distribution than standard figure 
8 coils.  
 Bilateral rTMS: HF of the left DLPFC stimulation is combined with 
LF of the right DLPFC stimulation (either simultaneously or sequen-
tially). 
 Syncronized rTMS: the stimulation is synchronized to an individual’s 
alpha frequency, which allows the use of lower magnetic field energy 
leading to greater patient comfort during stimulation. 
 Priming rTMS: delivering HF-TMS before LF-TMS to try to boost 
LF-TMS effectiveness. [8]. 
 
Comparators 
Sham stimulation coils have been marketed since the 2000’s, based on differ-
ent technical solutions. The sham coils used to produce almost no scalp sen-
sations, therefore, even less perceptive patients might have found out if they 
received active or sham treatment. The first development of sham coils in-
cluded a system that produced a cutaneous electrical stimulation.  
ECT has been in practice since the 1930s. The practice of ECT has under-
gone a number of modifications since its introduction and it has established 
standards. With the present-day technique, many of the previously significant 
medical complications of ECT have been eliminated [13]. 
[B0004] – Who administers rTMS, sham stimulation  
and ECT and in what context and level of care are they provided? 
A physician should perform the initial motor threshold determination and 
identify the appropriate coil location for subsequent treatments. The indi-
vidual daily treatment sessions, including subsequent motor threshold deter-
minations, can be administered by a nurse, physician assistant, or medical 
assistant. That applies as long as the physician is accessible via telephone in 
case of emergency and as long as he supervises the treatment through evalu-
ating the clinical course of the daily treatment sessions to determine if any 
modifications are necessary and to respond to any possible adverse events. 
Manufacturers’ training should be provided to all operators both on the tech-
nology itself and on the specific TMS system to be used. In addition, all per-
sonnel should have cardiopulmonary or basic life support training to be able 
to recognize and initially manage generalized seizures. The operator should 
provide updates, progress notes, or both every day to the prescribing physi-
cian for monitoring purposes. Mood scales are recommended to be used to 
document the changes in depression [7, 8, 41].  
rTMS is administered on an ambulant setting in a hospital or appropriately 
equipped outpatient clinic. One session is delivered daily, 5 times a week. 
Administration is labour-intensive and time-consuming for both the patients 
and clinicians. [4, 7]. A session lasts typically 30-40 minutes [8]. The course 
of rTMS treatment lasts from 10 to 30 sessions. There is, however, no vali-
dated standard protocol on how many sessions are needed to reach maximal 
effect. Clinical experience suggests 20 sessions before declaring treatment fai-
lure [11].  
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ECT requires a number of different specialists to be involved. The staff should 
comprise of an anaesthesiology nurse, a psychiatric nurse, plus 4 untrained 
nurses or nursing assistants, an anaesthesiologist, a psychiatrist, and an op-
erating department assistant. According to clinical experts, one ECT session 
takes about 25-40 minutes (5-10 minute treatment and 20-30 minutes prepa-
ration and post-treatment routine). ECT may only be performed by a psychia-
trist who is experienced with this treatment intervention [20]. ECT is typi-
cally conducted on inpatients, but outpatient (ambulatory) ECT practice is 
growing, largely because of its increasing use for continuation and mainte-
nance treatment [23]. ECT is typically delivered 2-3 times per week and the 
number of treatments sessions to achieve response/remission ranges between 
6 and 15. More than 3 treatments per week are not recommended as they are 
associated with higher frequency of cognitive side effects [11].  
[B0008] – What kind of special premises  
are needed to use rTMS, sham stimulation and ECT? and 
[B0009] – What equipment and supplies  
are needed to use rTMS, sham stimulation and ECT? 
For the use of rTMS a silent room equipped with a reclining chair is needed. 
The equipment consists of a generator and a coil. Sometimes, neuronavigation 
guided by MRI is used to localize the prefrontal cortex. During the treatment 
session, the magnetic pulse produces a clicking sound, which varies with dif-
ferent coil designs and intensity. For hearing protection, the use of ear plugs 
or other hearing protection capable of at least 30 dB sound reduction is rec-
ommended both for the patient and the treatment provider. The room where 
the treatment is administered should be equipped with oxygen and anticon-
vulsant medications in case a seizure occurs. Besides the stimulator and the 
coil, no further accessories are required. Optional accessories are e.g. a cap to 
indicate the patient’s therapy hot spot, an EMG device, a positioning arm for 
the coil, or a vacuum cushion to stabilise the patient’s head [7, 8, 10]. 
ECT is delivered in a controlled clinical setting under general anaesthesia and 
after application of a muscle relaxant. The minimum requirement for ECT 
facilities is three rooms: a quiet, comfortable waiting area, a treatment room, 
and a recovery area of a sufficient size to accommodate the rate and number 
of patients treated per session. The rooms should contain the necessary equip-
ment to monitor patients and treat them in an emergency. The machines cur-
rently recommended for use by the APA and the Royal College of Psychia-
trists are Mecta SR2 and JR2, Thymatron-DGx and Ectron series 5A Ectonus 
machines [12]. 
[A0021] – What is the reimbursement status of rTMS? 
Detailed information on the reimbursement status/recommendations can be 
found in Table A-12 and Table A-13 in Appendix 2. 
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4 Health problem and current 
use of the technology (CUR) 
4.1 Results 
4.1.1 Overview of the disease or health condition 
[A0002] – What is treatment-resistant major depressive disorder? 
Treatment-resistant major depressive disorder (TRD) often refers to major 
depressive disorder (MDD) that does not respond satisfactorily to at least two 
trials of antidepressant monotherapy. However, the definition has not been 
standardized yet. Defining treatment resistant depression is also complicat-
ed due to the lack of consensus in describing acute antidepressant responses. 
In many studies, response is classified according to the amount of improve-
ment from baseline on the depression rating scale.  
 No response – improvement < 25 percent 
 Partial response – improvement 25 to 49 percent 
 Response – improvement ≥ 50 percent, but less than the threshold 
for remission 
 Remission – depression rating scale score less than or equal to a  
specific cut-off that defines the normal range (score on the HRSD-17 
or on the MASD ≤ 7) [1]. 
[A0003] – What are the known risk factors  
for treatment-resistant major depressive disorder? 
Treatment resistant, unipolar major depression has been associated  
with many risk factors, including: 
 Comorbid general medical disorders like coronary heart disease,  
hypothyroidism, diabetes, HIV infection etc. 
 Chronic pain 
 Medications (e.g. interferons and glucocorticoids) 
 Comorbid psychiatric disorders 
 Anxiety: affects the speed to response to medication and remission 
of symptoms. A history of any anxiety disorder predicts a signifi-
cantly slower rate of recovery. Thus, the clinical evaluation of treat-
ment-resistant depression must include screening for anxiety symp-
toms and disorders. 
 Substance abuse: acute and chronic effects of substances may cause 
or worsen depressive symptoms, affect compliance, and contribute 
to treatment resistance. Furthermore, the presence of a mood dis-
order increases the likelihood of a substance use disorder or makes 
the patient more prone to relapse. 
 Personality disorders: evidence indicates that depressed patients with 
personality disorders are less responsive to antidepressant therapy 
compared to patients with no Axis II pathology and have a worse 
prognosis for long-term outcomes [3]. 
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 Severe intensity of depressive symptoms 
 Suicidal thoughts and behaviour 
 Adverse life events (e.g. marital discord) 
 Early age of onset of major depression (e.g. age<18 years) 
 Recurrent depressive episodes 
 Low socioeconomic status 
 Gender (female) 
 Family history  
Studies have found that the association of other factors with treatment  
resistance is inconsistent and thus less clinically useful [1, 3]. 
[A0004] – What is the natural course of treatment-resistant  
major depressive disorder? 
Symptoms of MDD develop over days to weeks. In some individuals, prodro-
mal symptoms, including generalized anxiety, panic attacks, phobias, or de-
pressive symptoms that do not meet the diagnostic threshold, may occur over 
the preceding several months. Yet in others, MDD may develop suddenly as 
a result of severe psychosocial stress. The duration of a major depressive epi-
sode also varies. In treated patients, the median time to recovery is approxi-
mately 20 weeks; in untreated patients, however, it can last 6 months or long-
er. Major depressive episode is unremitting in 15% of patients and recurrent 
in 35%. About half of the patients with a first onset episode recover and have 
no further episodes. After three episodes, the risk of recurrence is close to 
100% in the absence of prophylactic treatment. The course of recurrent ma-
jor depressive episodes also varies [20]. 
 
4.1.2 Effects of the disease or health condition 
[A0005] – What are the symptoms and the burden  
of treatment-resistant major depressive disorder for the patient? 
The most serious complication of a major depressive episode is suicide (in-
cluding suicide/homicide). MDD is also associated with significant medical 
comorbidity and it complicates recovery from other medical illnesses such as 
myocardial infarction [20].  
Comorbid conditions are more prevalent among TRD patients. They include 
joint, limb, or back pain, hypertension, dyslipidaemia, malaise or fatigue, anx-
iety, and personality disorder. Suicidal ideation is estimated to a rate of 15% 
± 8% in TRD patients, 6% in treatment-responsive depression, and 1% in the 
general population [42]. Medication-related adverse events like decreased sex-
ual desire, orgasmic dysfuntion, blurred vision, dissociative reactions, ataxia, 
mixed states (dysphoric mania or agitated depression), tremor, and nausea 
also burden MDD patients.  
[A0006] – What are the consequences of treatment-resistant  
major depressive disorder for the society? 
The WHO ranks MDD among the diseases that are most debilitating to the 
society, partly because of the increased utilization of health care resources, 
diminished quality of life, and indirect personal and societal costs associated 
with it [43].  
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Beyond the impact of MDD on the patient alone, it also affects the patient’s 
social network, including children, spouse, parents, friends, colleagues, and 
significant others. If the patient is a parent, the disorder may affect his or 
her ability to fulfil parental role expectations and increase the likelihood of 
children becoming depressed as well. Major depressive episodes are associ-
ated with occupational dysfunction, including unemployment, absenteeism, 
and decreased work productivity. In fact, in terms of the level of disability for 
the population as a whole, MDD is second to chronic back and neck pain in 
disability days per year in the WHO ranking [20, 43]. 
The annual added social cost of MDD consists of the frequent visits to med-
ical facilities, higher rate of hospitalization, higher costs of antidepressant 
medications, psychotherapy, other therapies, and indirect costs of lost produc-
tivity for both patients and their family members [42, 44]. 
 
4.1.3 Current clinical management  
of the disease or health condition 
[A0024] – How is treatment-resistant major depressive disorder 
currently diagnosed according to published guidelines and in practice? 
MDD is currently diagnosed by using the Diagnostic Criteria for Major De-
pressive Disorder and Depressive Episodes (DSM-IV-TR) (details in Appen-
dix 4) 
Because of differences in treatment, the diagnosis of unipolar major depres-
sion should be confirmed and other diagnosis such as bipolar depression or 
dysthymic disorder ruled out. The treatment history of patients who may be 
treatment resistant is usually assessed through a clinical interview as well as 
a review of the medical record [1].  
As underpinned by several studies, approximately 50% of MDD patients do 
not benefit from the first course of antidepressant treatment [4]. There is some 
variability in the number and type of treatment failures that constitute to the 
presence of TRD. Many guidelines refer to TRD as patients who have failed 
to respond to at least two adequate trials of antidepressant medications from 
different drug classes. In addition, various TRD staging models have been 
designed as a means of measuring TRD severity [6]. Thase and Rush devel-
oped a staging system that is an aid in the application of treatment strategies 
in a stepwise fashion.  
 
Figure 4-1: Thase-Rush Treatment-Resistant Depression (TRD) Staging Method.  
Source: [44] 
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In the diagnostic process, the first step is to rule out pseudoresistance. Fac-
tors to be considered in this process can be divided into three areas: physician 
factors, patient factors, and accuracy of the diagnosis. The physician factors 
mean the prescribing habits of doctors (not increasing the dosage levels or dis-
continuing the antidepressant before an adequate trial has been completed 
are two major causes that contribute to pseudoresistance). Patient factors in-
clude premature discontinuation of medication, unusual pharmacokinetics, 
patient noncompliance, which often remains hidden. It has been estimated 
that up to 20% of TRD might be attributable to non-adherence. Frequent ex-
amples for the third factor, misdiagnosis, are substance-induced mood disor-
ders secondary to alcohol, substances, or medications, and depression second-
ary to medical conditions such as hypothyroidism. The presence of unrecog-
nized depressive subtypes should also be carefully evaluated because they 
need a different treatment approach [3, 44].  
From a healthcare provider point of view, clinicians must work through the 
treatment algorithm in a timely manner and ensure that the patient adheres 
to the treatment strategy before pronouncing it resistant to a strategy and go-
ing on with the subsequent one. The duration of an adequate trial should last 
6-12 weeks before deciding if a regimen has sufficiently relieved symptoms. 
For patients who show little improvement (less than 25% reduction of base-
line symptoms) after 4-6 weeks, next step treatment is administered [45].  
[A0025] – How is treatment-resistant major depressive disorder  
currently managed according to published guidelines and in practice? 
Many clinical practice guidelines (CPG) address depression management. 
Nevertheless, despite how common it is that depressed patients experience 
at least two unsuccessful treatment attempts, at this point in time, no single 
guideline has treatment-resistant depression as its main (or even secondary) 
topic. The available guidelines are presented in Table A-1 and Table A-2 in 
Appendix 1.  
From the above, it is clear that there is a lack of internationally accepted 
treatment algorithm both for the treatment of MDD generally and for the 
management of TRD.  
Summarizing the similarities in the guidelines, the treatment strategies for 
patients with unipolar major depression who do not respond adequately to 
initial treatment with an antidepressant medication include five main strat-
egies [46]: 
1. optimization: aximize dose for adequate time and check serum levels of 
prescribed antidepressant if supported by evidence based data 
2. switching: changing from one ineffective antidepressant to similar or 
different class of antidepressant; selective serotonin reuptake inhibitors 
(SSRI)/serotonin-norepinephrine reuptake inhibitors (SNRI) to tricy-
clic antidepressants (TCA), monoamine oxidase inhibitors (MAOI), 
and atypical antipsychotics with antidepressant properties 
3. combination: adding another antidepressant from different classes, eg. 
TCA + MAOI, SSRI + TCA, SSRI + atypical antidepressant, SSRI + 
buspirone, etc 
4. augmentation: adding a second agent that is not an antidepressant, but 
may enhance the antidepressant effect of the drug in question, eg, lith-
ium, thyroid hormones, pindolol, psychostimulants, atypical antipsy-
chotics, sex hormones, anticonvulsants/mood stabilizers, and dopamine 
agonists 
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5. somatic therapies: ECT, vagus nerve stimulation (VNS), rTMS, magnet-
ic seizure therapy (MST), deep brain stimulation (DBS), and transcra-
nial direct current stimulation (TDCS) 
Adapted from the guidelines, the following treatment hierachy was considered 
for the assessment: 
First-line treatment of MDD is usually an SSRI and psychotherapy. If the 
patient is resistant to this treatment, the first strategy is optimization.  
Second-line treatment strategies: for mild to moderate depression  
that is treatment resistant 
1. Switching antidepressants: many options are available,  
the most common ones: 
 SNRIs e.g. venlafaxine 
 Atypical antidepressants e.g. buproprion, mirtazapine 
 TCAs e.g. imipramine, nortriptyline 
 MAOIs e.g. tranylcypromine, phenelzine 
 When choosing the antidepressant, the treatment history, comorbid 
general medical conditions, patient preference, and costs are also 
considered.  
2. Augmentation: for patients who obtain little symptom relief (reduction 
of baseline symptoms by less than 25%) augmentation is recommended 
as the second-line treatment. The most common options for augmen-
tation are: 
 Second-generation antipsychotics 
 Lithium 
 Thyroid hormone 
 Second antidepressant from a different class 
Third-and subsequent-line treatment strategies: for patients who do not  
respond satisfactorily to several courses of first- and second-line treatments:  
 rTMS 
 ECT 
 Other somatic therapies e.g. VNS, DBS 
 Augmentation with omega-3 fatty acids, folate,  
S-adenosyl methionine, or pramipexole [44, 45, 47]. 
 
4.1.4 Target population 
[A0007] – What is the target population of this assessment? 
Patients with unipolar, treatment resistant major depression are the target 
population of the current assessment. TRD is typically limited to patients who 
meet criteria only for unipolar MDD [44]. It is important to differentiate be-
tween unipolar and bipolar depression because the pathopsychology and the 
treatment mechanism to be applied differ. Antidepressant interventions are 
associated with a risk of triggering mania in bipolar depression. Currently, 
there is no sufficient data to establish recommendations regarding rTMS for 
bipolar depression [5].  
5.  somatische Therapien 
1st-Line Therapie: SSRI 
2nd-Line Therapie: 
Änderung in 
Antidepressiva, 
Kombinationstherapien, 
Zusatz von Wirkstoffen 
die Antidepressiva 
Wirksamkeit erhöhen 
3rd-Line Therapie:  
rTMS, ECT und andere 
somatische Therapien 
PatientInnen  
mit unipolarer, 
therapieresistenter 
Depression 
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[A0023] – How many people belong to the target population? 
The prevalence of unipolar treatment resistant major depression is not clear 
due to the lack of internationally acknowledged and standardized definition. 
However, based on the Thase-Rush TRD Staging Model, there are reasonable 
estimates available for Stage 1 and 2 TRD. The prevalence estimate varies ac-
cording as response or remission is used as the criterion outcome. 
 If response is used as outcome, according to the definition of response, 
the prevalence rate for Stage 1 patients is 30-40% or 50% (unrespon-
sive to or do not benefit from the first trial of antidepressant medica-
tion) [3-5, 44]. Stage 2 TRD (failure to achieve response criteria after 
2 courses of adequate treatment) may be estimated to occur in approx-
imately 15-35% of patients [5, 6, 44].  
 If remission is used as outcome, based on the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study, the prevalence 
rate for Stage 1 TRD (patients who fail to obtain a complete remission 
after one adequate trial of antidepressant) has been reported to be 60 
to 70% [1, 44].  
In Austria, 120,000 to 140,000 patients per year are diagnosed with depression, 
from which only 24,000 to 36,000 are treated sufficiently and achieve remis-
sion [48]. From the rest 84,000 to 116,000 patients, response will not occur in 
8,400 to 17,400 people, taking the 10-15% estimation into account.  
[A0011] – How much is rTMS utilized?  
We found no data and were not provided with information on the utilization 
of rTMS by the manufacturers.  
 
Prävalenz der TRD 
unbekannt 
Österreich:  
120.00-140.000 
PatientInnen mit 
Depression;  
8.400-17.400 TRD 
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5 Clinical effectiveness (EFF) 
5.1 Results 
5.1.1 Included studies 
rTMS vs sham 
23 studies met the inclusion criteria in the HQO report. We found additional 
two RCTs [14, 15] that met our inclusion criteria and are included in the pre-
sent analysis. One of them [15] is the 6 month follow-up of a study included 
in the HQO report [16]. A total of 1,180 patients were analysed in the studies, 
615 in the active rTMS arm and 565 in the sham arm. The HQO report did 
not include two studies [49, 50] that failed to comply with the safety guide-
lines in terms of the maximum duration of trains and number of pulses de-
livered. A few other studies [16, 51-53] also slightly exceeded the maximum 
duration of trains and the number of pulses delivered, but they applied low-
er frequencies. Therefore, they were kept in the analysis. A few studies used 
intensity below 80% MT, which is not addressed in the safety guidelines [7]; 
they were also kept in the analysis.  
17 studies reported depression scores at baseline and at the end of treatment. 
Baseline depression scores in the rTMS group measured on the HDRS-17 
ranged from 19 to 28, and in the sham group it ranged from 21 to 27. In 11 
studies, the mean depressive symptoms at baseline were above 25, indicating 
severe depression. In the remaining studies, the mean depression score ranged 
from 19 to 24, indicating a moderate depression severity. In 16 studies, pa-
tients had failed to benefit from two or more antidepressant medications, nine 
studies also included patients who had failed to improve after at least one 
antidepressant medication. In 17 studies, patients received rTMS while re-
ceiving antidepressants and in eight studies, patients did not receive any an-
tidepressants during the treatment. 14 studies did not include any bipolar pa-
tients, 10 studies included also bipolar, but only to the extent of 1.7 to 16.7% 
of all participants of the study, and one study did not report on the inclusion 
of bipolar patients. The frequency of stimulation ranged from 5 to 20 Hz, the 
intensity was between 80 and 120% of patients’ MT. The number of trains per 
session ranged from 15 to 75, and the train duration was between 2 to 10 s. The 
number of pulses per session ranged from 800 to 3,000 and the total number 
of pulses during rTMS treatment ranged from 8,000 to 90,000. The inter-train 
interval varied across studies and ranged from 22 to 58 s. All studies used 
the figure 8 coil.  
Details of the RCTs can be found in evidence tables Table A-5  
in Appendix 1. 
1 sekundär Studie  
mit 23 RCTs und  
2 zusätzliche RCTs 
erfüllten 
Einschlusskriterien 
 
1.180 PatientInnen 
615 bekamen rTMS 
Therapie 
Ausgangswerte  
der HDRS-17 Skala 
variierten von  
19-28 in der rTMS 
Gruppe und 21-27 in  
der Kontrollgruppe 
 
in 17 Studien erhielten 
PatientInnen rTMS und 
Antidepressiva;  
in 8 Studien nur  
rTMS Therapie 
 
Stimulationsfrequenz 
von 5-20 Hz, 
15-75 Stimulationen  
per Sitzung  
 
alle Studien 
verwendeten  
‚figure 8’ Spulen 
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rTMS vs ECT 
Six studies were found by authors of the HQO report that compared rTMS 
with ECT. Most of the studies were conducted in the early 2000s. The total 
number of patients was 266, 133 in each arm. Two of the studies reported 6 
month follow-up data as well [17, 18]. Four studies reported that the outcome 
assessors were blinded, in two studies they were not blinded, of which one 
study [54] did not comply with the safety standards and therefore was not in-
cluded in the meta-analysis. In two studies patients were taking medication 
during the trial, in two studies patients were completely medication-free and 
in two trials patients were allowed to take lorazepam or clonazepam during 
the trial. Two studies reported that patients failed to benefit from two antide-
pressant trials, while two studies did not state the number, but include how 
many patients failed ECT before the trial, one study reported that patients 
failed at least one antidepressant trial and one study reported the number of 
failed antidepressants in the current episode. Baseline depression scores 
measured on the HDRS-17 ranged from 24 to 26 in the rTMS group and 25 
to 28 in the ECT group. Only one study reported on suicide scores. The char-
acteristics of the intervention varied also, one study used 20 Hz frequency 
stimulation, four studies used 10 Hz and one study did not report on the fre-
quency used. The intensity of the stimulation ranged from 90 to 110% of the 
MT, the number of trains from 20 to 30-35, the train duration from 2 to 10 s, 
the intertrain interval from 20 to 55 s, the pulses per session from 408 to 
2,500 and the number of sessions from 10 to 20. Hence the total number of 
pulses delivered also ranged from 4,080 to 50,000. All studies reported that 
they used a figure 8 coil.  
Details of the RCTs can be found in evidence tables Table A-6  
in Appendix 1. 
 
5.1.2 Mortality 
[D0001] – What is the expected beneficial effect of rTMS on mortality? 
Three studies in the HQO report included data on suicide scores or suicidal 
ideations. We identified no new studies reporting on suicide. One of these 
studies [19] compared rTMS with ECT. The suicide score decreased from 
mean (SD) 1.5 (0.8) to 1.2 (0.9) as measured by BDI (Beck depression inven-
tory) and from 1.9 (1.3) to 1.4 (1.2) as measured by HDRS in the rTMS group. 
In the ECT group the decrease was significantly greater: from baseline 1.4 
(1.0) to 0.5 (0.7) as measured by BDI and 2.3 (1.1) to 0.3 (0.5) as measured by 
HDRS (p<.001). The results suggest that ECT decreases suicidal scores more 
than rTMS. The other two studies compared rTMS with sham rTMS [16, 55] 
and reported that no death occurred, but a single suspected suicide gesture in 
the sham group [16] and in the active stimulation group [55] was observed 
respectively.  
 
6 Studien verglichen 
rTMS und ECT 
 
insgesamt  
266 PatientInnen,  
133 pro Interventions 
und Kontrollgruppe 
 
2 Studien ohne 
Begleitmedikation 
 
Ausgangswerte  
der HDRS-17 Skala 
variierten von 24-26 in 
der rTMS Gruppe und 
25-28 in der ECT Gruppe 
 
Stimulationsfrequenz 
von 10-20 Hz, 
20-35 Stimulationen  
per Sitzung  
 
alle Studien 
verwendeten  
‚figure 8’ Spulen 
3 Studien berichteten 
Daten zu Suizidalität 
 
rTMS vs ECT: höhere 
Verminderung bei ECT 
 
jeweils ein 
Selbstmordversuch in 
der rTMS und der 
Kontrollgruppe 
Clinical effectiveness (EFF) 
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5.1.3 Morbidity 
[D0005] – How does rTMS affect symptoms and findings  
(severity, frequency) of treatment-resistant major depressive disorder? 
rTMS vs sham 
The mean difference in depression scores was reported in 15 studies that com-
plied with the safety standards. Hence, only data from these studies were in-
cluded in the meta-analysis. We found one additional study [14] that met our 
inclusion criteria. Since the authors of the new study didn’t report the stand-
ard deviation, a new meta-analysis for this outcome was not justified. The au-
thors of the HQO report calculated the weighted mean difference of depres-
sion scores from baseline to the end of treatment, which is 2.31 points (95% CI 
1.19-3.43), p<.001) favouring rTMS. There was a low degree of heterogenei-
ty among studies (I2=19.8%, p=.223). On average, rTMS reduced depression 
scores by about 2.31 points more than sham, which is below the mean value 
that was deemed a priori clinically important (threshold of 3.5 points). The 
standardized mean difference was calculated using Cohen’s method and the 
effect size was 0.33 (95% CI 0.17-0.5, p<.001) with a low degree of heteroge-
neity among studies (I2=14.7%, p=.289).  
 
Figure 5-1: Weighted mean difference: rTMS vs sham; Source: HQO 
rTMS um durchschnittl. 
2.31 Punkte höhere 
Verbesserung in 
Depressionsskala 
 
jedoch erst ab mehr als 
3.5 Punkten klinisch 
relevant 
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Figure 5-2: Standardized mean difference: rTMS vs sham; Source: HQO  
rTMS vs ECT 
Four studies reported depression scores at baseline and at the end of treatment 
(one study reported mean differences only, without standard deviation data). 
The weighted mean difference was -5.97 points (95% CI -11.00 to -0.94, p= 
.020) in favour of ECT. The degree of heterogeneity among studies was high 
(I2=72.2%, p=.013). This point value is higher than the 3.5 points, which was 
defined a priori as clinically important.  
 
ECT um 5.97 Punkte 
Verbesserung in 
Depressionsskala, 
Unterschied klinisch 
relevant;  
hohe Heterogenität  
der Studien 
Clinical effectiveness (EFF) 
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Figure 5-3: Weighted mean difference: rTMS vs ECT; Source: HQO  
The standardized mean deviation was calculated using Cohen’s method, the 
effect size was -0.67 (95% CI -1.23 to -0.10, p=.021) in favour of ECT, which is 
considered a large effect size. The heterogeneity among studies was high   
(I2=70.6%, p=.017).  
 
Figure 5-4: Standardized mean different: rTMS vs ECT; Source: HQO 
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[D0006] – How does rTMS affect progression (or recurrence)  
of treatment-resistant major depressive disorder?  
rTMS vs sham 
Remission rates were reported in the HQO report in 13 studies. The pooled 
risk ratio has been calculated only for the ones that complied with the safety 
standards, hence, two studies [49, 50] were excluded from the analysis. The 
one RCT [14] that was identified in the update of the HQO report also report-
ed on remission. Therefore, we calculated the pooled risk ratio for 12 studies, 
which was 2.16 (95% CI 1.42-3.29, p=.0003). This pooled estimate suggests 
that patients may be twice more likely to experience remission with rTMS 
than with sham. No heterogeneity was observed among the studies (I2=0.0%, 
p=.7164). Note that in Fitzgerald 2003 [56], no patients achieved remission 
in either arm and therefore, it did not contribute to the summary estimate.  
 
Figure 5-5: Remission rate at the end of treatment: rTMs vs sham 
The risk difference, which, in this case could be named benefit difference for 
remission, comparing rTMS with sham, was 0.10 (95% CI, 0.03-0.17, p=.0048). 
That indicates a 10% benefit increase in remission rate favouring active treat-
ment over sham. The heterogeneity among studies was moderate (I2=58.9%, 
p=. 005). This means that patients treated with active rTMS are more likely 
to achieve a remission from their disease than the sham group. 
Remissionsraten:  
aus 12 Studien,  
RR: 2.16 (1.42-3.29) 
10 % höhere 
Remissionsraten in 
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Figure 5-6: Risk difference for remission rate: rTMS vs sham 
Response rates were reported in 20 studies in the HQO report, but only 18 
studies complied with the safety standards (two studies [49, 50] were exclud-
ed from the meta-analysis). Additionally, the one RCT [14] that was identified 
in the update of the HQO report also reported on response. Hence, we calcu-
lated the pooled risk ratio for response rate across 19 studies, which was 1.82 
(95% CI 1.18-2.82, p=.0068). This pooled estimate suggests that patients may 
be twice more likely to experience treatment response with rTMS than with 
sham. There was a moderate degree of heterogeneity among studies (I2=50%, 
p=.01).  
The benefit difference for response was 0.13 (95% CI 0.05-0.22, p= .0014) 
indicating a 13% increase in response rate comparing rTMS with sham. There 
was a high degree of heterogeneity among studies (I2=74.1%, p<.0001). Note 
that in Holtzheimer 2004 [57] and in Fitzgerald 2003 [56], no patients re-
sponded to the treatment in either arm, therefore, it did not contribute to 
the summary estimate. 
Ansprechrate:  
aus 19 Studien, 
RR 1.82 (1.18-2.82) 
13 % Verbesserung der 
Ansprechrate bei rTMS 
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Figure 5-7: Response rate at the end of treatment: rTMS vs sham 
 
Figure 5-8: Risk difference for response rate: rTMS vs sham 
Clinical effectiveness (EFF) 
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rTMS vs ECT 
Only three of the six studies that complied with safety standards in the HQO 
report included data on remission and, therefore, were included in the pooled 
risk ratio calculation, which was 1.44 (95% CI 0.64-3.23, p=.375) at the end 
of treatment, favouring ECT. However, these results are not significant. There 
was a high degree of heterogeneity among studies (I2=69.1%, p=.039). The 
pooled risk ratio did not reach significance level, as the studies used differ-
ent ECT protocols and were very heterogeneous. 
 
Figure 5-9: Remission rate: rTMS vs ECT; Source: HQO 
Three of the six studies that complied with the safety standards reported on 
response rate in the HQO report. The pooled risk ratio for response at the end 
of treatment was 1.72 (95% CI 0.95-3.11, p=.072) favouring ECT. There was 
again a high degree of heterogeneity among studies (I2=60.6%, p=.079). While 
the effect is not statistically significant, this pooled estimate would suggest a 
higher response with ECT than with rTMS. The benefit increase was 29% 
(95% CI 0.07-0.5, p=.010) favouring ECT.  
Remissionsrate aus  
6 Studien, 
kein signifikanter 
Unterschied zwischen 
rTMS und ECT 
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Figure 5-10: Response rate: rTMS vs ECT; Source: HQO 
[D0011] – What is the effect of rTMS on patients’ body functions? and  
[D0016] – How does the use of rTMS affect activities of daily living? 
Only one study [15] assessed changes in performing activities of daily living 
and patients’ body functions within the general QoL assessment measured by 
the SF-36 tool physical functioning, bodily pain, vitality, and role physical 
subscales. On the role physical subscale, the improvement was not statisti-
cally significant either at 4- and 6-week or at 6 month time points. The phys-
ical functioning improvement was statistically significant from the baseline 
score of 45.9 (10.5) to 47.3 (9.6) at week 6 (p=0.019) in the intervention group, 
while from baseline 43.2 (11.3) to 44.6 (10.5) at week 6 (p=0.043) in the sham 
group. Bodily pain scores improved from baseline 43.5 (9.5) to 44.7 (9.3) at 
week 4 (p=0.038) and to 45.5 (9.2) at week 6 (p=0.002) in the intervention 
group. In the sham group, the improvement was not statistically significant. 
Vitality scores also improved from baseline score of 31.8 (6.8) to 35.1 (9.4) at 
week 4 (p<0.001) and to 36.2 (11.2) at week 6 (p<0.001) in the intervention 
group and from baseline 29.9 (5.9) to 32.6 (8.5) at week 4 (p<0.001) and to 
33.0 (9.4) at week 6 (p<0.001) in the sham group. The long-term outcomes of 
6 months showed no statistically significant improvements in both groups. 
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5.1.4 Health-related quality of life 
[D0012] – What is the effect of rTMS  
on generic health-related quality of life? 
One RCT [15] described QoL outcomes from acute treatment with rTMS. 
There was a statistically significant improvement favouring rTMS for the 
SF-36 subscale scores of general health at both the 4- and 6-week time points 
(from baseline 41.1 (9.8) to 42.4 (9.7) at week 4 (p=0.049), and to 42.6 (10.1) 
(p=0.047) at week 6). Statistically significant improvement favouring rTMS 
was also seen in the Q-LES-Q total score at 4-and 6-week time points (from 
baseline 37.6 (8.2) to 41.3 (10.3) (p<0.001) at week 4 and to 42.4 (12.3) 
(p<0.001) at week 6). These significant improvements on the SF-36 subscale 
of general health and the Q-LES-Q favouring rTMS were also reported at the 
6-months follow up.  
[D0013] – What is the effect of rTMS on disease-specific quality of life? 
The same RCT [15] described QoL outcomes from acute treatment with 
rTMS. There was a statistically significant improvement favouring rTMS for 
the SF-36 subscale scores of mental health at both the 4- and 6-week time 
points (from baseline 25.1 (8.7) to 29.3 (11.3) (p<0.001) at week 4 and to 30.5 
(13.0) (p<0.001) at week 6). The improvement on the SF-36 was predominant-
ly evident in the domains of mental health and general health perceptions.  
 
5.1.5 Satisfaction 
[D0017] – Were patients satisfied with rTMS? 
There were no studies identified that addressed patient satisfaction per se.  
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keine Evidenz verfügbar 
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6 Safety (SAF) 
6.1 Results 
6.1.1 Included studies 
The same secondary studies used in the Clinical Effectiveness domain were 
assessed for inclusion in the Safety domain. We included 1 SR, which was 
the most recently published SR that met our inclusion criteria. The review 
was updated within the present assessment and two additional primary stud-
ies were included.  
rTMS vs sham 
In the updated HQO report, 16 studies reported on adverse events. One study 
provided scores on a side effect scale [58].  
rTMS vs ECT 
Only one study did not report in any form of adverse events [54]. Only one 
study reported on seizure [19, 59], there studies reported on headache [19, 59, 
60], one on device-related insomnia [60], one on transient impairment of work-
ing memory [19] and two studies used side-effects rating scores [18, 61], but 
did not report explicitly which side-effects occurred. No data was reported on 
other adverse events, such as syncope, scalp discomfort and pain, facial 
twitching, vertigo, induced current circuits in implanted devices, transient 
hearing loss, transient induction of hypomania, and mild confusion.  
 
6.1.2 Patient safety 
[C0008] – How safe is rTMS in relation to sham stimulation and ECT? 
rTMs vs sham 
The most common side-effect presented in the studies was headache. The rate 
of headache ranged from 0 to 60% in the rTMS group and 0 to 50% in the 
sham group. Pain or discomfort of the scalp was also frequent with rates rang-
ing from 4.5% to 78.9% in the rTMS and from 0 to 21% in the sham groups. 
The rate of gastrointestinal problems ranged from 7% to 22% in the rTMS 
group and 0 to 22% in the sham group. Eye problems were also common rang-
ing from 5.6% to 21% among rTMS patients and 0 to 1.9% in sham-treated 
patients. Serious adverse events, including seizures did not occur in any of 
the 11 studies that reported on this outcome. Transient impairment of work-
ing memory, another serious adverse event was reported in only two studies 
[62, 63] and occurred in five patients (16.7%) in the rTMS group and one pa-
tient (4.3%) in the sham group. Induced electrical current in implanted de-
vices was not reported in any of the studies.  
rTMS vs ECT 
No serious safety concerns were identified. The most common side-effect was 
headache in rTMS-treated patients with a range of 3-25% across studies. No 
adverse events occurred in ECT-treated patients.  
16 Studien des HQO 
Assessments berichteten 
AEs für rTMS vs 
Scheinintervention 
diverse 
Sicherheitsendpunkte 
berichtet, nur 1 Studie 
berichtete keine AE 
häufigste NW: 
Kopfschmerz  
(bei bis zu 60 % rTMS 
vs 50 % Sham)  
Schmerzen, Unbehagen 
der Kopfhaut  
(bis zu 80 % in rTMS  
und 20 % in Sham)  
Augenprobleme  
(bis 21 % bei rTMS  
und 1.9 % bei Sham) 
keine SAEs  
AEs: Kopfschmerz 
keine AEs bei ECT 
Gruppe 
Repetitive transcranial magnetic stimulation for treatment-resistant major depression 
60 LBI-HTA | 2017 
[C0002] – Are the harms related  
to dosage or frequency of applying rTMS? 
The currently available evidence is insufficient to address which aspects could 
affect the frequency and/or severity of harms associated with rTMS.  
[C0005] – What are the susceptible patient groups  
that are more likely to be harmed through the use of rTMS? 
No subgroup analysis was performed in the included studies, therefore, there 
is no data available to answer this assessment element.  
[C0007] – Are rTMS, sham stimulation  
and ECT associated with user-dependent harms? 
Effects of a learning curve have not been addressed in any of the studies  
included for the present safety analysis.  
[B0010] – What kind of data/records and/or registry  
is needed to monitor the use of rTMS, sham stimulation and ECT? 
Both for ECT and rTMS use, there is a need for record keeping protocol, re-
cording the adverse events, service level data such as the number of patients 
treated, the number of treatments, and patient satisfaction. A quality assur-
ance should be done through monitoring the above data, the servicing of the 
equipment, and the staff training by the facilities providing the technologies.  
 
keine Evidenz 
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keine Evidenz 
vorhanden 
Aufzeichnungen von 
AEs und SAEs für rTMS 
und ECT notwendig 
Safety (SAF) 
 
Table 6-1: Frequency of adverse events in comparative studies  
Adverse  
events 
rTMS vs sham rTMS vs ECT 
Studies  
reporting data 
N (%) of 
rTMS pts 
with event 
N (%) of 
sham pts 
with event 
% range  
of event in 
the included 
studies rTMS 
% range  
of event in 
the included 
studies sham 
Studies 
reporting 
data 
N (%)  
of rTMS pts 
with event 
N (%)  
of ECT pts  
with event 
% range  
of event in 
the included 
studies rTMS 
% range  
of event in 
the included 
studies ECT 
Headache [16, 51-53, 55, 56, 63-69] 144 (32) 45 (11) 0-60 0-50 [19, 59, 60] 9 (12.3) 0 3-25 0 
Scalp discomfort [16, 51, 52, 56, 62, 63, 
65, 68, 70] 
70 (19) 16 (5) 4.5-33 0-21 NA NA NA NA NA 
Vertigo [52, 55, 56, 63, 64, 71] 7 (3.3) 8 (3.9) 0-16.7 0-14 NA NA NA NA NA 
Seizure [16, 49-51, 64, 65, 67, 
68, 70-72] 
0 0 0 0 [19, 59] 0 0 0 0 
Gastrointestinal 
problems 
[16, 52, 55, 62, 63, 68] 25 (8) 7 (2.4) 5-22 0-22 NA NA NA NA NA 
Eye problems [16, 55, 63, 68] 15 (7.2) 3 (1.6) 5.6-21 0-1.9 NA NA NA NA NA 
Face twitching [16, 52, 63, 68] 15 (5.3) 6 (2.2) 0-20.6 0-3.2 NA NA NA NA NA 
Insomnia  [52, 63, 65] 9 (6.7) 11 (8.2) 4.5-7.6 0-10 [60] 2 (10) 0 0 0 
Syncope  [52, 63] 10 (9) 6 (5.4) 5-27.8 4-14 NA NA NA NA NA 
Hypomania [53, 68] 2 (5.1) 0 0 0 NA NA NA NA NA 
Cognitive 
impairment 
[62, 63] 5 (16.7) 1 (4.3) 0-41.7 0-7 [19] 0 0 0 0 
Death [16] 0 0 0 0 NA NA NA NA NA 
Abbreviations: ECT electroconvulsive therapy, N number, pts patients, rTMS repetitive transcranial magnetic stimulation 
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) Schema [105] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement a third researcher was involved to solve the difference. 
A more detailed list of criteria applied can be found in the recommendations 
of the GRADE Working Group [105].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit a 
conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
For effectiveness related endpoints response and remission rates were con-
sidered critical, for safety-related endpoints serious adverse events were de-
fined as critical outcomes. The mean difference in depression scores was con-
sidered an important, but not critical outcome. A major limitation in the use 
of mean difference as an outcome is that it is not showing directly if the pa-
tient has responded to the treatment.  
Overall, the strength of evidence for the effectiveness and safety of rTMS in 
comparison to both sham and ECT is very low. 
 
 
 
Qualität der Evidenz 
nach GRADE 
entscheidene Endpunkte 
für Wirksamkeit und 
Sicherheit 
Stärke der Evidenz  
für rTMS im Vergleich 
zu sham und ECT  
sehr niedrig 
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Table 7-1: Evidence profile: efficacy and safety of rTMS vs sham for TRD 
Quality assessment № of patients Effect 
Quality Importance № of 
studies 
Study 
design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations rTMS sham 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Mean difference in depression scores (assessed with: HDRS) 
16  randomised 
trials 
serious 
a,b,c 
not serious not serious not serious none 466 421 not  
estimable f 
MD 2.31  
(1.19 to 3.43) 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Response rate 
19  randomised 
trials 
serious 
a,b,c 
serious d not serious serious e none 144/550 
(26.2%) 
61/506 
(12.1%) 
RR 1.82 
(1.18 to 
2.82) 
99 more  
per 1,000 
(from 22 more  
to 219 more) 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Remission rate 
12  randomised 
trials 
serious 
a,b,c 
not serious not serious serious e none 78/449 
(17.4%) 
28/417 
(6.7%) 
RR 2.16 
(1.42 to 
3.29) 
82 more  
per 1,000 
(from 30 more  
to 162 more) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Transient impairment of working memory 
2  randomised 
trials 
serious 
a,b,g 
not serious not serious very  
serious e 
none 5/30 
(16.7%) 
1/23 
(4.3%) 
RR 3.83 
(0.48 to 
30.59) 
123 more  
per 1,000 
(from 23 fewer  
to 1,000 more) 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Seizures 
11  randomised 
trials 
serious 
a,b,g 
not serious not serious serious e none 0/341 
(0.0%) 
0/285 
(0.0%) 
RR 0.84 
(0.01 to 
42.01) 
0 fewer per 1,000 
(from 0 fewer  
to 0 fewer) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Abbreviations: CI: Confidence interval; RR: Risk ratio, MD: mean difference 
a The blinding of medical personnel was unclear in many studies and in some studies the personnel who administered the intervention was aware of the treatment type (if active or sham).  
b Many studies did not report details about randomization (sequence generation, allocation concealment)  
c ITT principle was not always adequately realized.  
d The degree of heterogeneity among studies was moderate (I-square=50%, p<. 0001))  
e The number of events is lower than 300.  
f Continuous outcome 
g The studies were not designed to find differences in safety outcomes (the power of the studies is calculated for efficacy outcomes)  
Sources: [13, 14] 
 
  
Quality of evidence 
 
Table 7-2: Evidence profile: efficacy and safety of rTMS vs ECT for TRD 
Quality assessment № of patients Effect Quality Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision Other 
considerations 
ECT rTMS Relative 
(95% CI) 
Absolute 
(95% CI) 
Mean difference in depression scores (assessed with: HDRS/HAMD) 
4  randomised 
trials 
serious 
a,b,c 
serious d not serious serious e none 96 89 not 
estimablek 
MD -5.97  
(-11.00 to -0.94) 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Response rate 
3  randomised 
trials 
serious 
a,f 
serious g not serious serious h none 41/62 
(66.1%) 
24/64 
(37.5%) 
RR 1.72 
(0.95 to 
3.11) 
270 more per 
1 000 
(from 19 fewer  
to 791 more) 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Remission rate 
3  randomised 
trials 
serious a serious i not serious serious h none 30/58 
(51.7%) 
21/60 
(35.0%) 
RR 1.44 
(0.64 to 
3.23) 
154 more per 
1 000 
(from 126 fewer 
to 781 more) 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Transient impairment of working memory 
1  randomised 
trials 
serious 
a,b,c,j 
not serious not serious serious e,h none 0/40 
(0.0%) 
0/33 
(0.0%) 
RR 1.13 
(0.02 to 
55.96) 
0 fewer per 1 000 
(from 0 fewer  
to 0 fewer) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Seizures 
2  randomised 
trials 
serious 
a,b,f,j 
not serious not serious serious e,h none 0/60 
(0.0%) 
0/53 
(0.0%) 
RR 1.13 
(0.02 to 
55.96) 
2 more per 1 000 
(from 18 fewer  
to 1,000 more) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Abbreviations: CI:  Confidence interval; RR: Risk ratio 
a Blinding is not possible because of the nature of the intervention.  g There was a high degree of heterogeneity among studies (I-square=60.6%, p=. 079)  
b The studies did not report details about allocation concealment.  h Small number of events.  
c Some studies were unclear about the assessors’ blinding.  i There was a high degree of heterogeneity among studies (I-square=69.1%, p=. 039)  
d There was a high degree of heterogeneity among studies  
(I-squre=70.6%, p=. 017)  
j The studies were not designed to find differences in safety outcomes  
(the power of the studies is calculated for efficacy outcomes)  
e Small number of patients.  k Continuous outcome 
f One study was unclear about assessors’ blinding.   
Source: [13] 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  

 LBI-HTA | 2017 67 
8 Discussion 
The aim of this report was to assess the clinical effectiveness and safety of 
rTMS compared to sham stmulation or ECT. We considered studies that ap-
plied unilateral high-frequency stimulation to the left DLPFC in both the 
sham controlled and the ECT comparison studies. 
 
Interpretation of findings 
We identified one SR and two RCTs to assess the clinical effectiveness and 
safety of rTMS for patients with TRD. A total of 1180 patients were analysed 
in the studies that compared rTMS with sham stimulation, and 266 in the 
studies that compared rTMS with ECT.  
The body of evidence indicates that rTMS is generally safe and well-tolerat-
ed. The most serious adverse effect is seizure, which was not observed in any 
of the studies. As described in the safety guideline [7], if seizures happen, they 
are usually self-limited, require no medications, and do not recur. The stud-
ies did not address the issue of which patient groups are more likely to be 
harmed by using the technology.  
TMS had a small short-term effect for improving depression in comparison 
with sham, but follow-up studies did not show that the small effect will con-
tinue for longer periods. In comparison with ECT, the critical endpoints re-
mission and response rates showed no statistically significant difference. How-
ever, the mean difference in depression scores was statistically and clinically 
significant favouring ECT.  
Study quality, validity and overall level of evidence 
The overall quality of the body of evidence is very low for both sham and ECT 
comparison studies.  
The methodological limitations of the studies included in this assessment are 
likely to influence the treatment effect size. First of all, the treatment proto-
cols of rTMS varied among the studies, especially in the sham controlled ones. 
The HQO report conducted three subgroup analyses of the weighted mean 
difference of depression scores to investigate the effect of the various treat-
ment parameters like frequency, total pulses, and total sessions on the treat-
ment outcome. The results show that studies that applied a frequency of 20 
Hz with shorter train duration had a larger treatment effect than those with 
10 or less Hz. This suggests that studies with suboptimal treatment parame-
ters are more likely to result in suboptimal efficacy, although it is still unclear 
what the most optimal parameters are to reach the best outcome. In the ECT 
controlled trials, the heterogeneity among studies can be explained by the 
variation of treatment parameters used in ECT application (unilateral or bi-
lateral). The HQO report also conducted a subgroup analysis for ECT elec-
trode placement. The subgroup of studies that used bilateral ECT in at least 
40% of patients showed larger treatment effect than studies that used only 
unilateral or bilateral in less than 40% of patients.  
Forschungsschwerpunkt: 
Wirksamkeit und 
Sicherheit von rTMS  
1 SR und 2 RCTs 
Gesamtzahl der 
PatientInnen: 
1180 (rTMS vs sham)  
266 (rTMS vs ECT)  
 
rTMS ist sicher,  
gut toleriert 
wirksamer als 
Scheinintervention, 
Wirksamkeit gegenüber 
ECT unklar 
Qualität der Evidenz 
niedrig bei beiden 
Komperatoren 
Methodologische 
Limitierungen:  
Unterschiedliche 
Behandlungsprotokolle 
mit verschiedenen 
Frequenzen,  
Anzahl an Impulsen  
etc.  
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The definition of remission varied greatly in the studies (from ≤7 to ≤10 us-
ing the HDRS-17 and <8 to ≤10 using the HDRS-21). Hence, some studies 
qualified more patients as remitters than others. The level of treatment re-
sistance was also not uniform across the studies, suggesting that some stud-
ies might have included patients with lower severity TRD than others.  
Most of the included studies that compare rTMS and ECT had a high risk of 
bias in the blinding domain for patients and medical staff as well as in out-
come assessors in some cases. However, given the nature of the intervention, 
blinding is not possible, because ECT would require general anaesthesia, 
while rTMS not. Most of the sham controlled studies had a combination of 
unclear and low risk of bias, and a few had high risk of bias. In these studies, 
blinding was the area where the studies were often lacking clarity. Methods 
of random sequence generation and allocation concealment were largely un-
clear; however, this could have been due to a lack of detail rather than an ar-
ea of bias.  
The sample sizes of the RCTs were small in both the sham and the ECT trials, 
therefore, it is difficult to draw definitive conclusions about the true level of 
efficacy.  
The treatment intensity is influenced by the coil to cortex distance. The stand-
ard protocol, followed by the earliest studies, applied the 5 cm method. Recent 
studies have re-evaluated this method and found that it may be anatomically 
incorrect and therefore limiting the treatment potential of rTMS. If the coil 
is not placed at the right area, the stimulation intensities need to be adjusted 
as they might be too high, contributing to subject discomfort, increased inci-
dence of headaches, facial pain, and might result in higher incidence of drop-
out. On the contrary, if stimulation is delivered at a too low intensity, the ef-
ficacy of the treatment might be compromised.  
The most serious limitation of the included studies comparing rTMS and 
ECT is that only some of them reported on adverse events and only one study 
[18] measured cognitive impairment, which is the most common adverse event 
in ECT therapy.  
Factors that may influence the external validity 
There was heterogeneity in how the studies defined TRD (ranging from fail-
ure of one antidepressant treatment to failure of two antidepressants or even 
failure of an ECT therapy). Some studies excluded patients who already had 
ECT treatment. Interpretation of the data is hindered by the non-unified TRD 
definitions. The number of failed treatments might have an effect on the ef-
fectiveness of the technology, therefore, it would be necessary to consider a 
uniform definition for TRD and apply it consistently in the clinical trials. 
The clinical studies conducted with rTMS do not always reflect the intended 
clinical use of the device. If it is intended to be used as monotherapy, the study 
protocol should allow only the use as monotherapy and not as add-on thera-
py and the treatment parameters should also be carefully defined and unified 
across studies. 
Definitionen zu 
entscheidendem 
Endpunkt Remission 
sehr unterschiedlich  
in Studien  
Studie, die rTMS mit 
ECT verglichen hatten 
hohes Biasrisiko,  
keine ausreichende 
Verblindung 
Fallzahlen im 
Allgemeinen zu klein um 
konkrete Aussagen zur 
Wirksamkeit zu machen 
eventuelle 
Beeinflussung der 
Ergebnisse durch 
anatomisch inkorrekte 
Anbringung 
nur wenige Studien 
berichteten relevante 
Sicherheitsendpunkte 
hohe Heterogenität der 
Definition für TRD 
in manchen Studien  
als Monotherapie,  
in anderen als Zusatz  
zu AD Therapie 
Discussion 
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We considered sham and ECT as comparators in our assessment. As there is 
no standard treatment algorithm available, we chose the comparator based 
on what is currently the most effective treatment to achieve response for very 
severe depression that has not responded to any other treatment. Although, 
as it is suggested by CANMAT [11], rTMS response rates are poor in pa-
tients where ECT has failed, indicating that rTMS should rather be consid-
ered prior to ECT and patients who have not responded to ECT are unlikely 
to respond to rTMS. rTMS and ECT differ in their mechanisms, tolerability, 
and acceptability by patients and may be best considered as complementary 
rather than competing techniques. TMS may be an option in the early stages 
(Stage 1 or 2) after one or two antidepressant therapies have failed. The place 
in the treatment hierarchy could precede more invasive interventions such as 
ECT, VNS and DBS, after failure to respond to 4 or more adequate antide-
pressant treatments [4, 24]. 
Relevance of the outcomes assessed  
to the potential patient-relevant benefits 
Ideally, outcomes such as quality of life and function would be primary out-
comes that determine the impact of the intervention, but this was not report-
ed in the included studies, except for one. A major limitation in the outcomes 
is that they are not measuring directly the improvement in the patients’ qual-
ity of life and that there is only short-term data available. Some studies re-
ported relapse, but we have no information how the treatment impacted pa-
tients’ lives in terms of daily functioning, returning to work etc. 
Patient satisfaction was not measured by any dedicated tool, but some of the 
studies mentioned that withdrawal (drop-out) occurred due to inconvenience 
of daily travelling to sessions, inability to attend sessions, attendance per-
ceived to be too stressful, and lack of perceived benefits (although these were 
only sporadic events). Satisfaction would be a very important outcome as it 
would show acceptability of the intervention. 
Some ethical, organizational and social aspects are also associated with the 
use or non-use of rTMS and can be found in Appendix 3. 
Evidence gaps and ongoing studies 
Although the authors of the HQO report collected data if the treatment was 
delivered as mono- or add-on therapy, they did not conduct a subgroup anal-
ysis for this category (16 studies applied rTMS or sham as an add-on therapy 
and seven as monotherapy). If clinicians get to know the augmentation effect 
of the intervention, it could further help them in defining the place of the 
technology in the treatment hierarchy.  
Only a few studies provided follow-up data, hence, we cannot assess the long-
term effectiveness and benefits of rTMS. The follow-up ranged from 1 to 6 
months. There is a need for more studies with long-term (6 month) follow-up 
data to support the evidence on long-term clinical effectiveness.  
We identified four ongoing studies investigating rTMS compared to sham 
with the number of enrolled patients ranging from 28 to 168. The estimated 
completion date of three trials has passed in 2016 or earlier, but no results 
have been published yet. The fourth study has not registered its completion 
date. We also identified five studies comparing DTMS with sham or other 
rTMS (LF, HF) techniques. DTMS is delivered with the H-coil that can reach 
deeper brain areas than the conventional coils. Some other novelties are also 
being investigated in clinical trials, for example the sTMS, aTMS, and TBS. 
kein Therapie-
Algorithmus für TRD 
vorhanden 
daher Vergleich mit ECT 
als Standardtherapie;  
 
Potenzial als 
komplementäre 
Intervention in frühen 
Stadien der TRD und  
vor ECT denkbar 
QoL wurde nur von 
einer Studie berichtet 
 
keine Langzeitdaten 
trotz der hohen 
Relevanz wurde 
PatientInnen 
Zufriedenheit  
nicht berichtet 
keine 
Subgruppenanalyse  
von rTMS als 
Monotherapie oder 
Kombinationstherapie 
(mit AD) 
nur wenige Follow-up 
Daten berichtet,  
nur bis zu 6 Monate 
keine Langzeitdaten 
vorhanden 
 
 
4 laufende Studien  
für rTMS vs Sham  
5 Studien zu DTMS  
und rTMS 

 LBI-HTA | 2017 71 
9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
x The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence indicates, that the assessed technology rTMS is more 
effective than and as safe as sham. The body of evidence indicates that rTMS 
is generally safe and well-tolerated. rTMS had a small short-term effect for im-
proving depression in comparison with sham, but follow-up studies did not 
show that the small effect will continue for longer periods. However, the qual-
ity of evidence is considered very low. New study results will potentially in-
fluence the effect estimate considerably. 
The current evidence is not sufficient to prove that rTMS is as effective and 
safe as ECT. There is evidence that ECT is more effective in reducing depres-
sion scores, however, no significant differences were found in terms of remis-
sion and response in comparison to rTMS. No serious safety concerns were 
observed; side effects appear to be equivalent between rTMS and ECT.  
Due to the low quality of evidence of the included studies, we recommend 
rTMS for patients with TRD with restrictions. The technology might be an 
option for patients in the early stages (Stage 1 or 2) of TRD. The place in the 
treatment hierarchy could precede more invasive interventions such as ECT, 
VNS and DBS.  
There are four ongoing studies investigating rTMS compared to sham with 
the number of enrolled patients ranging from 28 to 168, a size which would 
not have a significant influence on magnitude of the effect of our findings. 
The re-evaluation is recommended only if several high-quality clinical trials 
with sufficient number of enrolled patients (n>300) will be completed and if 
they provide additional long-term data on safety and/or effectiveness outcomes.  
 
 
rTMS wirksamer als und 
gleich sicher wie 
Scheinbehandlung 
unzureichende Evidenz 
um die Wirksamkeit und 
Sicherheit gegenüber 
ECT zu belegen 
Qualität der Evidenz 
niedrig, 
Empfehlung mit 
Einschränkung  
4 laufende Studien 
Re-Evaluierung:  
nur bei Studien mir 
ausreichender Fallzahl 
und Langzeitdaten 
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Appendix 1: 
Methods and description of the evidence used  
Documentation of the Search Strategies 
Search strategy for SRs 
Medline via Ovid 
Database: Ovid MEDLINE(R) Epub Ahead of Print <December 29, 2016>, Ovid MEDLINE(R) <1946 to December 
Week 1 2016>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 29, 2016>, Ovid 
MEDLINE(R) Daily Update <December 07, 2016> 
1 exp Depressive Disorder, Major/(28225) 
2 ((major or severe) adj3 depress*).ti,ab. (51492) 
3 exp Depressive Disorder, Treatment-Resistant/(771) 
4 *Depressive Disorder/th [Therapy] (6771) 
5 *Depression/th [Therapy] (6904) 
6 1 or 2 or 3 or 4 or 5 (72016) 
7 exp Transcranial Magnetic Stimulation/(10226) 
8 ((repetiti* or repeat*) adj3 (Transcrani* adj3 Magnet* Stimul*)).ti,ab. (3774) 
9 rTMS.ti,ab. (3698) 
10 7 or 8 or 9 (11420) 
11 6 and 10 (1102) 
12 limit 11 to (meta analysis or systematic reviews) (121) 
13 (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) or (meta-
analy* or metaanaly* or “research synthesis” or ((information or data) adj3 synthesis) or (data adj2 
extract*))).ti,ab. or (cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not 
“psycinfo database”) or pubmed or scopus or “sociological abstracts” or “web of science”).ab. or (“cochrane 
database of systematic reviews” or evidence report technology assessment or evidence report technology 
assessment summary).jn. or Evidence Report: Technology Assessment*.jn. or ((review adj5 (rationale or 
evidence)).ti,ab. and review.pt.) or meta-analysis as topic/or Meta-Analysis.pt. (340943) 
14 11 and 13 (152) 
15 12 or 14 (170) 
16 remove duplicates from 15 (146) 
30.12.2016 
 
Embase 
No. Query Results Results Date 
#13. ‘major depression’/exp OR ((major OR severe) NEAR/1 depress*):ti,ab OR 
‘treatment resistant depression’/exp OR ‘depression’/mj/dm_th AND 
(‘transcranial magnetic stimulation’/exp OR ((repetiti* OR repeat*) NEAR/3 
(transcrani* OR magnet* OR stimul*)):ti,ab OR rtms:ti,ab) AND (‘meta 
analysis’/de OR ‘meta analysis (topic)’/de OR ‘systematic review’/de) 
182 30 Dec 2016 
#12. ‘major depression’/exp OR ((major OR severe) NEAR/1 depress*):ti,ab OR 
‘treatment resistant depression’/exp OR ‘depression’/mj/dm_th AND 
(‘transcranial magnetic stimulation’/exp OR ((repetiti* OR repeat*) NEAR/3 
(transcrani* OR magnet* OR stimul*)):ti,ab OR rtms:ti,ab) 
1,870 30 Dec 2016 
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#11. ‘major depression’/exp OR ((major OR severe) NEAR/1 depress*):ti,ab OR 
‘treatment resistant depression’/exp OR ‘depression’/mj/dm_th AND 
(‘transcranial magnetic stimulation’/exp OR ((repetiti* OR repeat*) NEAR/3 
(transcrani* OR magnet* OR stimul*)):ti,ab OR rtms:ti,ab) AND ([cochrane 
review]/lim OR [systematic review]/lim OR [meta analysis]/lim) 
146 30 Dec 2016 
#10. ‘major depression’/exp OR ((major OR severe) NEAR/1 depress*):ti,ab OR 
‘treatment resistant depression’/exp OR ‘depression’/mj/dm_th AND 
(‘transcranial magnetic stimulation’/exp OR ((repetiti* OR repeat*) NEAR/3 
(transcrani* OR magnet* OR stimul*)):ti,ab OR rtms:ti,ab) 
1,870 30 Dec 2016 
#9. ‘transcranial magnetic stimulation’/exp OR ((repetiti* OR repeat*) NEAR/3 
(transcrani* OR magnet* OR stimul*)):ti,ab OR rtms:ti,ab 
31,969 30 Dec 2016 
#8. rtms:ti,ab 4,758 30 Dec 2016 
#7. ((repetiti* OR repeat*) NEAR/3 (transcrani* OR magnet* OR stimul*)):ti,ab 18,884 30 Dec 2016 
#6. ‘transcranial magnetic stimulation’/exp 17,310 30 Dec 2016 
#5. ‘major depression’/exp OR ((major OR severe) NEAR/1 depress*):ti,ab OR 
‘treatment resistant depression’/exp OR ‘depression’/mj/dm_th 
85,145 30 Dec 2016 
#4. ‘depression’/mj/dm_th 15,872 30 Dec 2016 
#3. ‘treatment resistant depression’/exp 1,464 30 Dec 2016 
#2. ((major OR severe) NEAR/1 depress*):ti,ab 54,691 30 Dec 2016 
#1. ‘major depression’/exp 48,114 30 Dec 2016 
 
CRD 
#### rTMS for TRD 
Search Date: 30.12.2016 
1 MeSH DESCRIPTOR Depressive Disorder, Major EXPLODE ALL TREES 
2 ((major OR severe) NEAR depress*) 
3 MeSH DESCRIPTOR Depressive Disorder, Treatment-Resistant EXPLODE ALL TREES 
4 MeSH DESCRIPTOR depressive disorder EXPLODE ALL TREES WITH QUALIFIER TH 
5 MeSH DESCRIPTOR depression EXPLODE ALL TREES WITH QUALIFIER TH 
6 #1 OR #2 OR #3 OR #4 OR #5 
7 MeSH DESCRIPTOR Transcranial Magnetic Stimulation EXPLODE ALL TREES 
8 ((repetiti* OR repeat*) NEAR (Transcrani* OR Magnet* OR Stimul*)) 
9 (rTMS) 
10 #7 OR #8 OR #9 
11 #6 AND #10 
46 Hits 
 
Cochrane database 
Search Name: rTMS for TRD 
Last Saved: 30/12/2016 16:16:23.558 
ID Search 
#1 MeSH descriptor: [Depressive Disorder, Major] explode all trees 
#2 (major or severe) near depress*:ti,ab,kw (Word variations have been searched) 
#3 MeSH descriptor: [Depressive Disorder, Treatment-Resistant] explode all trees 
#4 MeSH descriptor: [Depressive Disorder] this term only and with qualifier(s): [Therapy – TH] 
#5 MeSH descriptor: [Depression] this term only and with qualifier(s): [Therapy – TH] 
#6 #1 or #2 or #3 or #4 or #5  
#7 MeSH descriptor: [Transcranial Magnetic Stimulation] explode all trees 
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#8 (repetiti* or repeat*) near (Transcrani* or Magnet* or Stimul*):ti,ab,kw (Word variations have been searched) 
#9 rTMS:ti,ab,kw (Word variations have been searched) 
#10 #7 or #8 or #9  
#11 #6 and #10 in Cochrane Reviews (Reviews and Protocols), Other Reviews, Methods Studies, Technology 
Assessments and Economic Evaluations 
47 Hits 
 
PubMed Search String 
Search Name: rTMS for TRD  
Date of Search: 30.12.2016 
((Major Depressive Disorder OR Severe Depressive Disorder OR Treatment-Resistant Depressive Disorder OR Major 
Depression OR Severe Depression OR “Depressive Disorder/therapy”[Majr] OR “Depression/therapy”[Majr])) AND 
(Transcranial Magnetic Stimulation OR repetitive Transcranial Magnetic Stimulation OR rTMS[tiab]) Filters: 
Systematic Reviews/Meta-Analyses 
Total: 126 Hits 
 
Database: PsycINFO <1806 to January Week 5 2017> 
1 exp Major Depression/(110594) 
2 ((major or severe) adj3 depress*).ti,ab. (41312) 
3 exp Treatment Resistant Depression/(1828) 
4 1 or 2 or 3 (120952) 
5 exp Transcranial Magnetic Stimulation/(6458) 
6 ((repetiti* or repeat*) adj3 (Transcrani* adj3 Magnet* Stimul*)).ti,ab. (2235) 
7 rTMS.ti,ab. (2310) 
8 5 or 6 or 7 (6821) 
9 4 and 8 (971) 
10 limit 9 to (“0830 systematic review” or 1200 meta analysis) (58) 
11 (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) or (meta-
analy* or metaanaly* or “research synthesis” or ((information or data) adj3 synthesis) or (data adj2 
extract*))).ti,ab. or (cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not 
“psycinfo database”) or pubmed or scopus or “sociological abstracts” or “web of science”).ab. or (“cochrane 
database of systematic reviews” or evidence report technology assessment or evidence report technology 
assessment summary).jn. or Evidence Report: Technology Assessment*.jn. or ((review adj5 (rationale or 
evidence)).ti,ab. and review.pt.) or meta-analysis as topic/or Meta-Analysis.pt. (59199) 
12 9 and 11 (121) 
13 10 or 12 (122) 
08.02.2017 
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Search strategy for primary studies 
Cochrane database 
Search Name: rTMS for TRD  
Last Saved: 07/02/2017 15:05:35.760 
ID Search 
#1 MeSH descriptor: [Depression] this term only 
#2 MeSH descriptor: [Depressive Disorder] explode all trees 
#3 MeSH descriptor: [Depressive Disorder, Major] this term only 
#4 MeSH descriptor: [Depressive Disorder, Treatment-Resistant] this term only 
#5 depressi* or dysthymic or melancholia or TRD or “involutional psychos*” or paraphrenia:ti,ab,kw  
#6 #1 or #2 or #3 or #4 or #5  
#7 MeSH descriptor: [Transcranial Magnetic Stimulation] this term only 
#8 ((transcranial or trans-cranial) near (magnetic near stimulation*)) or rtms or tms:ti,ab,kw  
#9 #7 or #8  
#10 #6 and #9 Online Publication Date from Nov 2014 to Feb 2017 (Word variations have been searched) 
#11 #6 and #9 Publication Year from 2014 to 2017 
#12 #10 or #11 in Trials 
176 Hits 
 
Embase 
No. Query Results Results Date 
#14. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) AND [20-2-2014]/sd NOT [6-2-2017]/sd 
AND ([controlled clinical trial]/lim OR [randomized controlled trial]/lim) OR 
(‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) AND [20-2-2014]/sd NOT [6-2-2017]/sd 
AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de OR ‘controlled clinical trial’/de 
OR ‘controlled study’/de OR ‘double blind procedure’/de OR ‘major clinical 
study’/de OR ‘multicenter study’/de OR ‘randomized controlled trial’/de OR 
‘randomized controlled trial (topic)’/de)) 
351 7 Feb 2017 
#13. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) AND [20-2-2014]/sd NOT [6-2-2017]/sd 
AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de OR ‘controlled clinical trial’/de 
OR ‘controlled study’/de OR ‘double blind procedure’/de OR ‘major clinical 
study’/de OR ‘multicenter study’/de OR ‘randomized controlled trial’/de OR 
‘randomized controlled trial (topic)’/de) 
351 7 Feb 2017 
#12. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) AND [20-2-2014]/sd NOT [6-2-2017]/sd 
752 7 Feb 2017 
Appendix 1: Methods and description of the evidence used 
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#11. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) AND [20-2-2014]/sd NOT [6-2-2017]/sd 
AND ([controlled clinical trial]/lim OR [randomized controlled trial]/lim) 
107 7 Feb 2017 
#10. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) AND [20-2-2014]/sd NOT [6-2-2017]/sd 
752 7 Feb 2017 
#9. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab AND (‘transcranial magnetic 
stimulation’/mj OR ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic 
stimulation*’ OR rtms OR tms)):ab,ti) 
2,377 7 Feb 2017 
#8. ‘transcranial magnetic stimulation’/mj OR ((transcranial OR ‘trans cranial’) 
NEAR/1 (‘magnetic stimulation*’ OR rtms OR tms)):ab,ti 
15,176 7 Feb 2017 
#7. ((transcranial OR ‘trans cranial’) NEAR/1 (‘magnetic stimulation*’ OR rtms OR 
tms)):ab,ti 
14,343 7 Feb 2017 
#6. ‘transcranial magnetic stimulation’/mj 7,453 7 Feb 2017 
#5. ‘depression’/mj OR ‘major depression’/mj OR ‘treatment resistant depression’/mj 
OR depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab 
435,603 7 Feb 2017 
#4. depressi*:ti,ab OR dysthymic:ti,ab OR melancholia:ti,ab OR trd:ti,ab OR 
‘involutional psychos*’:ti,ab OR paraphrenia:ti,ab 
409,946 7 Feb 2017 
#3. ‘treatment resistant depression’/mj 808 7 Feb 2017 
#2. ‘major depression’/mj 22,274 7 Feb 2017 
#1. ‘depression’/mj 129,167 7 Feb 2017 
 
Medline via Ovid 
Database: Ovid MEDLINE(R) <1946 to January Week 4 2017>, Ovid MEDLINE(R) Epub Ahead of Print <February 
06, 2017>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <February 06, 2017>, Ovid MEDLINE(R) 
Daily Update <February 06, 2017>, Ovid MEDLINE(R) Versions 
1 Depression/(93575) 
2 exp Depressive Disorder/(94576) 
3 Depressive Disorder, Major/(24010) 
4 Depressive Disorder, Treatment-Resistant/(667) 
5 (depressi* or dysthymic or melancholia or TRD or “involutional psychos*” or paraphrenia).ti,ab. (311657) 
6 1 or 2 or 3 or 4 or 5 (355014) 
7 Transcranial Magnetic Stimulation/(8595) 
8 (((transcranial or trans-cranial) adj2 (magnetic adj2 stimulation*)) or rtms or tms).mp. (16992) 
9 7 or 8 (16992) 
10 6 and 9 (1898) 
11 remove duplicates from 10 (1861) 
12 limit 11 to ed=20141120-20170206 (312) 
13 limit 12 to (clinical study or clinical trial, all or comparative study or controlled clinical trial or pragmatic 
clinical trial or randomized controlled trial) (62) 
14 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/not humans.sh.) (3444658) 
15 12 and 14 (129) 
16 13 or 15 (134) 
07.02.2017 
Repetitive transcranial magnetic stimulation for treatment-resistant major depression 
84 LBI-HTA | 2017 
Database: PsycINFO <1806 to January Week 5 2017> 
1 exp Major Depression/(110594) 
2 (depressi* or dysthymic or melancholia or TRD or “involutional psychos*” or paraphrenia).ti,ab. (238680) 
3 1 or 2 (245404) 
4 exp Transcranial Magnetic Stimulation/(6458) 
5  (((transcranial or trans-cranial) adj2 (magnetic adj2 stimulation*)) or rtms or tms).mp. (8579) 
6 4 or 5 (8579) 
7 3 and 6 (1496) 
8 limit 7 to (“0300 clinical trial” or “0451 prospective study” or “0453 retrospective study”) (130) 
9 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.sh. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/not humans.sh.) (598811) 
10 7 and 9 (636) 
11 8 or 10 (662) 
12 limit 11 to yr=”2014-2017” (188) 
07.02.2017 
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Description of the evidence used 
Guidelines for diagnosis and management 
Table A-1: Overview of guidelines: diagnosis and management of MDD 
Society/organisatio
n issuing guidance 
Date  
of issue 
Quality appraisal  
(AGREE II) 
Methodology  
(evidence and recommendations) 
Summary  
of recommendation 
Level  
of evidence 
American 
Psychiatric 
Association (APA) 
[20] 
2000, 
partial 
update 
2005, 
revision 
2010 
Scope and purpose: 0,64 
Stakeholder involvement: 0,31 
Rigour of development: 0,45 
Clarity of presentation: 0,61 
Applicability: 0,25 
Editorial Independencde: 0,88 
Global quality of the CPG 
E1: 4 
E2: 4 
Each recommendation falls into one  
of three categories of endorsement: 
[I] Recommended with substantial 
clinical confidence 
[II] Recommended with moderate 
clinical confidence 
[III] May be recommended on the 
basis of individual circumstances 
For patients whose symptoms have not responded 
adequately to medication, ECT remains the most 
effective form of therapy and should be considered. 
In patients capable of adhering to dietary and 
medication restrictions, an additional option is changing 
to a nonselective MAOI after allowing sufficient time 
between medications to avoid deleterious interactions. 
 
Transdermal selegiline, a relatively selective MAO B 
inhibitor with fewer dietary and medication restrictions, or 
transcranial magnetic stimulation could also be considered. 
Vagus nerve stimulation (VNS) may be an additional option 
for individuals who have not responded to at least four 
adequate trials of antidepressant treatment, including ECT. 
I 
 
 
Changing to 
MAOI: II 
Leaving sufficient 
time between 
medications: I 
II 
 
 
III 
World Federation 
of Societies of 
Biological 
Psychiatry 
(WFSBP) [23] 
2013 
(update 
or 
previous 
guideline 
Scope and purpose: 0,69 
Stakeholder involvement: 0,42 
Rigour of development: 0,51 
Clarity of presentation: 0,64 
Applicability: 0,06 
Editorial Independence: 0,58 
Global quality of the CPG: 
E1: 5 
E2: 4 
Evidence-based classification of 
recommendations 
Strength of evidence for its efficacy, 
safety, and feasibility: 
CE A: Full evidence from controlled trials 
CE B: Limited positive evidence from 
controlled trials 
CE C: Evidence from uncontrolled 
studies or case reports/expert opinion 
CE D: Inconsistent results 
CE E: Negative evidence 
CE F: Lack of evidence. 
Recommendations derived from CE and 
additional aspects (safety, tolerability, 
and interaction potential) 
RG 1: CE A evidence and good  
risk – benefit ratio 
RG 2: CE A evidence and moderate 
risk – benefit ratio 
RG 3: CE B evidence 
RG 4: CE C evidence 
RG 5: CE D evidence 
There is currently insufficient evidence for the clinical 
efficacy that allows recommending TMS in the standard 
clinical setting. Further research is needed. 
(CE D, RG 5) 
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Society/organisatio
n issuing guidance 
Date  
of issue 
Quality appraisal  
(AGREE II) 
Methodology  
(evidence and recommendations) 
Summary  
of recommendation 
Level  
of evidence 
Deutsche 
Gesellschaft für 
Psychiatrie und 
Psychotherapie, 
Psychosomatik 
und 
Nervenheilkunde 
(DGPPPN) [21] 
2015 Scope and purpose: 0,69 
Stakeholder involvement: 0,62 
Rigour of development: 0,51 
Clarity of presentation: 0,64 
Applicability: 0,26 
Editorial Independence: 0,78 
Evidence level: 
Ia: evidence from meta-analysis of 
minimum 3 RCTs 
Ib: evidence from minimum 1 RCT or 1 
meta-analysis of less than 3 RCTs 
IIa: evidence from at least a good 
quality non-RCT 
IIb: evidence from a quasi-experimental, 
good quality descriptive study 
III: evidence from a good non-
experimental observational study 
IV: evidence from expert committees, 
standpoints, clinical experience 
Recommendations: 
A: “must be done”: evidence level Ia or Ib 
B: “should be done”: evidence level II 
or III or extrapolated Ia or Ib 
0:“Can be done”: evidence level IV or 
extrapolation of IIa, IIb or III. There 
were no clinical studies of good quality 
available. 
HF-rTMS can be applied in treatment-resistant patients 
who have previously failed one antidepressant trial. 
0 
Spanish Ministry 
of Health 
(AVALIA-t) [73] 
2014 Scope and purpose: 0,83 
Stakeholder involvement: 
0,83 
Rigour of development: 0,79 
Clarity of presentation: 0,72 
Applicability: 0,71 
Editorial Independence: 0,67 
Global quality of the CPG: 
E1: 6 
E2: 
SIGN methodology is applied. 
For qualitative evidence (Q): evidence 
obtained from relevant and good 
quality qualitative studies. This 
category is not considered by SIGN 
methodology. 
TMS as an add on therapy for treatment  
resistant depression 
Currently, transcranial magnetic stimulation is not 
recommended for the treatment of depression due to 
the uncertainty related to its clinical efficacy. 
Electroconvulsive therapy should be considered as an 
alternative treatment in patients with severe depression, 
mainly if there is a need of a rapid response due to a high 
number of suicidal thoughts, severe physical 
deterioration, or when other treatments have failed. 
The decision of using ECT should be taken with the 
patient/or his/her family, taking into account the 
diagnosis, type and severity of symptoms, clinical 
history, balance between risk and benefits, other 
alternatives, and patients preferences. 
If ECT is necessary, it is recommended to put a special 
emphasis on offering all the necessary information, 
focusing on the procedure`s purpose, secondary effects, 
and treatment plan. 
 
 
B 
 
 
A 
 
 
 
 
Q 
 
 
 
 
Q 
Abbreviations: APA American Psychiatric Association, AGREE II Advancing guideline development, reporting and evaluation in healthcare, CPG clinical practice guideline,  
DGPPPN Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, ECT electroconvulsive therapy, HF-rTMS high-frequency repetitive transcranial 
magnetic stimulation, MAOI monoamine oxidase inhibitors, MAOB monoamine oxidase B, RCT randomized controlled trial, SIGN Scottish Intercollegiate Guidelines Network 
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Table A-2: Overview of guidelines focusing on rTMS 
Society/organisation 
issuing guidance 
Date of 
issue 
Quality appraisal  
(AGREE II) 
Methodology (evidence and 
recommendations) 
Summary  
of recommendation 
Level  
of evidence 
Canadian Network 
for Mood and 
Anxiety 
Treatments 
(CANMAT) [11] 
2009 
(updated 
in 2016) 
Scope and purpose: 0,61 
Stakeholder involvement: 0,44 
Rigour of development: 0,46 
Clarity of presentation: 0,64 
Applicability: 0,13 
Editorial Independence: 0,50 
Global quality of the CPG: 
E1: 5 
E2: 4 
CANMAT-defined criteria for level of 
evidence. Recommendations for lines of 
treatment are based on the quality of 
evidence and clinical expert consensus. 
rTMS is considered first line treatment  
for patients who have failed at least  
1 antidepressant. 
 
Both HF to the left DLPFC and LF to the  
right DLPFC are first-line rTMS protocol 
recommendations. 
A second-line recommendation is to switch non-
responders to the other stimulation protocol. 
Bilateral stimulation is considered a second 
line rTMS protocol. 
Stimulation to bilateral DLPFC is 
recommended as a third-line rTMS protocol. 
TBS protocols are recommended as second-line. 
Acute efficacy: level 1; 
maintenance efficacy: 
level 3, safety and 
tolerability: level 1 
Level 1 
 
 
Level 3 
 
Level 1 
 
Level 3 
 
Level 3 
National Institute 
for Health and 
Clinical Excellence 
(NICE) [22] 
2015 Scope and purpose: 0,61 
Stakeholder involvement: 0,67 
Rigour of development: 0,65 
Clarity of presentation: 0,72 
Applicability: 0,71 
Editorial Independence: 0,67 
Global quality of the CPG: 
E1: 5 
E2: 5 
Standard arrangements 
The evidence should be valid, relevant and  
of good quality, sufficiently consistent in 
nature. It should show that the frequency 
and severity of adverse effects of the pro-
cedure are similar to, or less than, those of 
any comparable and established procedures 
and should show benefits within an 
appropriate time of the procedure. 
Special arrangements 
A special arrangements recommendation 
states that clinicians using the procedure must 
inform the clinical governance lead in their 
trust, tell the patient about the uncertainties 
regarding the safety and efficacy of the 
procedure and collect further data by means 
of audit or research. The Committee recom-
mends these arrangements because there are 
significant uncertainties in the evidence on 
efficacy or safety, or an inadequate quantity 
of evidence. The Committee may also 
consider the balance of risks and benefits of 
the procedure to see if special arrangements 
should be in place. This recommendation is 
often made when the procedure is considered 
to be an emerging practice in the NHS. 
Do not use 
When the evidence suggests that a procedure 
has no efficacy or poses unacceptable safety 
risks. 
The evidence on rTMS for depression shows 
no major safety concerns. The evidence on its 
efficacy in the short-term is adequate, 
although the clinical response is variable. 
rTMS for depression may be used with 
normal arrangements for clinical governance 
and audit. 
During the consent process, clinicians should, 
in particular, inform patients about the other 
treatment options available, and make sure 
that patients understand that the procedure 
may not bring them benefit. 
NICE encourages publication of further 
evidence on patient selection, details of the 
precise type and regime of stimulation used, 
the use of maintenance treatment and long-
term outcomes. 
Standard 
arrangement 
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Society/organisation 
issuing guidance 
Date of 
issue 
Quality appraisal  
(AGREE II) 
Methodology (evidence and 
recommendations) 
Summary  
of recommendation 
Level  
of evidence 
Royal Australian 
and New Zealand 
College of 
Psychiatrists CPG 
for mood disorders 
(RANZCP)  
2015 Scope and purpose: 0,61 
Stakeholder involvement: 0,44 
Rigour of development: 0,46 
Clarity of presentation: 0,64 
Applicability: 0,13 
Editorial Independence: 0,50 
Global quality of the CPG: 
E1: 5 
E2: 4 
Two types of recommendations: 
1, Evidence-based recommendations (EBRs) 
are formulated when there is a sufficiently 
consistent evidence from interventional 
studies to support a recommendation on a 
given topic. For each EBR, strength of 
evidence is rated using the NHMRC levels of 
evidence for interventional studies and is 
graded accordingly (e.g., EBR I, II, III, or IV). 
2, The absence of evidence is not evidence of 
absence, so a second type of recommendation 
is also employed and termed a consensus 
based recommendation (CBR). 
rTMS is a safe and effective treatment for 
more severe presentations of depression and 
should be considered first-line for psychotic 
depression or when an immediate response is 
necessary. 
Patients with non-psychotic depression may 
be treated with rTMS once they have failed 
one or more trials of standard antidepressant 
medications and psychological therapies. 
EBR I 
 
 
 
 
EBR I 
French guideline 
(Lefaucheur) 
[74] 
2011 Scope and purpose: 0,50 
Stakeholder involvement: 0,44 
Rigour of development: 0,38 
Clarity of presentation: 0,53 
Applicability: 0,06 
Editorial Independence: 0,33 
Global quality of the CPG: 
E1: 3 
E2: 3 
Classification (I–IV) of studies according to 
level of evidence. A Class I study is a prospec-
tive, randomized, placebo-controlled clinical 
trial with blinded outcome assessment in a 
number of patients that is representative  
(n ≥25 receiving active treatment). 
A Class II study is a randomized, placebo-
controlled trial with a smaller sample size  
(n < 25), or a placebo controlled large 
retrospective study. Class III studies include 
all other controlled trials with some bias or 
methodological problems. Class IV studies are 
uncontrolled studies, case series, and case 
reports. These classifications are applied to 
rate the level of evidence (A–C). Level A 
(‘‘definitely effective or ineffective’’): at least 
2 Class I studies or one Class I study and at least 
2 consistent, Class II studies. Level B (‘‘probably 
effective or ineffective’’): at least 2 Class II 
studies or one Class II study and at least 2 
consistent, Class III studies. Level C (‘‘possibly 
effective or ineffective’’): one Class II study 
or at least 2 Class III studies are required. No 
recommendation will be made in the absence 
of at least 2 Class III studies providing similar 
results on the same type of clinical features 
with similar stimulation methods. 
Definite antidepressant effect of high 
frequency rTMS on the left DLPFC for the 
treatment of MDD. 
There is probably no difference in the effect 
between right and left side stimulations. 
No recommendation for bilateral rTMS 
combining HF rTMS of the left DLPFC and LF 
rTMS of the right DLPFC. 
Level A 
 
 
Level C 
 
Level B 
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Society/organisation 
issuing guidance 
Date of 
issue 
Quality appraisal  
(AGREE II) 
Methodology (evidence and 
recommendations) 
Summary  
of recommendation 
Level  
of evidence 
Rossi 2009 [7] 2009 Scope and purpose: 0,44 
Stakeholder involvement: 0,39 
Rigour of development: 0,09 
Clarity of presentation: 0,19 
Applicability: 0,06 
Editorial Independence: 0,04 
Global quality of the CPG: 
E1: 3 
E2: 2 
Consensus No recommendations. Information about 
safety, ethical considerations, and  
application of the technology. 
The present updated guideline discusses safety 
of conventional TMS protocols, addresses the 
undesired effects and risks of emerging TMS 
interventions, the applications of TMS in 
patients with implanted electrodes in the 
central nervous system, and safety aspects of 
TMS in neuroimaging environments. 
It covers recommended limits of stimulation 
parameters and other important precautions, 
monitoring of subjects, expertise of the rTMS 
team, and ethical issues. While all the 
recommendations are expert based, they 
utilize published data to the extent possible. 
 
Clinical 
neurophysiology 
[5] 
2015 Scope and purpose: 0,61 
Stakeholder involvement: 0,36 
Rigour of development: 0,31 
Clarity of presentation: 0,50 
Applicability: 0,06 
Editorial Independence: 0,25 
Global quality of the CPG: 
E1: 3 
E2: 3 
Critical assessment of all selected 
publications in order to classify them 
according to the criteria used in the previos 
French version of the guideline (Lefaucheur 
et al., 2011a) and derived from those 
proposed by the European Federation of 
Neurological Societies (Brainin et al., 2004). 
Definite antidepressant effect of HF rTMS  
of the left DLPFC. 
Probable antidepressant effect of LF rTMS of 
the right DLPFC and probably no differential 
antidepressant effect between right LF rTMS 
and left HF rTMS. 
No recommendation for bilateral rTMS 
combining HF rTMS of the left DLPFC and  
LF rTMS of the right DLPFC. 
Definite antidepressant effect of rTMS of 
DLPFC in unipolar depression, but no 
recommendation for bipolar depression. 
Antidepressant effect of rTMS of DLPFC is 
probably additive to the efficacy of anti-
depressant drugs and possibly potentiating. 
No recommendation for the overall 
respective antidepressant efficacy of rTMS  
of DLPFC compared to ECT. 
Level A 
 
Level B 
 
 
 
Level B 
 
 
Level A 
 
 
Level B 
 
 
Level C 
Abbreviations: AGREE II Advancing guideline development, reporting and evaluation in healthcare, CANMAT Canadian Network for Mood and Anxiety Treatments, CBR consensus based 
recommendation, CPG clinical practice guideline, DLPFC dorsolateral prefrontal cortex, EBR evidence-based recommendations, ECT electroconvulsive therapy, HF-rTMS high-frequency repetitive 
transcranial magnetic stimulation, LF low frequency, MDD major depressive disorder, NHMRC National Health and Medical Research Council, NICE National Institute for Health and 
Clinical Excellence, NHS National Health Service, RANZCP Royal Australian and New Zealand College of Psychiatris 
 
 
  
R
ep
etitive tran
scran
ial m
agn
etic stim
u
latio
n
 fo
r treatm
en
t-resistan
t m
ajo
r d
ep
ressio
n
 
9
0
 
LB
I-H
T
A
| 20
17 
Main characteristics of systematic reviews assessed for eligibility 
Table A-3: Systematic reviews comparing rTMS with sham rTMS 
Author 
and year 
Study  
type 
Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main  
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score 
(# no, can’t 
answer, not 
applicable) 
Berlim, 
2014 [75] 
SR 1371 pts,  
29 RCTs 
To summarize the 
evidence on HF rTMS for 
treating MDD, including: 
(a) response and 
remission; (b) utility of 
HF rTMS as mono- or 
add-on therapy; (c) 
differential efficacy of HF 
rTMS in unipolar vs in 
mixed samples, and in pts 
with TRD vs in pts with a 
less resistant illness; (d) 
impact of the strategy for 
managing missing data 
and of alternative 
stimulation parameters 
on the efficacy of HF 
rTMS; (e) its acceptability 
(indexed by drop-out 
rates). 
HF rTMS vs 
sham rTMS 
Response, 
remission 
Inclusion: 
sham controlled double-
blind RCTs with parallel or 
crossover design, 
pts with MDD (diagnosed 
according to DSM-IV or 
ICD -10), 
age 18-75 yrs, 
HF rTMS to the left DLPFC 
for ≥10 sessions, 
English language 
Avery 2006, Anderson 2007, 
Bakim 2012, Berman 2000, 
Blumberger 2012, Boutros 2002, 
Fitzgerald 2003, Fitzgerald 2012, 
Garcia-Toro 2001, George 1997, 
George 2000, George 2010, 
Hernandez-Ribas 2013, 
Holtzheimer 2004, Hoppner 2003, 
Koerselman 2004, Loo 2007, 
Mogg 2008, Mosimann 2004, 
Nahas 2003, O’Reardon 2007, 
Padberg 2002,  
Palliere-Martinot 2010,  
Rossini 2005, Stern 2007,  
Su 2005,Triggs 2010,  
Zhang 2011, Zheng 2010 
1995-
2012 
10 
(#2 can’t 
answer) 
Berlim, 
2013 [76] 
SR 
and 
MA 
392 pts,  
6 RCTs 
To examine whether HF 
rTMS can hasten the 
therapeutic effects of 
standard antidepressants 
in MDD. 
HF rTMS vs 
sham rTMS (all 
the patients 
concomitant 
new anti-
depressant 
medication) 
Response, 
remission, 
acceptability 
Inclusion: 
sham controlled double-
blind RCTs with parallel or 
crossover design, 
≥ 5 pts per study arm, 
pts with unipolar or  
bipolar MDD, 
age 18-75 yrs, 
HF rTMS to the left DLPFC 
for ≥ 5 sessions, 
started concomitantly  
with new antidepressant 
medication, 
English language 
Bretlau 2008, Garcia-Toro 2001, 
Herwig 2007, Huang 2012, 
Rossini 2005, Rumi 2005 
1995-
2012 
10 
(#2 can’t 
answer) 
Brunoni, 
2016 [77] 
SR 
and 
NMA 
4233 pts, 
81 RCTs 
To establish a clinically 
meaningful hierarchy of 
efficacy and tolerability 
of different rTMs 
modalities for MDD. 
rTMS (HF, LF, 
B, pTMS, aTMS, 
sTMS, DTMS, 
TBS) vs sham 
rTMS 
Response, 
remission 
Inclusion: 
RCTs, 
pts with unipolar or  
bipolar depression 
N/A n.a.-
2016 
7  
(#4,5,6,11 no) 
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Author 
and year 
Study  
type 
Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main  
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score 
(# no, can’t 
answer, not 
applicable) 
Gaynes, 
2014 [78] 
SR 782 pts,  
18 RCTs 
To evaluate the efficacy 
of rTMS in pts with TRD 
(2 or more antidepressant 
failures). 
rTMS vs  
sham rTMS 
Standardized 
mean 
difference in 
depression 
scores, 
response, 
remission 
Inclusion: 
RCTs, good or fair quality 
meta-analyses, 
any duration, 
pts with MDD that failed 
to achieve improvement 
after 2 or more adequate 
antidepressant medication 
treatments 
Avery 2006, Bakim 2012, 
Blumberger 2012, Bocchio-
Chiavetto 2008, Boutros 2002, 
Fitzgerald 2003, Fitzgerald 2006, 
Fitzgerald 2012, Garcia-Toro 2001, 
Garcia-Toro 2006, Holtzheimer 
2004, Kauffmann 2004, 
Padberg 1999, Pallanti 2010, 
Pascual-Leone 1996, Su 2005, 
Triggs 2010, Zheng 2010 
1980-
2013 
10  
(#5 no) 
Hovington, 
2013 [79] 
SR of 
SRs 
11 SRs To summarize several 
MAs exploring the 
efficacy of rTMS in either 
MDD or schizophrenia in 
order to examine the 
methodologies that 
increase the efficacy of 
rTMS. 
rTMS vs  
sham rTMS 
Standardized 
mean 
difference in 
depression 
scores, 
response, 
remission 
Inclusion: 
age ≥ 18 yrs, 
primary diagnosis of MDD, 
English language, 
published in peer-reviewed 
journal, 
MA provides effect sizes of 
primary studies 
Burt 2002, Couturier 2005, 
Gross 2007, Herrmann 2006, 
Holtzheimer 2001, Kozel 2002, 
Lam 2008, Martin 2003, 
McNamara 2001, Schutter 2009, 
Slotema 2010 
1993-
2010 
4 
(#2 can’t 
answer,  
#3-5,7,8,10 
no) 
HQO, 
2016 [13] 
SR rTMS vs 
sham 
rTMS:  
1156 pts,  
23 RCTs 
To examine the 
antidepressant efficacy  
of rTMS in patients with 
TRD. 
HF rTMS vs 
sham rTMS, 
HF rTMS vs 
ECT 
Standardized 
mean 
difference in 
depression 
scores, 
response, 
remission 
Inclusion: 
RCTs, 
age ≥ 18 yrs, 
HF rTMS for ≥ 10 sessions, 
only unipolar pts or max. 
20% bipolar pts, 
≥ 80% of pts with TRD 
Avery 1999, Avery 2006,  
Bakim 2012, Berman 2000, 
Blumberger 2012, Bretlau 2008, 
Boutros 2002, Chen 2013, 
Fitzgerald 2003, Fitzgerald 2012, 
Garcia-Toro 2001, George 2010, 
Holtzheimer 2004, Hoppner 2003, 
Loo 1999, Loo 2007, Mogg 2008, 
Mosimann 2004, O’Reardon 2007, 
Padberg 2002, Stern 2007,  
Su 2005, Triggs 2010 
1994-
2014 
9 
(#4,5 no) 
Kedzior, 
2014a 
[80] 
SR 
and 
MA 
801 pts,  
18 RCTs 
To update a previous SR 
of the authors (Kedzior 
2014b), to compare the 
overall mean weighted 
effect sizes of the studies 
in the previous SR with 
the new studies, and to 
find out if any patient 
characteristics or TMS 
parameters would be 
associated with the short-
term antidepressant 
properties of rTMS. 
rTMS (L, R, B) 
vs sham rTMS 
(L, R, B) 
Standardized 
mean 
difference in 
depression 
scores 
Inclusion: 
sham controlled RCTs  
with parallel design, 
HAMD, BDI or  
MADRS scales, 
pts with MDD (diagnosed 
according to DSM-IV or 
ICD-10) 
Aguirre 2011, Bakim 2012, 
Blumberger 2012, Chen 2013, 
Fitzgerald 2012, George 2010, 
He 2011, Hernandez-Ribas 2013, 
Huang 2012, Lingeswaran 2011, 
Pallanti 2010,  
Palliere-Martinot 2010,  
Peng 2012, Ray 2011, 
Spampinato 2013, Speer 2013, 
Triggs 2010, Zheng 2010 
2008-
2013 
9 
(#4,5 no) 
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Study  
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Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main  
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score 
(# no, can’t 
answer, not 
applicable) 
Kedzior, 
2014b [81] 
SR 
and 
MA 
1583 pts, 
40 RCTs, 
To apply a uniform and 
transparent meta-analytical 
procedure to reanalyse the 
data from the past 13 MA 
in order to find out if the 
new MA would produce 
only a moderate short-term 
antidepressant effect or it 
would increase due to the 
uniform statistical 
approach, and to test if the 
inclusion of more data than 
any one of the past MA 
alone would allow to detect 
significant predictors of 
the short-term response  
to rTMS due to a higher 
statistical power of an 
overall analysis. 
rTMS (L, R, B) 
vs sham rTMS 
(L, R, B) 
Standardized 
mean 
difference in 
depression 
scores 
Inclusion: 
double-blind RCTs with 
parallel design, 
pts with MDD (diagnosed 
according to DSM-IV or 
ICD -10), 
HAMD, BDI or MADRS 
scales, 
adequate data to compute 
effect sizes, depression 
measured at baseline and 
last session of rTMS or 
sham 
Anderson 2007, Avery 1999, 
Avery 2006, Berman 2000, 
Bretlau 2008, Bortolomasi 2007, 
Boutros 2002, Buchholtz 2004, 
Eschweiler 2000, Fitzgerald 2003, 
Fitzgerald 2006, Garcia-Toro 
2001a, Garcia-Toro 2001b, 
Garcia-Toro 2006, George 1997, 
George 2000, Hausmann 2004, 
Herwig 2007, Höppner 2003, 
Holtzheimer 2004, Januel 2006, 
Kauffmann 2004, Kimbrell 1999, 
Klein 1999, Koerselman 2004, 
Loo 1999, Loo 2007, Loo 2003, 
Manes 2001, Mogg 2008, 
Mosimann 2004, Nahas 2003, 
O’Reardon 2007, Padberg 2002, 
Padberg 1999, Poulet 2004, 
Rossini 2005, Rumi 2005,  
Stern 2007, Su 2005 
1997-
2008 
8 
(#5 no,  
#3,4 not 
applicable) 
Kedzior, 
2015 [82] 
SR 
and 
MA 
495 pts,  
16 RCTs 
To investigate the 
durability of the 
antidepressant effect of 
rTMS compared to sham 
using a continuous 
outcome instead of 
response rates. 
HF rTMS vs. 
sham rTMS 
Standardized 
mean 
difference in 
depression 
scores 
Inclusion: 
double-blind RCTs with 
parallel design, 
pts with MDD (diagnosed 
according to DSM-IV or 
ICD -10), 
HAMD or MADRS scales, 
HF rTMS to the left DLPFC 
Avery 1999, Anderson 2007, 
Bretlau 2008, Bortolomasi 2007, 
Buchholtz 2004, Eschweiler 2000, 
Garcia-Toro 2001a,  
Garcia-Toro 2001b,  
Holtzheimer 2004, Koerselman 
2004, Manes 2001, Mogg 2008, 
Huang 2012, Poulet 2004, 
Rossini 2005, Triggs 2010 
n.a.–
2013 
10 
(#4 no) 
Lepping, 
2014 [83] 
SR rTMS vs 
sham 
rTMS: 
1646 pts, 
32 RCTs 
To assess the clinical 
relevance of the efficacy 
of rTMS. 
rTMS  
(HF, LF, B) vs 
sham rTMS, 
rTMs vs ECT 
Standardized 
mean 
difference in 
depression 
scores 
Inclusion: 
human subjects with 
depression irrespective of 
the subtype and criteria 
used, 
rTMS as mono- or add-on 
therapy, 
HAMD scale, 
RCTs or non-RCTs, 
published in peer-reviewed 
journal, 
full-text available, 
sample size for each study 
arm reported 
Avery 2006, Bakim 2012, 
Bretlau 2008, Chen 2013, 
Garcia-Toro 2001,  
Garcia-Toro 2006, George 2010, 
George 1997, George 2000, 
Hansen 2004, Hausmann 2004, 
Hernandez-Ribas 2013,  
Herwig 2003, Herwig 2007, 
Holtzheimer 2004, Januel 2006, 
Kauffmann 2004, Klein 1999, 
Koerselman 2004, Loo 2006, 
Manes 2001, Martinot 2010, 
Moller 2006, Mosimann 2004, 
Nahas 2001, O’Reardon 2007, 
Padberg 2002, Rossini 2005, 
Stern 2007, Su 2005,  
Triggs 2010, Zheng 2010 
n.a.-
2014 
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Author 
and year 
Study  
type 
Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main  
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score 
(# no, can’t 
answer, not 
applicable) 
Liu, 2014 
[84] 
SR 
and 
MA 
279 pts,  
7 RCTs 
To evalute the efficacy 
and tolerability of rTMS 
used as an augmentative 
therapy. 
rTMS vs  
sham rTMS  
(all the 
patients  
with stable 
andidepressant 
treatment) 
Response, 
remission 
Inclusion: 
double-blind, sham 
controlled RCTs, 
rTMS as augmentation, 
age 18-75 yrs, 
pts with MDD, psychotic 
symptoms excluded, 
HAMD, MADRS scales, 
English language 
Bakim 2012, Bretlau 2008,  
Chen 2013, Garcia-Toro 2001, 
Garcia-Toro 2006,  
Martinot 2010, Rossini 2005 
1995-
2013 
9  
(#2 and 5 no) 
Leggett, 
2015 [85] 
SR 
and 
MA 
rTMS vs 
sham 
rTMS: 
1903 pts, 
45 RCTs 
To establish the efficacy 
and optimal protocol for 
rTMS among adults and 
youth with TRD. 
rTMS vs  
sham rTMS, 
rTMS vs ECT, 
HF rTMS vs  
LF rTMS, 
B-rTMS vs 
unilateral rTMS 
Response, 
remission 
Inclusion: 
TRD or pts who have had ≥ 
2 previous treatments, 
age >18 yrs, 
bipolar or unipolar 
depression, 
HAMD, MADRS, BDI 
scales, 
not been treated with 
rTMS prior to the study, 
RCT 
Avery 2006, Bakim 2012,  
Bares 2009, Berman 2000, 
Blumberger 2012, Boutros 2002, 
Chen 2013, Fitzgerald 2003, 
Fitzgerald 2012, Garcia-Toro 2006, 
George 2010, Hernandez-Ribas 
2013, Holtzheimer 2004, Jorge 
2004, Jorge 2008, Kauffmann 
2004, Loo 2007, Manes 2001, 
Mantovani 2013, McDonald 2006, 
Mosimann 2004, O’Reardon 2007, 
Padberg 2002, Palliere-Martinot 
2010, Peng 2012, Rossini 2005,  
Stern 2007, Su 2005, Zheng 2010 
n.a.–
2014 
9 
(#4,5 no) 
Leggett, 
2014 [86] 
SR 
and 
MA 
rTMS vs 
sham 
rTMS: 
1903 pts, 
45 RCTs 
To summarize the 
available evidence on 
rTMS for pts with TRD. 
rTMS vs sham 
rTMS, 
rTMS vs ECT,  
HF rTMS vs  
LF rTMS, 
B-rTMS vs 
unilateral 
rTMS, 
rTMS vs 
various other 
rTMS protocols 
Standardized 
mean 
difference in 
depression 
scores, 
response, 
remission 
Pts with TRD, 
age ≥ 18 yrs, 
bipolar or unipolar 
depression, 
HAMD, MADRS or BDI 
scales, 
not treated with rTMS 
before, 
RCT, 
reporting on efficacy in 
comparison to sham, 
pharmacological therapy, 
ECT or cognitive therapy or 
one type of rTMS vs 
another type of rTMS 
Avery 1999, Avery 2006, 
Baeken 2013, Bakim 2012,  
Bares 2009, Berman 2000, 
Blumberger 2012, Bretlau 2008, 
Bortolomasi 2007, Boutros 2002, 
Chen 2013, Fitzgerald 2003, 
Fitzgerald 2006, Fitzgerald 2012, 
Garcia-Toro 2001, Garcia-Toro 
2006, George 2010, Hernandez-
Ribas 2013, Holtzheimer 2004, 
Jorge 2004, Jorge 2008, 
Kauffmann 2004, Lisanby 2009, 
Loo 1999, Loo 2007, Loo 2003, 
Manes 2001, Mantovani 2013, 
McDonald 2006, Moller 2006, 
Moser 2002, Mosimann 2004, 
O’Reardon 2007, Padberg 2002, 
Padberg 1999, Palliere-Martinot 
2010, Pascal-Leone 1996, Peng 
2012, Rossini 2005, Speer 2009, 
Speer 2013, Stern 2007, Su 2005, 
Triggs 2010, Zheng 2010 
n.a.–
2014 
9 
(#4,5 no) 
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Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
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endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score 
(# no, can’t 
answer, not 
applicable) 
Serafini, 
2014 [87] 
SR rTMS vs 
sham 
rTMS: 265 
pts, 5 RCTs 
Systematically investigate 
the role of rTMS in 
improving 
neurocognition in 
patients with TRD 
L-rTMS vs 
sham rTMS, 
L-rTMs vs ECT, 
DTMS, rTMS of 
the anterior 
middle frontal 
gyrus vs  
sham rTMS,  
R-rTMS,  
L-rTMS 
Depression 
severity, 
verbal 
memory and 
fluency, 
response and 
remission, 
working 
memory, 
attention, 
visuospatial 
memory 
Inclusion: 
published in peer-reviewed 
journal, 
pts with TRD, 
analysis of the effect of 
neurocognitive functioning 
Avery 2006, Fitzgerald 2009, 
Hoy 2012, Padberg 1999, 
Vanderhasselt 2009 
1995-
2014 
4 
(#4,5,7,8,9,10,
11 no) 
Abbreviations: AMSTAR A MeaSurement Tool to Assess systematic Reviews, aTMS accelerated repetitive transcranial magnetic stimulation, B bilateral, BDI Beck Depression Inventory,  
B-rTMS bilateral repetitive transcranial magnetic stimulation, DLPFC dorsolateral prefrontal cortex, DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition,  
DTMS deep transcranial magnetic stimulation, ECT electroconvulsive therapy, HAMD Hamilton Depression Scale, HF high frequency, Hz Hertz, ICD International Statistical Classification of 
Diseases and Related Health Problems, LF low frequency, L-rTMS left-side repetitive transcranial magnetic stimulation, MA meta-analysis, MADRS Montgomery–Åsberg Depression Rating Scale, 
MDD major depressive disorder, pts patients, N/A not available, pTMS paired transcranial magnetic stimulation, rTMS repetitive transcranial magnetic stimulation, R-rTMS right-side repetitive 
transcranial magnetic stimulation, RCT randomized controlled trial, sTMS synchronized transcranial magnetic stimulation, SR systematic review, TBS Theta Burst Stimulation,  
TRD treatment-resistant depression, yrs years 
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Table A-4: Systematic reviews comparing rTMS with ECT 
Author 
and year 
Study  
type 
Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main 
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score  
(# no, can’t 
answer, not 
applicable) 
Berlim, 
2013 
[88] 
SR 
and 
MA 
294 pts,  
7 RCTs 
To summarize the best 
available evidence on 
the comparative efficacy 
and acceptability of  
HF-rTMS and ECT for 
treating MDD. 
HF rTMS vs 
ECT 
Standardized 
mean 
difference in 
depression 
scores, 
remission, 
acceptability 
Inclusion: RCTs with parallel or 
crossover design, ≥ 5 pts with MDD 
per study arm, age 18-75 yrs, 
unipolar or bipolar depression,  
HF rTMS (≥ 5 Hz) of the left DLPFC 
vs ECT (bilateral or unilateral) for  
≥ 10 and 6 sessions respectively, 
either as mono-or add-on therapy 
Eranti 2007,  
Grunhaus 2000, 
Grunhaus 2003,  
Janicak 2002,  
Keshtkar 2011,  
Pidmore 2000,  
Rosa 2006 
1995-
2012 
9  
(#2 can’t 
answer,  
#4 no) 
Micallef-
Trigona, 
2014 
[89] 
SR 
and 
MA 
384 pts,  
9 RCTs 
To compare ECT with 
rTMS for the management 
of TRD. The null hypo-
thesis is being tested: 
there is no statistically 
significant difference in 
the antidepressant 
efficacy between the two 
types of treatment. 
rTMS vs ECT Standardized 
mean 
difference in 
depression 
scores 
Inclusion: prospective RCTs with 
parallel design that compare ECT 
with rTMS, English language, human 
subjects aged >18 yrs with informed 
consent, HAMD scale and report on 
score before and after the treat-
ment, unipolar depression or bipolar 
with a current depressive episode 
Eranti 2007,  
Grunhaus 2000, 
Grunhaus 2003,  
Hansen 2011,  
Janicak 2002,  
Keshtkar 2011,  
O’Connor 2003,  
Rosa 2006, Schulze-
Rauschenbach 2005 
1806-
2013 
6  
(#2, #9 can’t 
answer and 
#4,#5,#7 no) 
Vallejo-
Torres, 
2015 
[90] 
Eco-
nomic 
eval-
uation 
n.a. pts,  
7 RCTs 
To develop a decision 
analytical model of the 
cost-effectiveness of ECT 
vs rTMS for TRD. 
rTMS vs ECT Response, 
relapse, 
remission, 
adverse effect 
Inclusion: RCTs comparing rTMS 
with ECT, age 18-75 yrs, unipolar or 
bipolar MDD starting treatment 
with ECT or rTMS without new 
antidepressant therapy, resistance 
to standard treatment or 
refractoriness of depression 
Dannon 2002,  
Eranti 2007,  
Grunhaus 2003, 
Grunhaus 2000, J 
anicak 2002,  
Keshtkar 2011,  
Rosa 2006 
n.a. Not  
applicable 
Xie, 2013 
[91] 
SR 
and 
MA 
395 pts,  
9 RCTs 
To assess how rTMS 
stimulus parameters 
influence the efficacy of 
rTMS relative to ECT in 
treating MDD. 
rTMS vs ECT Remission, 
response, 
drop-out 
Inclusion: RCTs comparing rTMS 
with ECT, HAMD scale, pts >18 yrs 
without metallic implants or foreign 
bodies, dementia, personal or family 
history of epileptic seizures, severe 
suicidal risk, organic brain damage, 
severe agitation or delirium, 
substance abuse, alcohol or drug 
dependence, and/or medically unfit 
for general anesthesia, providing 
informed consent 
Eranti 2007,  
Grunhaus 2000, 
Grunhaus 2003,  
Hansen 2011,  
Janicak 2002,  
Keshtkar 2011,  
Pridmore 2000,  
Rosa 2006,  
Wang 2004 
n.a.-2012 10  
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and year 
Study  
type 
Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main 
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score  
(# no, can’t 
answer, not 
applicable) 
Chen, 
2017 
[92] 
SR 
and 
MA 
L-rTMS vs 
ECT:  
343 pts,  
8 RCTs 
To assess the efficacy 
and acceptability of ECT, 
B-rTMS, R-rTMS, and L-
rTMS on MDD. 
L-rTMS vs  
B-rTMS, 
L-rTMS vs ECT, 
L-rTMS vs  
R-rTMS, 
R-rTMS vs ECT, 
R-rTMS vs  
B-rTMS 
Response, 
drop-out 
Inclusion: RCT, HAMD MADRS or 
CGI scale, age >18 yrs, pts without 
metallic implants or foreign bodies, 
dementia, personal or family 
history of epileptic seizures, severe 
suicidal risk, organic brain damage, 
severe agitation or delirium, 
substance abuse, alcohol or drug 
dependence, and/or medically unfit 
for general anesthesia. Pregnant pts 
also excluded. 
Eranti 2007, Grunhaus 
2000, Pridmore 2000, 
Rosa 2006, Wan 2011, 
Wang 2004 
n.a.-
2016 
10  
(#5 no) 
Ren, 
2014 
[93] 
SR 
and 
MA 
429 pts,  
10 RCTs 
To compare rTMS and 
ECT taking into account 
clinically meaningful out-
comes and to investigate 
the differences in self-
rated mood improvement, 
general mental state, 
cognitive function and 
adverse effects. 
rTMS vs ECT Response, 
remission, 
acceptability 
Inclusion: 
RCTs that compare rTMS with ECT 
Pts with unipolar or bipolar MDD 
with or without psychotic features 
HF of the left DLPFC or LF to the right 
DLPFC as add-on- or monotherapy 
ECT at any intensity and localization 
as add-on- or monotherapy 
Dannon 2002,  
Eranti 2007,  
Grunhaus 2000, 
Grunhaus 2003,  
Hansen 2011,  
Janicak 2002,  
Keshtkar 2011,  
Pridmore 2000, Rosa 
2006, Wang 2004 
n.a.-2013 10  
(#5 no) 
HQO, 
2016 [13] 
SR 
and 
MA 
HF rTMS 
vs ECT: 
266 pts,  
6 RCTs 
To examine the 
antidepressant efficacy 
of rTMS in patients  
with TRD. 
HF rTMS vs 
sham rTMS, 
HF rTMS vs 
ECT 
Standardized 
mean 
difference in 
depression 
scores, 
response, 
remission 
Inclusion: 
RCTs, 
age ≥ 18 yrs, 
HF rTMS for ≥ 10 sessions, 
only unipolar pts or max. 20% 
bipolar pts, 
≥ 80% of pts with TRD 
Eranti 2007,  
Grunhaus 2000, 
Grunhaus 2003, 
Keshtkar 2011,  
Pridmore 2000 and 
Dannon 2002,  
Rosa 2006 
1994-
2014 
9 
(#4,5 no) 
Leggett, 
2014 
[86] 
SR 
and 
MA 
rTMS vs 
ECT:  
205 pts,  
6 RCTs 
To summarize the 
available evidence on 
rTMS for pts with TRD. 
rTMS vs sham 
rTMS, 
rTMS vs ECT,  
HF rTMS vs  
LF rTMS, 
B-rTMS vs 
unilateral 
rTMS, 
rTMS vs 
various other 
rTMS protocols 
Standardized 
mean 
difference in 
depression 
scores, 
response, 
remission 
Pts with TRD, 
age ≥ 18 yrs, 
bipolar or unipolar depression, 
HAMD, MADRS or BDI scales, 
not treated with rTMS before, 
RCT, 
reporting on efficacy in comparison 
to sham, pharmacological therapy, 
ECT or cognitive therapy or one type 
of rTMS vs another type of rTMS 
Grunhaus 2003,  
Janicak 2002,  
Keshtkar 2011,  
Pridmore 2000a, 
Pridmore 2000b,  
Rosa 2006 
n.a.–
2014 
9 
(#4,5 no) 
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Author 
and year 
Study  
type 
Number of 
patients, 
number of 
RCTs 
Aim  
of the study 
Intervention(s) 
vs 
Comparison(s) 
Main 
endpoints 
Inclusion  
criteria 
Included  
studies 
Period 
searched 
AMSTAR Score  
(# no, can’t 
answer, not 
applicable) 
Leggett, 
2015 [85] 
SR 
and 
MA 
rTMS vs 
ECT:  
205 pts,  
6 RCTs 
To establish the efficacy 
and optimal protocol for 
rTMS among adults and 
youth with TRD. 
rTMS vs  
sham rTMS, 
rTMS vs ECT,  
HF rTMS vs  
LF rTMS, 
B-rTMS vs 
unilateral 
rTMS 
Response, 
remission 
Inclusion: 
TRD or pts who have had 
 ≥ 2 previous treatments, 
age >18 yrs, 
bipolar or unipolar depression, 
HAMD, MADRS, BDI scales, 
not been treated with rTMS prior  
to the study, 
RCT 
Grunhaus 2003,  
Janicak 2002,  
Kesthkar 2011,  
Pridmore 2000a, 
Pridmore 2000b,  
Rosa 2006 
n.a.–
2014 
9 
(#4,5 no) 
Lepping, 
2014 
[83] 
SR rTMS vs 
ECT:  
212 pts,  
5 RCTs 
To assess the clinical 
relevance of the 
reported efficacy of 
rTMS. 
rTMS  
(HF, LF,B) vs  
sham rTMS, 
rTMs vs ECT 
Standardized 
mean 
difference in 
depression 
scores 
Inclusion: 
human subjects with depression 
irrespective of the subtype and 
criteria used, 
rTMS as mono- or add-on therapy, 
HAMD scale, 
RCTs or non-RCTs, 
published in peer-reviewed journal, 
full-text available, 
sample size for each study arm 
reported 
Dannon 2000, 
Grunhaus 2003,  
Janicak 2002,  
Keshtkar 2011,  
Wang 2004 
n.a.-
2014 
5 
(#4,5,7,8,9, 10 
no or can’t 
answer) 
Serafini, 
2015 [87] 
SR rTMS vs 
ECT:  
118 pts,  
3 RCTs 
Systematically 
investigate the role of 
rTMS in improving 
neurocognition in 
patients with TRD 
rTMS vs  
sham rTMS, 
rTMS vs ECT, 
DTMS, rTMS  
of the anterior 
middle frontal 
gyrus vs sham 
rTMS, R-rTMS, 
L-rTMS 
Depression 
severity, verbal 
memory and 
fluency, 
response and 
remission, 
working 
memory, 
attention, 
visuospatial 
memory 
Inclusion: 
published in peer-reviewed journal, 
pts with TRD, 
analysis of the effect of 
neurocognitive functioning 
McLoughlin 2007,  
Rosa 2006,  
Schulze-Rauschenbach 
2005 
1995-
2014 
4  
(#4,5,7,8,9, 
10,11 no) 
Abbreviations: AMSTAR A MeaSurement Tool to Assess systematic Reviews, B bilateral, BDI Beck Depression Inventory, B-rTMS bilateral repetitive transcranial magnetic stimulation,  
CGI Clinical Global Impression, DLPFC dorsolateral prefrontal cortex, DTMS deep transcranial magnetic stimulation, ECT electroconvulsive therapy, HAMD Hamilton Depression Scale,  
HF high frequency, Hz Hertz, LF low frequency, L-rTMS left-side repetitive transcranial magnetic stimulation, MADRS Montgomery–Åsberg Depression Rating Scale, MDD major depressive 
disorder, pts patients, rTMS repetitive transcranial magnetic stimulation, R-rTMS right-side repetitive transcranial magnetic stimulation, RCT randomized controlled trial, SR systematic review, 
TRD treatment-resistant depression, yrs years 
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Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-5: Characteristics of randomised controlled studies comparing rTMS with sham rTMS 
Study characteristics 
Author, year,  
reference number 
Kang,  
2016 [14] 
Chen,  
2013 [94] 
Bakim,  
2012 [51] 
Blumberger,  
2012 [65] 
Fitzgerald,  
2012 [72] 
George,  
2010 [52] 
Study Registration 
number (Registry 
identifier) 
NCT01325831 N/A N/A NCT00305045 N/A NCT00149838 
Country South Korea Taiwan Turkey Canada Australia USA 
Sponsor Yonsei University 
College of Medicine 
Tzu-Chi General 
Hospital, Tzu-Chi 
University, National 
Science Council 
N/A Ontario Mental Health 
Foundation, Canadian 
Institutes of Health 
Research, NHMRC, 
NARSAD 
NHMRC National Institute of 
Mental Health 
Comparator Sham Sham Sham Sham Sham and bilateral 
rTMS 
Sham 
Study design RCT RCT RCT RCT RCT Multisite RCT 
Number of patients 
(active vs sham) 
24 (13 vs 11) 20 (10 vs 10) 35 (23 vs 12) 46 (24 vs 22) 44 (24 vs 20) 190 (92 vs 98) 
Study duration 2009-2011 Jan 2008 – Oct 2008 July 2007 – N/A Jan 2006 – Jan 2009 Jan 2008 – Nov 2010 Oct 2004 – March 2009 
Objectives To investigate the thera-
peutic effects of and the 
underlying neurobiolo-
gical changes 2-week HF-
rTMS on the left DLPFC in 
patients with TRD. 
To measure the acute 
antidepressant effect of 
rTMS and to evaluate 
participants 1 month 
after completion of 
the treatment. 
To investigate the 
efficacy of rTMS at two 
different intensities as an 
AD treatment to 
antidepressants in 
patients with TRD. 
To compare the efficacy 
of bilateral rTMS with 
unilateral and sham rTMS 
and to evaluate the 
tolerability and side 
effects. 
To investigate whether 
there is an advantage in 
efficacy of sequential 
bilateral rTMS 
compared to standard 
HF left sided rTMS. 
To test whether daily left 
prefrontal rTMS safely and 
effectively treats major 
depressive disorder. 
Model used Magstim Rapid,  
figure 8 coil 
Magstim Magstim Rapid2 Medtronic rTMS,  
figure 8 coil 
Medtronic Magpro30 Neuronetics Inc. 
Inclusion criteria MDD after DSM-IV-TR 
diagnostic criteria, 
current major depressive 
episode, failed to achieve 
adequate improvement 
(≤ 50% on HDRS-17) 
after at least 8 w of 
treatment with ≥ 1 SRRI 
MDD patients failed 
to achieve adequate 
improvement (≤ 50%  
on HDRS-17) after ≥ 2 
antidepressant 
treatments 
Unipolar MDD, recurrent 
or single episode without 
psychotic features, age 
18-65 yrs, right-handed, 
no response to adequate 
courses of ≥ 2 different 
classes of antidepressants, 
no change in the 
treatment regimen ≥ 4 w, 
scored ≥ 18 on HDRS-17 
and ≥ 20 on MADRS 
Age 18-85 yrs, DSM-IV 
diagnosis of MDD 
without psychotic 
features, TRD, ≥ 21 on 
HDRS, stable doses of 
psychotropic medications 
≥ 4 w prior to 
randomization, capable 
to consent, currently 
outpatient 
Diagnosis of moderate  
to severe depression 
(scoring >15 on  
HDRS-17) 
Age 18-70 yrs, free of anti-
depressant medication, 
DSM-IV diagnosis of MDD, 
current episode lasting  
< 5 yrs, ≥ 20 on HDRS, 
stable during 2 w free  
of medication, TRD 
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Study characteristics 
Author, year,  
reference number 
Kang,  
2016 [14] 
Chen,  
2013 [94] 
Bakim,  
2012 [51] 
Blumberger,  
2012 [65] 
Fitzgerald,  
2012 [72] 
George,  
2010 [52] 
Exclusion criteria Current or past history of 
psychotic disorder other 
than MDD (including 
anxiety disorder, 
substance use disorder), 
seizure, mental 
retardation, high risk  
of suicide, cognitive 
impairment (score <24 
on the Mini-Mental 
State Examination), or 
contraindications  
for fMRI 
High risk of suicide, 
any physical 
abnormality such as a 
head injury or 
epilepsy or if patients 
had an implanted 
pacemaker 
Comorbidity of any other 
Axis I disorder, current or 
past history of epilepsy, 
head trauma, encephalitis, 
meningitis, or other 
cerebrovascular disease, 
pregnancy, pace-maker or 
medical pump implants, 
metal implant in the 
skull, any use of ECT, 
antipsychotics or 
anticonvulsants which 
may change the MT, 
inability to read in 
Turkish 
DSM-IV substance 
dependence in the last  
6 mo (excl. nicotine), 
substance abuse in the 
last month, borderline 
personality disorder or 
antisocial personality 
disorder, bipolar I, II or 
NOS, had significant 
unstable medical or 
neurologic illness or 
history of seizures, 
acutely suicidal, pregnant, 
metal implants in the 
cranium, dementia or a 
current MMSE score < 26, 
received benzodiazepines, 
MAOI, or buproprion 
during the previous 4 w, 
prior treatment with 
rTMS for any indication 
Bipolar disorder, 
significant active 
medical/neurological 
illness, or 
contraindication to 
rTMS. Concurrent Axis I 
psychiatric disorders 
were not excluded,  
with the exception of 
schizophrenia spectrum 
disorders 
Other Axis I disorders, 
failed to respond to ECT, 
pervious treatment with 
rTMS or VNS, family 
history of seizure, 
neurologic disorder, 
ferromagnetic material in 
body or near head, 
pregnancy, taking 
medication which lowers 
seizure threshold, positive 
urine test for cocaine, 
marijuana,  
PCP or opiates 
Add-on or 
monotherapy 
Add-on Add-on Add-on Add-on Add-on Mono 
Follow-up duration N/A 4 w N/A N/A 6 w1 6 w1 
Loss-to-FU, n (%) N/A 0 N/A N/A 3 (12.5) vs 0 N/A 
Depression scale used HDRS-17 HDRS-17 HDRS-17, MADRS HDRS-17 HDRS-17, MADRS HDRS-24, MADRS 
Frequency, Hz 10 20 20 10 10 10 
Trains, n 20 20 20 29 30 75 
Train duration, s 5 2 2 5 5 4 
Inter-train interval, s 25 N/A 28 30 N/A 26 
Pulses per session 1000 800 800 1450 1500 3000 
Number of sessions 
(duration of 
intervention) 
10 (2 w) 10 (2 w) 30 (6 w) 30 (6 w) 15 (3 w) 15 (3 w) 
Total pulses 10000 8000 24000 21750 22500 45000 
Unilateral/bilateral, 
side if unilateral 
Unilateral, left DLPFC, 5 
cm rule 
Unilateral, left 
DLPFC, 5 cm rule 
Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left DLPFC 
Intensity of the 
stimulation (% RMT) 
110 90 80/110 100/120 120 120 
                                                             
1 After 3 week treatment, extension to 6 weeks  
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Study characteristics 
Author, year,  
reference number 
Kang,  
2016 [14] 
Chen,  
2013 [94] 
Bakim,  
2012 [51] 
Blumberger,  
2012 [65] 
Fitzgerald,  
2012 [72] 
George,  
2010 [52] 
Patient characteristics (active vs sham) 
Age, y mean (SD) 42.8 (19.1) vs 52.2 (20.1) 44.1 (4.4) vs 47.3 (3.5) 43.09 (8.18) vs 44.4 (10.2) 48.9 (13.4) vs 45.8 (13.4) 43.3 (12.7) vs 44.9 (15.7) 47.7 (10.6) vs 46.5 (12.3) 
Sex, male/female, n 3/9 vs 1/8 3/7 vs 6/4 3/20 vs 1/11 12/14 vs 6/14 9/15 vs 12/8 34/58 vs 48/50 
Previous therapy All participants were 
taking antidepressants 
(SSRI) for > 8 w 
≥ 2 antidepressant 
treatments 
72.7% patients in the 
110% group and 58.3% 
patients both in the 80% 
and sham groups used 
SNRIs, the rest used SSRIs 
≥ 2 antidepressant 
treatments 
SSRI: 8 vs 3 
SNRI: 3 vs 5 
Tricyclic antidepressant:  
5 vs 3 
Mirtazapine: 2 vs 1 
Trazodone: 2 vs 1 
Lithium: 0 vs 1 
Benzodiazepine: 9 vs 7 
Atypical antipsychotics:  
2 vs 1 
≥ 2 antidepressant 
treatments. (mean 
number of courses 
across episodes 
5.20±3.3) 
1-4 or intolerant to ≥ 3 
Depression score at 
baseline, mean (SD) 
24.1 (6.4) vs 20.0 (4.6) 23.5 (1.9) vs 24.9 (1.9) HDRS: 24.09 (2.77) vs 
25.58 (3.82) 
MADRS: 27.81 (3.09) vs 
28.75 (5.59) 
26.0 (3.3) vs 25.2 (2.8) HDRS: 23.7 (3.8) vs  
22.9 (2.1) 
MADRS: 32.0 (4.6) vs 
32.0 (3.5) 
HDRS: 26.3 (5.0) vs  
26.5 (4.8) 
MADRS: 29.5 (6.9) vs  
29.8 (6.4) 
QoL (SF-36,  
Q-LES-Q) at baseline 
N/A N/A N/A N/A N/A N/A 
Suicidal ideation/ 
suicide score at 
baseline 
N/A N/A N/A N/A N/A N/A 
Outcomes 
Efficacy (active vs sham) 
Depression score at 
end of treatment 
and last FU, mean 
(SD) 
2 w: 10.1 (3.8) vs  
15.3 (4.3) 
2 w: 9.6 (1.5) vs  
12.3 (1.4) 
4 w FU: 9.8 (1.6) vs 
16.4 (1.5) 
6 w: 
HDRS: 11.64 (8.12) vs  
19.5 (7.83) 
MADRS: 13.54 (8.35) vs 
21.91 (8.42) 
6 w: 20.3 (5.1) vs  
18.9 (6.4) 
3 w: HDRS: 19.6 (4.2) vs 
22.6 (5.0) 
MADRS: 27.5 (6.0) vs 
30.0 (6.2) 
6 w FU: HDRS:  
13.0 (7.0) vs N/A 
MADRS: 18.6 (9.7) vs N/A 
3 w: HDRS: 21.61 (9.26) vs 
23.38 (7.43) 
MADRS: 24.59 (11.44) vs 
27.75 (9.06) 
6 w FU: N/A 
Response, n (%) 9 (75) vs 0 7 (70) vs 8 (80) 8 (73) vs 2 (17) 1 (4.5) vs 2 (10) 0 vs 1 (4) 13 (14) vs 5 (5) 
Remission, n (%) 3 (25) vs 0 N/A 6 (55) vs 1 (8) 1 (4.5) vs 1 (5) N/A 13 (14) vs 5 (5) 
QoL (SF-36, Q-LES-Q) 
at end of treatment 
N/A N/A N/A N/A N/A N/A 
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Study characteristics 
Author, year,  
reference number 
Kang,  
2016 [14] 
Chen,  
2013 [94] 
Bakim,  
2012 [51] 
Blumberger,  
2012 [65] 
Fitzgerald,  
2012 [72] 
George,  
2010 [52] 
Drop-out, n (%) N/A N/A N/A Drop-out due to lack of 
perceived benefit, inability 
to attend sessions:  
8 (33.3) vs 3 (13.6) 
Discontinuation of 
intervention due to 
withdrawal, mild 
worsening of symptoms 
and unable to tolerate 
travel: 0 vs 3 (15) 
11 (12) vs 9 (9) 
Suicidal ideation/ 
suicide score post-
treatment 
N/A N/A N/A N/A N/A N/A 
Safety, n of pts (%) (active vs sham) 
SADEs 
Seizure N/A N/A 02 02 02 N/A 
Transient cognitive 
impairment 
N/A N/A 02 02 02 N/A 
Induced currents 
circuits in implanted 
devices 
N/A N/A N/A N/A N/A N/A 
ADEs 
Headache N/A N/A 4 (17.4) vs 1 (8.3) 1 (4.2) vs 0 N/A 29 (32) vs 23 (23) 
Syncope (fainting) N/A N/A N/A N/A N/A 5 (5) vs 4 (4) 
Scalp discomfort N/A N/A 2 (8.7) vs 0 1 (4.2) vs 0 N/A 17 (18) vs 10 (10) 
Pain N/A N/A N/A N/A N/A 1 (1) vs 1 (1) 
Facial twitching N/A N/A N/A N/A N/A 0 vs 1 (1) 
Vertigo N/A N/A N/A N/A N/A 2 (2) vs 2 (2) 
Device-related 
insomnia/drowsiness 
N/A N/A N/A 1 (4.2) vs 0 N/A 7 (8) vs 10 (10) 
Transient induction  
of hypomania 
N/A N/A N/A N/A N/A N/A 
Mild confusion N/A N/A N/A N/A N/A N/A 
Transient hearing 
loss/tinnitus 
N/A N/A N/A N/A N/A N/A 
Other AEs      Worsening of depression/ 
anxiety: 6 (7) vs 8 (8) 
Gastrointestinal 6 (7) vs 3 (3) 
Muscle aches: 4 (4) vs 4 (4) 
Other: 18 (20) vs 15 (15) 
 
                                                             
2 It is stated that no serious adverse event occurred, but not stated separately for seizure and cognitive impairment. 
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Study characteristics 
Author, year, 
reference number 
Stern,  
2007 [50] 
Triggs,  
2010 [63] 
Mogg,  
2008 [71] 
Bretlau,  
2008 [58] 
O’Reardon, 2007 [16] 
Solvason, 2014 [15] 
Loo,  
2007 [68] 
Study Registration 
number (Registry 
identifier) 
N/A NCT00711568 ISRCTN70121208 N/A NCT00104611 N/A 
Country USA USA UK Denmark USA Australia 
Sponsor Spanish Ministerio de 
Educacion y Cienca, 
Milton Found, Stanley 
Vada NAMI Foundation, 
National Alliance for Re-
search in Schizophrenia 
and Depression, NIHM 
Veterans Affairs Guy’s and St Thomas’ 
Charitable Foundation, 
NCCHTA, National 
Alliance for Research  
on Schizophrenia and 
Depression, Psychiatry 
Research Trust 
Medicon Valley 
Academy,  
H Lundbeck A/S 
Neuronetics Inc. National Health 
and Medical 
Research Council 
Programme 
Comparator Sham, other rTMS 
protocols 
Sham, other rTMS 
protocols 
Sham Sham Sham Sham 
Study design RCT RCT RCT RCT Multisite RCT RCT 
Number of patients 
(active vs sham) 
25 (10 vs 15) 32 (18 vs 14) 59 (29 vs 30) 45 (22 vs 23) 301 (155 vs 146) 38 (19 vs 19) 
Study duration N/A 6 yrs March 2002-Aug 2004 Apr 2003–Dec 2005 Jan 2004-Aug 2005 N/A 
Objectives To test if both HF left-
sided and LF right-sided 
DLPFC stimulation have 
equivalent 
antidepressant effects. 
To compare HF-rTMS of 
the left and right DLPFC 
with sham in a parallel 
group design. 
To assess the efficacy of 
rTMS and report follow-
up data and on the 
success of blinding. 
To assess the efficacy of 
rTMS compared to sham 
and to compare results 
to Avery 2006 [64]. 
To test if rTMS over the left 
DLPFC is effective and safe in 
the acute treatment of MDD. 
Solvason 2014: To summarize 
the QoL outcomes of 
O’Reardon 2007 [16] 
To test the efficacy 
and safety of 
twice-daily rTMS 
over 2 weeks. 
Model used Magpro, Magstim Super 
Rapid 
Magstim Super Rapid, 
figure 8 coil 
Magstim Super Rapid, 
figure 8 coil 
Magstim Super Rapid, 
figure 8 coil 
Neuretics Model 2100 
Therapy System 
Magstim Super 
Rapid, figure 8 coil 
Inclusion criteria Right-handed, age  
21-80 yrs, MDD after 
SCID and DSM-IV criteria 
(score of 20 on the 
HDRS), no psychotic 
features, no other Axis I, 
naïve to TMS 
Age 18-75 yrs, TRD 
according to DSM-IV 
criteria and verified by 
the SCID, total score ≥ 18 
on HDRS-24, score ≥ 3 
on item number 1 of the 
HDRS-24 in two 
separate screening 
sessions 
Age >18 yrs, right-handed, 
diagnosis of MDD episode 
established by case-note 
review and confirmed by 
DSM-IV Axis I Disorders 
(SCID). Patients taking 
psychotropic medication 
were required to have 
been on a stable drug 
regimen for ≥ 4 w before 
study entry and to remain 
on the same medication 
during the study 
Age 18-75 yrs, DSM-IV 
diagnosis of current 
MDD, TRD 
Medication free outpatient, 
age 18-70 yrs, DSM-IV 
diagnosis of MDD, <3 yrs 
length of current episode,  
≥4 CGI, ≥20 on HDRS, 
symptom stability for 1 w, 
TRD 
DSM-IV diagnosis 
of MDD < 2 yrs in 
length, ≥25 on the 
MADRS, TRD 
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Study characteristics 
Author, year, 
reference number 
Stern,  
2007 [50] 
Triggs,  
2010 [63] 
Mogg,  
2008 [71] 
Bretlau,  
2008 [58] 
O’Reardon, 2007 [16] 
Solvason, 2014 [15] 
Loo,  
2007 [68] 
Exclusion criteria History of schizophrenia, 
schizoaffective disorder, 
bipolar, obsessive 
compulsive disorder, 
personality disorder; 
substance abuse (except 
nicotine) within past 
year, current acute or 
chronic medical condition 
requiring treatment with 
psychoactive 
medication, history or 
family history of epilepsy, 
prior brain surgery, 
metal in the head, 
implanted device, 
pregnancy, or unable to 
tolerate medication 
withdrawal (14-day 
washout period) 
History of schizophrenia, 
schizoaffective disorder, 
other functional psychosis, 
bipolar, alcohol or drug 
abuse within the past 
year, positive drug test, 
axis II Cluster A or Cluster 
B personality disorder or 
mental retardation, use 
of medications that may 
lower seizure threshold, 
history of epilepsy, 
intracranial tumour, 
major head trauma, 
central nervous system 
disease, implanted pace-
maker or medication 
pump, metal plate in 
skull, need for rapid 
clinical response due to 
psychosis, or suicidality, 
use of anticonvulsant 
mood stabilizers, or 
inability to consent 
History of seizures, head 
injury with loss of 
consciousness, brain 
surgery, presence of 
metallic implants, 
dementia or other Axis I 
diagnosis, substance 
dependency or abuse 
within the previous 6 m, 
previous rTMS 
treatment, inability  
to provide informed 
consent 
Organic brain disorder, 
substance abuse, severe 
anxiety disorder, 
personality disorder, 
history of epilepsy, 
metal implants in head 
or neck, pacemaker, 
suicidal ideation (score 
of > 2 on the suicide 
item of HDRS), those 
receiving antipsychotics, 
current episode > 24 mo, 
risk factors deterring 
escitalopram treatment, 
pregnancy 
Psychosis, bipolar disorder, 
obsessive compulsive disorder, 
posttraumatic stress disorder, 
eating disorder, no response 
to ECT, prior treatment with 
TMS, pregnant, personal or 
family history of seizures, 
neurologic disorder or 
medication that alters seizure 
threshold, ferromagnetic 
material in close proximity  
to head 
Axis I disorder, 
neurological illness, 
epilepsy, severe 
medical illness, 
implanted electronic 
devices, suicidal, or 
psychotic, patients 
failed >2 classes of 
antidepressants or 
a failed ECT 
Add-on or 
monotherapy 
Mono Add-on Add-on Mono Mono Add-on 
Follow-up duration 4 w3 3 mo 4 mo 3 mo 6 mo 6 w4 
Loss-to-FU, n (%) 0 3 (6) 4 (7) 1 (0.5) vs 5 (21.7) 56 (36) vs 125 (86) 1 (10) vs 4 (33) 
Depression scale used HDRS-21 HDRS-24 HDRS-17 HDRS-17 HDRS-17/24, MADRS HDRS-17, MADRS 
Frequency, Hz 10 5 10 8 10 10 
Trains, n 20 50 20 20 75 30 
Train duration, s 8 8 5 8 4 5 
Inter-train interval, s 52 22 55 52 26 25 
Pulses per session 1600 2000 1000 1280 3000 1500 
Number of sessions 
(duration of 
intervention) 
10 (2 w) 10 (2 w) 10 (2 w) 15 (3 w) 30 (6 w) 20 (2 w) 
Total pulses 16000 20000 10000 19200 90000 30000 
                                                             
3 After 2 weeks treatment, extension to 4 weeks 
4 After 2 weeks treatment, extension to 6 weeks 
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Study characteristics 
Author, year, 
reference number 
Stern,  
2007 [50] 
Triggs,  
2010 [63] 
Mogg,  
2008 [71] 
Bretlau,  
2008 [58] 
O’Reardon, 2007 [16] 
Solvason, 2014 [15] 
Loo,  
2007 [68] 
Unilateral/bilateral, 
side if unilateral 
Unilateral, left DLPFC Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left DLPFC, 5 cm 
rule 
Unilateral, left 
DLPFC 
Intensity of the 
stimulation (% RMT) 
110 100 110 90 120 110 
Patient characteristics (active vs sham) 
Age, y mean (SD) 53.2 (12.0) vs 53.3 (9) 46.7 (15.3) vs 41.9 (14.1) 55.0 (18.0) vs 52.0 (15.5) 53.1 (10.1) vs 57.8 (10) 47.0 (11.0) vs 48.7 (10.6) 49.8 (2.5) vs 45.7 (15) 
Sex, male/female, n 4/6 vs 6/9 4/14 vs 8/6 13/16 vs 9/21 7/15 vs 13/10 69/86 vs 72/74 9/10 vs 11/8 
Previous therapy ≥ 1 previous treatment 
(including ECT) 
≥ 2 separate trials of 
antidepressants 
including at least one 
SSRI or intolerant to ≥ 3 
including at least one 
SSRI 
≥ 2 treatments: 22 vs 24 
≥ 3 treatments: 15 vs 16 
treatment with ECT: 7 vs 10 
medications: SSRI  
(10 vs 7), tricyclic  
(9 vs 9), MAOI (0 vs 1), 
venlafaxine (10 vs 7), 
lithium (0 vs 4), 
antipsychotic (2 vs 6), 
benzodiazepine (2 vs 6), 
zopiclone (5 vs 7), no 
medication (2 vs 4) 
≥ 1 previous treatment 
ECT: 1 vs 2 
≥ 1 previous treatment ≥ 1 previous 
treatment, but 
maximum 2 failed 
treatments 
Depression score at 
baseline, mean (SD) 
27.8 (3.2) vs 27.4 (2.9) 28.2 (6.0) vs 27.5 (3.0) 20.5 (4.4) vs 21.6 (4.7) 25.3 (3.0) vs 24.7 (3.2) HAMD-17: 22.6 (3.3) vs  
22.9 (3.5) 
HAMD-17: 19.2 (3.7) 
vs 20.9 (4.2) 
MADRS: 29.5 (3.9) 
vs 32.6 (4.3) 
QoL (SF-36 PF,  
SF-36 general health, 
SF-36 mental health, 
bodily pain, vitality, 
Q-LES-Q) at baseline 
N/A N/A N/A N/A SF-36 PF: 45.9 (10.5) vs 43.2 (11.3) 
SF-36 gen. health:  
41.1 (9.8) vs 40.9 (9.5) 
SF-36 mental h.:  
25.1 (8.7) vs 24.6 (7.8) 
Q-LES-Q total score:  
37.6 (8.2) vs 36.5 (7.9) 
N/A 
Suicidal ideation/ 
suicide score at 
baseline 
N/A N/A N/A N/A N/A N/A 
Outcomes 
Efficacy (active vs sham) 
Depression score 
(at end of treatment 
and FU), mean (SD) 
2 w: 15.1 (6) vs 26.7 (3.6) 
4 w FU: 13.4 (5.6) vs 
26.8 (2.3) 
2 w: 19.8 (9.1) vs  
17.7 (10.4) 
3 mo FU: 16.3 (11.5) vs 
17.9 (11.6) 
2 w: 17.1 vs 18.8 
4 mo FU: 19.8 vs 15.1 
3 w: 16.4 (4.5) vs  
19.1 (4.8) 
3 mo FU: 11.1 (6.7) vs  
13.5 (7.2) 
6 w: 17.1 (7.7) vs 19.6 (7.0) 
6 mo FU: N/A 
2 w: 
HAMD-17: 11.8 (5.7) 
vs 15.4 (7.3) 
MADRS: 18.9 (7.7) 
vs 27.1 (10.2) 
6 w FU: N/A 
  
A
p
p
en
d
ix 1: M
eth
o
d
s an
d
 d
escrip
tio
n
 o
f th
e evid
en
ce u
sed
 
LB
I-H
T
A
| 20
17 
10
5 
Study characteristics 
Author, year, 
reference number 
Stern,  
2007 [50] 
Triggs,  
2010 [63] 
Mogg,  
2008 [71] 
Bretlau,  
2008 [58] 
O’Reardon, 2007 [16] 
Solvason, 2014 [15] 
Loo,  
2007 [68] 
Response, n (%) 2 w: 5 (50) vs 0 
4 w FU: 4 (40) vs 0 
2 w: 4 (22) vs 6 (43) 
3 mo FU: 6 (33) vs 4 (29) 
2 w: 9 (32) vs 3 (10) 
4 mo FU: N/A 
N/A 6 w: 38 (24.5) vs 20 (13.6) 
6 mo FU: N/A 
2 w: 6 (32) vs 3 (16) 
6 w FU: N/A 
Remission, n (%) 2 w: 3 (33) vs 0 
4 w FU: 4 (40) vs 0 
N/A 2 w: 7 (25) vs 3 (10) 
4 mo FU: N/A 
N/A 6 w: 24 (15.5) vs 13 (8.9) 
6 mo FU: N/A 
2 w: 3 (16) vs 2 (11) 
6 w FU: N/A 
QoL (SF-36 PF,  
SF-36 general health, 
SF-36 mental health, 
bodily pain, vitality, 
Q-LES-Q,), mean 
difference (SD) 
N/A N/A N/A N/A SF-36 PF: 
6 w: 47.3 (9.6) vs 44.6 (10.5) 
6 mo: 48.8 (10.4) vs 49.8 (8.1) 
SF-36 gen. health: 
6 w: 42.6 (10.1) vs 40.9 (10.1) 
6 mo: 45.5 (11.1) vs 44.8 (13.1) 
SF-36 mental h.: 
6 w: 30.5 (13.0) vs 27.1 (11.7) 
6 mo: 43.8 (11.3) vs 41.1 (11.9) 
Bodily pain scores 
6 w: 45.6 (10.2) vs 46.3 (9.3) 
6 mo: 47.5 (8.9) vs 51.3 (6.8) 
Vitality scores 
6 w: 38.1 (10.6) vs 38.2 (11.5) 
6 mo: 45.0 (11.1) vs 44.3 (15.3) 
Q-LES-Q score: 
6 w: 42.4 (12.3) vs 39.3 (10.2) 
6 mo: 56.0 (11.3) vs 55.3 (12.2) 
N/A 
Drop-out, n (%) 0 vs 3 (20) withdrew  
due to AEs (headache) 
N/A 0 vs 2 (7) withdrew  
due to AEs (tinnitus) 
0 vs 0 7 (4) vs 9 (6) (AE 4 vs 4, failed 
to return 1 vs 0, unsatisfactory 
response 1 vs 2, patient 
request unrelated to study  
1 vs 1, other issues 0 vs 2) 
1 (5) vs 1 (5) 
withdrew due to 
very depressed and 
attendance stressful, 
could not attend 
Suicidal ideation/ 
suicide score  
post-treatment 
N/A N/A N/A N/A 0 vs 1 (0.7) N/A 
Safety, n pts (active vs sham) 
SADEs 
Seizure 0 N/A 0 N/A 0 0 
Transient cognitive 
impairment 
N/A 0 vs 1 (7) N/A UKU scores5 at  
3 mo: 0 vs 0 
N/A N/A 
                                                             
5 Used for the assessment of side effects of psychopharmacological medications. 48 symptoms are rated in 4 categories. 
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Study characteristics 
Author, year, 
reference number 
Stern,  
2007 [50] 
Triggs,  
2010 [63] 
Mogg,  
2008 [71] 
Bretlau,  
2008 [58] 
O’Reardon, 2007 [16] 
Solvason, 2014 [15] 
Loo,  
2007 [68] 
Induced currents 
circuits in implanted 
devices 
N/A N/A N/A N/A N/A N/A 
ADEs 
Headache 9 in total 7 (39) vs 6 (43) N/A UKU scores at 3 mo:  
0.1 (0.3) vs 0.06 (0.24) 
59 (36) vs 6 (4)6 8 (42) vs 0 
Syncope (fainting) N/A 5 (28) vs 2 (14) N/A N/A N/A N/A 
Scalp discomfort N/A 6 (33) vs 3 (21) N/A N/A 18 (12) vs 2 (1) 15 (79) vs 0 
Pain N/A 1 (6) vs 0 N/A N/A 59 (38) vs 6 (4) N/A 
Facial twitching N/A 1 (6) vs 0 N/A N/A 11 (7) vs 5 (3) 3 (16) vs 0 
Vertigo/dizziness N/A 3 (17) vs 2 (14) 0 vs 2 (7) N/A N/A N/A 
Device-related 
insomnia/drowsiness 
N/A 1 (6) vs 1 (7) N/A UKU scores at 3 mo: 
0.24 (0.44) vs 0.39 
(0.61) 
N/A N/A 
Transient induction 
of hypomania 
N/A N/A N/A N/A N/A 1 (5) vs 0 
Mild confusion N/A N/A N/A N/A N/A N/A 
Transient hearing 
loss/tinnitus 
N/A N/A 0 vs 2 (7) N/A N/A N/A 
Other AEs 0 Neck muscle soreness:  
1 (6) vs 0 
Nausea: 4 (22) vs 0 
N/A UKU scores at 3 mo: 
Nausea: 0.05 vs 0.17 
Diarrhea: 0.1 vs 0 
Dry mouth: 0.14 vs 0.11 
Palpitations: 0.14 vs 0.12 
N/A Tearfulness:  
4 (21) vs 0 
Nausea: 0 vs 1 (5) 
Agitation: 1 (5) vs 0 
Feeling high:  
1 (5) vs 0 
 
  
                                                             
6 Referred to as application site pain in the study 
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Study characteristics 
Author, year, 
reference number 
Avery,  
2006 [64] 
Su,  
2005 [53] 
Holtzheimer,  
2004 [57] 
Mosimann,  
2004 [55] 
Fitzgerald,  
2003 [56] 
Hoppner,  
2003 [95] 
Study Registration 
number (Registry 
identifier)  
NA NA  NA NA NA NA 
Country USA Taiwan  USA Germany Australia Germany 
Sponsor National Insitute of Mental 
Health 
Taipei Veterans General 
Hospital 
University of 
Washington 
Swiss National Science 
Foundation 
National Health and 
Medical Research 
Council, Stanley Medical 
Research Insitute 
NA 
Comparator Sham Sham Sham Sham LF-rTMS/sham LF-rTMS/sham 
Study design RCT RCT RCT RCT RCT RCT 
Number of patients 
(active vs sham) 
68 (35 vs 33) 30 (20 vs 10) 15 (7 vs 8) 24 (15 vs 9) 60 (20 in each group) 30 (10 in each group) 
Study duration Jan 2001 – Febr 2004 N/A Jan 1998 – Dec 1999 N/A Oct 2000 – Sept, 2002 N/A 
Objectives To assess if patients 
receiving active TMS would 
show a greater anti-
depressant response rate 
than those receiving sham 
stimulation. 
To determine whether 
lelft DLPFC rTMS can 
alleviate TRD in Chinese 
patients and to investigate 
what demographic 
variables or clinical 
features may predict 
better response. 
To determine if rTMS 
would have greater 
antidepressant effects 
than sham stimulation 
and that rTMS would be 
safe and tolerable.  
To assess the effect of 
rTMS in older 
outpatients with TRD. 
To prospectively 
evaluate the efficacy of 
HF-TMS and LF-TMS in 
TRD and compared with 
a sham treated control 
group.  
To compare clinical 
effects of two different 
stimulation procedures 
with sham stimulation 
as add-on treatments in 
patients with depressive 
disorders. 
Model used Magpro Compact,  
MagPro X100, Magpro R30, 
figure 8 coil 
MAGSTIM Rapid II, 
MAGSTIM Model 2002, 
Neurosign Model 4000, 
figure 8 coil 
Magpro Compact, 
MagPro X100, Magpro 
R30, figure 8 coil 
MAGSTIM Rapid II, 
MAGSTIM Model 2002, 
Neurosign Model 4000, 
figure 8 coil 
MAGSTIM Rapid II, 
MAGSTIM Model 2002, 
Neurosign Model 4000, 
figure 8 coil  
Maglite r 25,  
figure 8 coil 
Inclusion criteria Age 21-65 yrs, current MDD 
as diagnosed by DSM-IV, 
TRD (failed to tolerate ≥ 2 
antidepressant trials,  
score ≥ 17 on HDRS 
Patients who met the 
DSM-IV criteria for a 
major depressive episode 
or bipolar disorder 
(based on the Mini-
International Psychiatric 
Interview), TRD  
Age 21-65 yrs, right 
handed, MDD as 
diagnosed by DSM-IV,  
no major psychiatric or 
medical comorbidity, 
TRD, score ≥ 18 on HDRS, 
not on medication  
Age 40-90 yrs, 
diagnosis of TRD 
according to DSM-IV 
and ICD-10  
N/A Depressive, right-
handed in-patients  
Exclusion criteria Prior rTMS, bipolar 
disorder, failure of ≥ 9 ECT, 
substance abuse or addiction 
in past 2 yrs, antisocial or 
borderline personality 
disorder, psychosis, seizure 
disorder, closed head injury 
with loss of consciousness, 
brain surgery, major 
psychiatric or medical 
comorbidity  
History of epilepsy, 
history of physical or 
neurological 
abnormalities, implanted 
pacemaker, substantial 
risk of suicide during the 
trial, previously had 
major head trauma or 
displayed any psychotic 
symptoms, previously 
had rTMS or ECT 
History of bipolar 
disorder, failure to 
respond to ECT therapy, 
history of substance 
abuse, psychosis, 
pregnancy 
Head injury, epilepsy, 
comorbid unstable 
medical or neurological 
illness, no birth control 
(women) 
Significant medical 
illness, neurologic 
disorders or other Axis I 
psychiatric disorders 
Patients with other 
relevant medical illness 
were excluded. 
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Study characteristics 
Author, year, 
reference number 
Avery,  
2006 [64] 
Su,  
2005 [53] 
Holtzheimer,  
2004 [57] 
Mosimann,  
2004 [55] 
Fitzgerald,  
2003 [56] 
Hoppner,  
2003 [95] 
Add-on or 
monotherapy 
Add on + Mono Add on Mono Add on Add on Add on 
Follow-up duration  6 mo 2 w 1 w (cross-over) N/A 2 w (cross-over) N/A 
Loss-to-FU, n (%) N/A 3 (33) 2 active vs. 1 sham N/A 1 N/A 
Depression scale used HDRS-17 HDRS-21, BDI, CGI HDRS-17, BDI HDRS-21, BDI MADRS HDRS-21 
Frequency, Hz  10 5 and 20 10  20  10  20 
Trains, n  32 40 32 40 20 20 
Train duration, s 5 8s, 2 s 5 2 5 2 
Inter-train interval, s 25-30  N/A 30-60 25 25 30 
Pulses per session 1600 1600 1600 1600 1000 800 
Number of sessions 
(duration of 
intervention) 
15 (3 w) 10 (2 w) 10 (2 w) 10 (2 w) 10 (2 w) 10 (2 w) 
Total pulses  24000  16000 16000 16000 10000 8000 
Unilateral/bilateral, 
side if unilateral 
Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left or right 
DLPFC 
Unilateral, left or right 
DLPFC, 5 cm rule 
Intensity of the 
stimulation (% RMT) 
110 100 110 100 100 90 
Patient characteristics (active vs sham) 
Age, y mean (SD)  44.3 (10.3) vs 44.2(9.7) 5Hz: 43.2(10.6) 
20Hz: 43.6 (12) 
Sham: 42.6 (11) 
40.4(8.5) vs 45.4(4.9) 60 (13.4) vs 64.4(13.0) 45.55 (11.45) vs 
49.5(11.24) 
60.36 (2.12) vs 52 (3.69) 
Sex, male/female, n 14/21 vs 17/16 5Hz: 3/7 
20Hz: 2/8 
Sham: 3/7 
3/4 vs 5/3 10/5 vs 4/5 13/7 vs 9/11 3/8 vs 3/6 
Previous therapy ≥2 failed trials of 
antidepressants 
History of positive ECT 
response: 3 vs 4 
Total number of 
medication trials: 8.23 vs 
8.91 
≥2 failed trials of 
antidepressants 
≥2 failed trials of 
antidepressants 
≥2 failed trials of 
antidepressants 
≥2 failed trials of 
antidepressants 
≥1 failed trials of 
antidepressants (incl. 
doxepin, trimipramine, 
mirtazapine, 
clomipramine, 
venlafaxine, 
maprotiline, mianserin 
etc.) 
Depression score at 
baseline, mean (SD) 
23.5(3.9) vs 23.5(2.9) 5Hz: 26.5(5.2) 
20Hz: 23.2(7.5) 
Sham: 22.7 (4.7) 
22.7(5.3) vs. 20.8 (6.3) 28 (4.6) vs 24.5 (7.3) 36.1 (7.5) vs 35.75 (8.14) N/A 
QoL (SF-36, Q-LES-
Q) at baseline 
N/A N/A N/A N/A N/A N/A 
  
A
p
p
en
d
ix 1: M
eth
o
d
s an
d
 d
escrip
tio
n
 o
f th
e evid
en
ce u
sed
 
LB
I-H
T
A
| 20
17 
10
9
 
Study characteristics 
Author, year, 
reference number 
Avery,  
2006 [64] 
Su,  
2005 [53] 
Holtzheimer,  
2004 [57] 
Mosimann,  
2004 [55] 
Fitzgerald,  
2003 [56] 
Hoppner,  
2003 [95] 
Suicidal ideation/ 
suicide score at 
baseline 
N/A N/A N/A N/A N/A N/A 
Outcomes 
Efficacy (active vs sham) 
Depression score at 
end of treatment and 
last FU, mean (SD) 
15.7 vs 19.8 
6 mo FU: 4.6 (2.7) vs N/A 
5Hz: 14.2(6.0) vs 12.3 (7.7) 
20Hz: 13.4(4.9) vs 9.8 (7.1) 
Sham: 3.7 (9.3) vs 19.0 (7.7) 
2 w: 14.6 (3.2) vs 15.3 (3.0)  
1 w FU: 18.8 (2.5) vs  
17.6 (2.1) 
23.3 (7.2) vs. 20.4 (6.6) 30.8 (7.5) vs 35.4 (7.5) N/A 
Response, n (%) 11 (31) vs 2 (6) 
6 mo FU: 5 vs 1  
(relapse at 6 mo: 6 vs 1) 
12 (60) vs 1 (10) 2 w: 2 (29) vs 1 (13) 
1 w FU: 0 vs 0  
(relapse at 1 w: 2 vs 1) 
1 (6.6) vs 0 0 vs 07 5 (50) vs 5 (50) 
Remission, n (%) 7 (20) vs 1 (3)  10 (50) vs 0 N/A N/A 0 vs 0 N/A 
QoL (SF-36, Q-LES-Q 
at end of treatment, 
mean SD) 
N/A N/A N/A N/A N/A N/A 
Drop-out, n (%) 0 vs 0  0 vs 1 (10) (due to 
worsening of depression 
symptoms) 
N/A N/A 0 1 (10) vs 0 (due to 
headache and insufficient 
effectiveness) 
Suicidal ideation/ 
suicide score post-
treatment 
N/A N/A N/A 1 (6.6) vs 0 N/A N/A 
Safety, n pts (active vs sham) 
SADEs 
Seizure  0 vs 0 N/A N/A N/A N/A N/A 
Transient 
impairment of 
working memory 
N/A N/A N/A N/A N/A N/A 
Induced currents 
circuits in implanted 
devices 
N/A N/A N/A N/A N/A N/A 
ADEs       
Headache  11 (31) vs 1 (3) 4 (20) vs 1 (10) N/A 0 vs 2 (22) 6 (10) in total N/A 
Syncope (fainting) N/A N/A N/A N/A N/A N/A 
Scalp discomfort N/A N/A N/A N/A 7 (11) in total N/A 
                                                             
7 The study defined response as >20% decrease on MADRS and reported response 8 (40) vs 2 (10).  
When applying the >50% decrease as the other studies the response is 0 in each groups.  
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Study characteristics 
Author, year, 
reference number 
Avery,  
2006 [64] 
Su,  
2005 [53] 
Holtzheimer,  
2004 [57] 
Mosimann,  
2004 [55] 
Fitzgerald,  
2003 [56] 
Hoppner,  
2003 [95] 
Pain  N/A N/A N/A N/A 7 (11) in total N/A 
Facial twitching  N/A N/A N/A N/A N/A N/A 
Vertigo  1 (3) vs 0  N/A N/A 0 vs 1 (6.7) 1 (5) vs 1 (5) N/A 
Device-related 
insomnia/Drowsiness 
N/A N/A N/A N/A N/A N/A 
Transient induction 
of hypomania 
N/A 1 vs 0  
(in the open label phase, 
the pt was bipolar) 
N/A N/A 0 N/A 
Mild confusion 0 vs 0 N/A N/A N/A N/A N/A 
Transient hearing loss  N/A N/A N/A N/A N/A N/A 
Other AEs N/A N/A N/A N/A N/A N/A 
 
Study characteristics 
Author, year, 
reference number 
Boutros,  
2002 [62] 
Padberg,  
2002 [49] 
Garcia-Toro,  
2001 [66] 
Berman,  
2000 [69] 
Loo,  
1999 [67] 
Avery,  
1999 [70] 
Study Registration 
number (Registry 
identifier)  
N/A N/A N/A N/A N/A N/A 
Country USA Germany Spain USA Australia USA 
Sponsor VA MERIT and 
K24DA00520-01AA 
awards 
German Federal 
Research Ministry 
N/A VA Merit Award (NNB), 
NIMH, State of 
Connecticut 
Australian National 
Health and Medical 
Research Council Mood 
Disorders Unit, private 
donations 
N/A 
Comparator Sham Sham Sham Sham Sham Sham 
Study design RCT RCT RCT RCT RCT RCT 
Number of patients 
(active vs sham) 
21 (12 vs 9) 30 (20 vs 10) 35 (17 vs 18) 20 (10 vs 10) 18 (9 vs 9) 6 (4 vs 2) 
Study duration N/A N/A N/A N/A N/A N/A 
Objectives To provide additional 
efficacy and safety data 
for use of subthreshold 
rTMS as an augmentation 
strategy in TRD patients 
without any modifica-
tions on their current 
pharmacological therapy. 
To investigate whether 
the antidepressant 
efficacy of rTMS may  
be related to the 
stimulation intensity 
applied. 
To clarify the role 
played by the HF-rTMS 
applied on the left DLPC 
as a coadjuvant to 
psychopharmacological 
treatment of TRD. 
To assess the efficacy of 
rTMS in unmedicated, 
TRD patients who meet 
criteria for major 
depression. 
The efficacy and safety 
of left DLPFC rTMS for 
treating TRD were 
examined. 
To present preliminary 
efficacy and safety of HF-
rTMS delivered to TRD pts 
compared to sham. 
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Study characteristics 
Author, year, 
reference number 
Boutros,  
2002 [62] 
Padberg,  
2002 [49] 
Garcia-Toro,  
2001 [66] 
Berman,  
2000 [69] 
Loo,  
1999 [67] 
Avery,  
1999 [70] 
Model used MAGSTIM Rapid II, 
MAGSTIM Model 2002, 
Neurosign Model 4000, 
figure 8 coil 
MAGSTIM Rapid II, 
MAGSTIM Model 2002, 
Neurosign Model 4000, 
figure 8 coil 
Magpro Compact, 
MagPro X100,  
Magpro R30,  
figure 8 coil 
Cadwell stimulator MAGSTIM Rapid II, 
MAGSTIM Model 2002, 
Neurosign Model 4000, 
figure 8 coil 
Cadwell stimulator 
Inclusion criteria Diagnosis of MDD, TRD, 
score ≥ 20 on HDRS 
Patients who met the 
DSM-IV criteria for 
MDD 
Age ≥ 18 yrs, DSM-IV 
diagnosis of unipolar 
MDD, TRD, right-
handed 
Age 18-70 yrs, met 
DSM-IV criteria for 
MDD, TRD, no diagnosis 
of substance or alcohol 
abuse, no history of 
neurologic illness 
MDD as diagnosed by 
DSM-IV, TRD, 
 ≥25 on MADRS 
MDD as diagnosed by  
DSM-IV criteria, or bipolar 
disorder depressed phase, 
failed ≥ 2 antidepressant 
trials in the current episode, 
no proconvulsant 
medications, on stable 
medication or no 
medication for ≥6 w before 
the study, right-handedness, 
≥ 20 on SIGH-SAD 
Exclusion criteria Suicidal ideations, 
prominent psychotic 
symptoms, history of 
neurological disorder, 
history of drug abuse 
within the past 3 mo 
Patients with organic 
brain disorders, 
pacemakers, mobile 
metal implants or 
implanted medication 
pumps 
History of seizures or 
neurosurgery, serious or 
uncontrolled medial 
illness, pacemaker or 
hearing aid, pregnancy, 
women of childbearing 
potential lacking 
effective contraceptive, 
high suicidal risk 
Pregnancy, EEG 
abnormality suggestive 
of epileptic 
predisposition, 
significant unstable 
medical illness 
Major physical or 
neurological 
abnormalities, treated 
with ECT during this 
depressive episode 
Metal in the body, cardiac 
pacemaker, implanted 
electronic device, history of 
head injury associated with 
loss of consciousness, brain 
surgery, epilepsy, active 
suicidal intent, other major 
psychiatric or medical 
illnesses 
Add-on or 
monotherapy 
Add on Add on Add on Mono Add on Add on 
Follow-up duration  5 mo N/A 1 mo 2 mo 1 mo 2 w 
Loss-to-FU, n (%) 6 (50) vs 7 (78) N/A 1 (6) vs 1 (6) (cross-
over) 
0 vs 3 (30) 2 (14) in total 0 vs 0 
Depression scale used HDRS-25 HDRS-21, MADRS HDRS-21, HARS,  
CGI, BDI 
HDRS-25, BDI, HARS HDRS, MADRS, BDI HDRS-21, BDI, CGI 
Frequency, Hz  20 10 20 20 10 10 
Trains, n  20 15 30 20 30 20 
Train duration, s 2 10 2 2 5 5 
Inter-train interval, s 58 30 20-40 58 30 55 
Pulses per session 800 1500 1200 800 1500 1000 
Number of sessions 
(duration of 
intervention) 
10 (2 w) 10 (2 w) 10 (2 w) 10 (2 w) 10 (2 w) 10 (2 w) 
Total pulses  8000 15000 12000 8000 1500 10000 
Unilateral/bilateral, 
side if unilateral 
Unilateral, left DLPFC Unilateral, left DLPFC Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC Unilateral, left DLPFC,  
5 cm rule 
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Study characteristics 
Author, year, 
reference number 
Boutros,  
2002 [62] 
Padberg,  
2002 [49] 
Garcia-Toro,  
2001 [66] 
Berman,  
2000 [69] 
Loo,  
1999 [67] 
Avery,  
1999 [70] 
Intensity of the 
stimulation (% RMT) 
80 100/90 90 80 110 80 
Patient characteristics (active vs sham) 
Age, y mean (SD)  49.5(8) vs 52(7) 100% 62.1 (4.6) 
90% 60.3 (4.11) 
sham 52.7 (5.7)) 
51.5 (15.9) vs 50.0 (11) 45.2 (83) vs 39.4 (3.4) 45.7(14.7) vs 50.9 (14.7) 44.25 vs 45 
Sex, male/female, n 8/4 vs 8/1 7/13 vs 2/8 10/7 vs 10/8 8/2 vs 6/4 N/A N/A 
Previous therapy ≥2 failed trials of 
antidepressants (incl. 
venlafaxine, 
mirtazapine, valproic, 
etc.) 
≥2 failed trials of 
antidepressants (incl. 
tricyclics, SSRI, MAOI, 
mirtazapine, 
venlafaxine, lithium, 
benzodiazepines, etc.) 
≥2 failed trials of 
antidepressants 
≥1 failed trials of 
antidepressants  
(incl. ECT) 
≥2 failed trials of 
antidepressants 
≥2 failed trials of 
antidepressants  
(incl. lorazepam, 
tranylcypromine) 
Depression score at 
baseline, mean (SD) 
34.4 (10.1) vs 31.7 (4.9) 100%: 23.6 (1.9) 
90%: 21.9 (1.8) 
Sham: 24.4 (2.1) 
27.11 (6.65) vs 25.6 
(4.92) 
37.1 (9.7) vs 37.3 (8.4) N/A 21.3 (6.7) vs 19.5 (8.1) 
QoL (SF-36,  
Q-LES-Q) at baseline 
N/A N/A N/A NA N/A N/A 
Suicidal ideation/ 
suicide score at 
baseline 
N/A N/A N/A NA N/A N/A 
Outcomes 
Efficacy (active vs sham) 
Depression score at 
end of treatment 
and last FU, mean 
(SD) 
N/A (the difference 
compared to baseline  
is reported) 
5 mo FU: 18 vs N/A 
N/A HDRS: 
18.94 (7.69) vs  
23.55 (6.07) 
HDRS: 
2 w: 24.6 (9.22) vs  
36.4 (9.05) 
2 mo FU: N/A 
N/A HDRS: 
2 w: 10.8 (3.5) vs 15.0 (2.5) 
2 w FU: 13.5 (10.8) vs  
13.5 (5.9) 
Response, n (%) 3 (25) vs 2 (22) 5 (25) vs 0 5 (29) vs 1 (6) 1 (10) vs 0 
2 mo FU: 1 (10) vs 0 
N/A N/A 
Remission, n (%) N/A 3 (33) vs 0 N/A NA N/A N/A 
QoL (SF-36, Q-LES-Q 
at end of treatment 
or last FU, mean SD) 
N/A N/A N/A NA N/A N/A 
Drop-out, n (%) 0 vs 1 (11) 1 in total 3 (18) vs 2 (11) 0 vs 3 (30) (due to lack 
of response) 
0 vs 0 0 vs 0 
Suicidal ideation/ 
suicide score post-
treatment 
N/A N/A N/A N/A N/A N/A 
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Study characteristics 
Author, year, 
reference number 
Boutros,  
2002 [62] 
Padberg,  
2002 [49] 
Garcia-Toro,  
2001 [66] 
Berman,  
2000 [69] 
Loo,  
1999 [67] 
Avery,  
1999 [70] 
Safety, n pts (%) (active vs sham) 
SADEs 
Seizure  N/A 0 vs 0 N/A N/A 0 vs 0 0 vs 0 
Transient impairment 
of working memory 
5 (42) vs 0 N/A N/A NA N/A N/A 
Induced currents 
circuits in implanted 
devices 
N/A N/A N/A NA N/A N/A 
ADEs 
Headache N/A 2 in total 6 (33) vs N/A 6 (60) vs 5 (50) 3 (33) vs 0 N/A 
Syncope (fainting) N/A N/A N/A NA N/A N/A 
Scalp discomfort 3 (25) vs 1(11) N/A 6 (33) vs N/A NA N/A N/A 
Pain  N/A N/A N/A NA N/A 4 (100) vs 2 (100) 
Facial twitching  N/A N/A N/A NA N/A NA 
Vertigo  N/A N/A N/A NA N/A NA 
Device-related 
insomnia/Drowsines
s 
N/A N/A N/A NA N/A NA 
Transient induction 
of hypomania 
N/A N/A N/A NA N/A N/A 
Mild confusion N/A N/A N/A N/A N/A N/A 
Transient hearing 
loss  
1 (8) vs 0 N/A N/A N/A 1 (11) vs 0 N/A 
Other AEs Diarrhoea: 1 (8) vs 0 Migraine: 0 vs 1 (10) 
Aversive tactile artefact: 
5 (25) vs 0 
N/A N/A N/A N/A 
Abbreviations: AE adverse event, ADE adverse device effect, BDI Beck Depression Inventory, CGI Clinical Global Impression, DLPFC dorsolateral prefrontal cortex, DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition, text revision, ECT electroconvulsive therapy, EEG electroencephalography, fMRI functional magnetic resonance imaging, FU follow-up, HARS Hamilton Anxiety Rating Scale, HDRS Hamilton Depression Rating Scale, 
HF high-frequency, Hz Hertz, LF low-frequency, MADRS Montgomery–Åsberg Depression Rating Scale, MDD major depressive disorder, MAOI monoamine oxidase inhibitors, MT motor threshold, mo month, n number, 
N/A not available, NAMI National Alliance on Mental Illness, NARSAD National Alliance for Research on Schizophrenia and Depression, NCCHTA National Coordinating Centre for Health Technology Assessment,  
NHMRC National Health and Medical Research Council, NIHM National Institute of Mental Health, PCP Phencyclidine, pts patients, QoL Quality of life, Q-LES-Q Quality of Life Enjoyment and Satisfaction Questionnaire,  
RCT randomized controlled trial, RMT resting motor threshold, rTMS repetitive transcranial magnetic stimulation, s second, SADE serious adverse device effect, SCID Structured Clinical Interview for DSM-IV, SD standard deviation, 
SF 36 PF Short Form (36) Health Survey Physical Functioning, SIGH-SAD Structured Interview Guide for the Hamilton Depression Rating Scale, SNRI serotonin-norepinephrine reuptake inhibitors, 
SSRI selective serotonin re-uptake inhibitors, TRD treatment-resistant depression, NOS Not Otherwise Specified, MMSE Mini-Mental State Examination, VNS vagus nerve stimulation, vs versus, w week, yrs years 
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Table A-6: Characteristics of randomised controlled studies comparing rTMS with ECT 
Study characteristics 
Author, year, 
reference number 
Kesthkar,  
2011 [19] 
Eranti,  
2007 [18] 
Rosa,  
2006 [54] 
Grunhaus  
2003 [60] 
Grunhaus 2000,  
Dannon 2002 [17, 59] 
Pridmore  
2000 [61] 
Study Registration 
number (Registry 
identifier)  
IRCT138902253930N1 ISRCTN67096930 N/A N/A N/A N/A 
Country Iran UK Brazil Israel Israel Australia 
Sponsor Shiraz University of 
Medical Sciences 
NCCHTA, Guy’s and  
St Thomas’s Charitable 
Foundation, National 
Alliance for Research  
on Schizophrenia and 
Depression 
N/A NARSAD NARSAD N/A 
Comparator ECT (bilateral) ECT ECT ECT (uni- and bilateral) ECT ECT 
Study design RCT Multicentre RCT RCT RCT RCT RCT 
Number of patients 
(I vs C) 
73 (33 vs 40) 46 (24 vs 22) 35 (20 vs 15) 40 (20 vs 20) 40 (20 vs 20) 32 (16 vs 16) 
Study duration N/A Jan 2002-Aug 2004 N/A N/A N/A N/A 
Objectives To compare the efficacy 
of rTMS and ECT in TRD 
patients and the effects 
on suicidal behaviour. 
To test the equivalence 
of rTMS and ECT. 
To compare depression 
symptoms improvement 
between rTMS and ECT. 
To compare ECT and 
rTMS for nonpsychotic 
TRD.  
To compare ECT and 
rTMS for psychotic TRD. 
To compare the 
antidepressant response 
to rTMS and ECT with 
treatment courses of 
unlimited length; to 
compare the side-effect 
profiles; to examine the 
evidence for dose-
response relationship. 
Model used Neuro-MS (Neurosoft), 
figure 8 coil 
Magstim Super Rapid 
Stimulator, figure 8 coil 
Magpro, figure 8 coil Magstim, figure 8 coil Magstim, figure 8 coil Magstim, figure 8 coil 
Inclusion criteria MDD according to  
DSM-IV 
Referral by a psychiatrist 
for ECT, MDD diagnosis 
by the DSM-IV Axis I 
Disorders (SCID), right-
handedness, >18 yrs 
Referral by a psychiatrist 
for ECT, aged 18-65 yrs, 
unipolar MDD according 
to DSM-IV without 
psychotic symptoms, 
HAMD-17 ≥22. 
Diagnosis of unipolar major 
depression by DSM-IV, 
score of at least 18 on 
Hamilton Depression 
Rating Scale, 18 years or 
older, treatment resistant. 
> 18 yrs, DSM-IV 
diagnosis of MDD,  
≥ 18 scored on HRSD-17. 
TRD, DSM-IV diagnosis 
of MDD, right-handed, 
age 25-70, no history  
of epilepsy. 
Exclusion criteria Previous rTMS, implanted 
device, history of seizure, 
bipolar disorder, 
substance abuse, history 
of significant head 
trauma, severe 
medication condition, 
previous nonresponse to 
ECT, pregnancy 
Metallic implants or 
foreign bodies, history of 
seizures, substance misuse 
in the previous 6 mo, 
medically unfit for general 
anaesthesia or ECT, ECT 
or rTMS in the previous 
6 mo, dementia, other 
axis I diagnosis, inability 
to provide consent 
History of epilepsy, past 
neurosurgery with metal 
clips, other neurological 
or psychiatric diseases, 
cardiac pacemakers, 
pregnancy. 
Additional Axis I 
diagnoses, major 
depression with 
psychosis, major 
depression due to 
medical condition or 
substance abuse. 
Additional Axis I 
diagnoses, history of 
seizures, no medical, 
neurological or 
neurosurgical disorder 
that would preclude the 
administration of rTMS 
or ECT. 
Serious medical illness, 
intracranial metal 
objects, mood disorder 
due to medical condition 
or substance abuse,  
co-morbidity for  
mental disorder. 
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Study characteristics 
Author, year, 
reference number 
Kesthkar,  
2011 [19] 
Eranti,  
2007 [18] 
Rosa,  
2006 [54] 
Grunhaus  
2003 [60] 
Grunhaus 2000,  
Dannon 2002 [17, 59] 
Pridmore  
2000 [61] 
Add-on or 
monotherapy 
Add-on Add-on  Mono Mono (only lorazepam 
allowed) 
Mono (only clonazepam 
allowed) 
Mono 
Follow-up duration  N/A 6 mo N/A N/A 6 mo N/A 
Loss-to-FU, n (%) N/A 3 (12) vs 6 (27) N/A N/A 2 (4.6) N/A 
Depression scale used HDRS-24, BDI HAMD-17 HAMD-17 HRSD-17 HRSD-17 HDRS 
Frequency, Hz  N/A 10 10 10 10 20 
Trains, n  N/A 20 25 20 20 30-35 
Train duration, s N/A 5 10 6 6 2 
Intertrain interval, s N/A 55 20 30 30 28 
Pulses per session 408 1000 2500 1200 1200 N/A 
Number of sessions 10 (2 w) 15 (3 w) 20 (4 w) 20 (4 w) 20 (4 w) Mean 12.2 
Total pulses  4080 15000 50000 24000 24000 N/A 
Unilateral/bilateral, 
side if unilateral 
Unilateral, left DLPFC Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC,  
5 cm rule 
Unilateral, left DLPFC 
Intensity of the 
stimulation (% RMT) 
90 110 100 90 90 100 
Patient characteristics (I vs C) 
Age, y mean (SD)  34.0 (9.9) vs 35.6 (8.1)  63.6 (17.3) vs 68.3 (13.4) 41.8 (10.2) vs 46.0 (10.6) 57.6 (13.7) vs 61.4 (16.6) 58.4 (15.7) vs 63.6 (15.0) 44.0 (11.9) vs 41.5 (12.9) 
Sex, male/female, n 13/20 vs 8/32 8/16 vs 6/16 8/12 vs 8/7 6/14 vs 5/15 8/12 vs 6/14 4/12 vs 3/13 
Previous therapy  ≥ 2 trials of 
antidepressants 
Number of anti-
depressant failed in the 
current episode 1.7 vs 1.7 
SSRI: 6 vs 5 
Tricyclics: 2 vs 2 
Venlafaxine: 10 vs 7 
Mirtazapine: 4 vs 5 
Lithium: 5 vs 6 
Benzodiazepines: 3 vs 4 
Zopiclone: 6 vs 3 
Anticonvasculsant mood 
stabilizers: 2 vs 3 
L-Tryptophan: 1 vs 0 
≥ 2 trials of 
antidepressants 
≥ 1 course of 
antidepressant 
(adequate level  
for ≥ 4 w) 
Previous ECT: 6 vs 9 Previous ECT: 6 vs 3 
Depression score at 
baseline, mean (SD) 
BDI: 34.0 (9.6) vs  
34.8 (9.9) 
HDRS: 21.0 (7.5) vs  
25.8 (6.1)  
BDI: 36.0 (8.7) vs  
37.8 (10.5) 
HAMD: 23.9 (7.0) vs 
24.8 (5.0) 
30.1 (4.7) vs 32.1 (5.0) 24.4 (3.9) vs 25.5 (5.9) 25.8 (6.1) vs 28.4 (9.3) HDRS:25.3 (4.1) vs  
25.8 (3.6) 
BDI: 33.9 (6.8) vs  
31.8 (6.6) 
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Study characteristics 
Author, year, 
reference number 
Kesthkar,  
2011 [19] 
Eranti,  
2007 [18] 
Rosa,  
2006 [54] 
Grunhaus  
2003 [60] 
Grunhaus 2000,  
Dannon 2002 [17, 59] 
Pridmore  
2000 [61] 
Suicide score at 
baseline, mean (SD) 
BDI: 1.5 (0.8) vs 1.4 (1.0) 
HDRS: 1.9 (1.3) vs 2.3 (1.1) 
Columbia ECT SSES:  
13.2 vs 14.2 
N/A N/A N/A N/A 
QoL (SF-36, Q- 
LES-Q) at baseline 
N/A N/A N/A N/A N/A N/A 
Outcomes 
Efficacy (I vs C) 
Depression score  
(at end of treatment, 
last FU), mean (SD) 
BDI: 26.5 (9.2) vs  
17.9 (8.3) 
HDRS: 15.1 (5.6) vs 
 8.4 (6.1) 
3 w: HAMD: 18.5 vs 10.7 N/A 13.3 (9.2) vs 13.2 (6.6) 15.4 (7.5) vs 11.2 (8.4) HDRS: 11.3 (8.5) vs  
8.3 (7.5) 
BDI: 19.2 (11.8) vs  
9.6 (8.9) 
Response, n (%) N/A 4 (17) vs 13 (59) 10 (50) vs 6 (40) 11 (55) vs 12 (60) 9 (45) vs 16 (80) 
6 mo FU: 5 vs  
12 (4 vs 4 relapsed) 
N/A 
Remission, n (%) N/A 4 (17) vs 13 (59) 
6 mo FU: 2/4 (50) vs 
6/12 (50) 
2 (10) vs 3 (20) 6 (30) vs 6 (30) N/A 11 (69) vs 11 (69) 
QoL (SF-36, Q-LES-Q) 
at end of treatment  
N/A N/A N/A N/A N/A N/A 
Drop-out, n (%) 5 (14) vs 10 (25) 
 due to AEs (2 vs 2), 
withdrew (3 vs 8) 
6 (13) pts discontinued 2 (10) vs 5 (33)  
(due to 1 hypomania and 
1 dissocaitive state in 
rTMS, 3 suspensions of 
the ECT treatment and  
2 non-attendance in ECT) 
N/A 0 N/A 
Suicide score post-
intervention, mean 
(SD) 
BDI: 1.2 (0.9) vs 0.5 (0.7) 
HDRS: 1.4 (1.2) vs 0.3 (0.5) 
Columbia ECT SSES:  
9.7 vs 6.7 
N/A N/A N/A N/A 
Safety, n of pts (%) (I vs C) 
SADEs 
Seizure  0 N/A N/A N/A 0 N/A 
Transient cognitive 
impairment  
0 N/A N/A N/A N/A N/A 
Induced current 
circuits in implanted 
devices 
N/A N/A N/A N/A N/A N/A 
ADEs       
Headache  1 (3) vs 0 N/A N/A 3 (15) vs 0 5 (25) vs 0 N/A 
Syncope (fainting) N/A N/A N/A N/A N/A N/A 
Scalp discomfort N/A N/A N/A N/A N/A N/A 
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Study characteristics 
Author, year, 
reference number 
Kesthkar,  
2011 [19] 
Eranti,  
2007 [18] 
Rosa,  
2006 [54] 
Grunhaus  
2003 [60] 
Grunhaus 2000,  
Dannon 2002 [17, 59] 
Pridmore  
2000 [61] 
Pain  N/A N/A N/A N/A N/A N/A 
Facial twitching  N/A N/A N/A N/A N/A N/A 
Vertigo  N/A N/A N/A N/A N/A N/A 
Device-related 
insomnia/drowsiness 
N/A N/A N/A 2 (10) vs 0 N/A N/A 
Transient induction 
of hypomania 
N/A N/A N/A N/A N/A N/A 
Mild confusion N/A N/A N/A N/A N/A N/A 
Transient hearing loss  N/A N/A N/A N/A N/A N/A 
Other AEs N/A N/A N/A N/A N/A Side-effects rating  
scores at baseline: 
8.1 (3.2) vs 7.9 (1.9)  
End of treatment:  
3.9 (2.9) vs 5.3 (4.3)  
Abbreviations: AE adverse event, ADE adverse device effect, BDI Beck Depression Inventory, C control, DLPFC dorsolateral prefrontal cortex, DSM-IV Diagnostic and Statistical Manual  
of Mental Disorders, 4th Edition, ECT electroconvulsive therapy, FU follow-up, HDRS Hamilton Depression Rating Scale, Hz Hertz, I intervention, major depressive disorder, mo month,  
n number, N/A not available, NARSAD National Alliance for Research on Schizophrenia and Depression, NCCHTA National Coordinating Centre for Health Technology Assessment,  
MDD major depressive disorder, pts patients, RMT resting motor threshold, RCT randomized controlled trial, rTMS repetitive transcranial magnetic stimulation, s second,  
SADE serious adverse device effect, SCID Structured Clinical Interview for DSM-IV, SD standard deviation, SSES suicide severity rating scale, SSRI selective serotonin re-uptake inhibitors, 
TRD treatment-resistant depression, vs versus, w week, yrs years 
 
Repetitive transcranial magnetic stimulation for treatment-resistant major depression 
 
List of ongoing and planned studies 
Table A-7: List of Phase III and IV ongoing studies: sham controlled rTMS trials 
Study  
Identifier 
Estimated 
completion date 
Study  
type 
Number  
of patients Intervention Comparator 
Patient  
population Endpoints 
NCT02213016 September 1, 
2016 
Interventional 80 rTMS Sham MDD Total scores on the HDRS, 
Performance on the WCST 
JPRN-
UMIN000007794 
N/A Interventional 90 a, Navigation-guided HF-rTMS, 
b, Navigation-guided LF-rTMS 
Sham MDD (monopolar 
depression) 
HDRS-17 and 24, side effects, BDI-II, 
STAI, neuropsychological testing 
(VFT, WCST, CST, TMT) 
NCT01191333 December 31, 
2016 
Interventional 164 rTMS Sham MDD Remission (HDRS-17 < 8), response 
(HDRS-17 diminution > 50%), 
anxiety (Covi Anxiety Scale), side 
(UKU side effect rating scale) 
NCT02466230 October, 2013 Interventional 28 rTMS Sham Depression Depression Severity measured by 
HDRS-24, Depression Severity 
measured by the Public Health 
Questionnaire-9 
Abbreviations: BDI Beck Depression Inventory, CST Color Stroop Test, HDRS Hamilton Depression Scale, HF high-frequency, MDD major depressive disorder, LF low-frequency,  
rTMS repetitive transcranial magnetic stimulation, STAI State-Trait Anxiety Inventory, TMT Trail Making Test, TRD treatment-resistant depression, VFT Verbal Fluency Test,  
WCST Wisconsin Card Sorting Test 
Sources: clinicaltrials.gov, EudraCT, WHO-ICTRP 
 
  
Appendix 1: Methods and description of the evidence used 
 
We found 13 Phase III and 8 Phase IV studies. From these 21 studies, we listed in detail those 4 that are investigating rTMS compared to sham.  
We found no trials investigating rTMS compared to ECT. Additionally, we found the following categories as presented in the table below. 
Table A-8: List of Phase III and IV ongoing studies with rTMS compared to other than sham 
Intervention  Comparator Number of ongoing trials 
TMS with EEG  TMS with Near Infrared Spectroscopy (NIRS) Monitoring 1 
rTMS + venlafaxine Venlafaxine alone or sham rTMS 1 
Maintenance rTMS Sham 1 
Bilateral theta Burst stimulation Sham 1 
Bilateral rTMS Monolateral rTMS 1 
10 Hz rTMS Theta Burst stimulation 1 
Sinchronized rTMS (NEST-I device) Sham 1 
rTMS + neuronavigation system rTMS + Standard location system 1 
Deep TMS Brainsway H7Coil H1 Coil as add on therapy 1 
Deep HF-TMS Deep LF-TMS 1 
Deep TMS  Sham 1 
Deep TMS  HF-rTMS 2 
Accelerated rTMS non-comparative 1 
Algorithm guided treatment stratification for MDD non-comparative 1 
Predictive biomarkers of effective treatment with TMS for MDD non-comparative 2 
Abbreviations: EEG electroencephalography, HF high-frequency, LF low-frequency, rTMS repetitive transcranial magnetic stimulation, TMS transcranial magnetic stimulation 
Sources: clinicaltrials.gov, EudraCT, WHO-ICTRP 
 
 
 
Repetitive transcranial magnetic stimulation for treatment-resistant major depression 
120 LBI-HTA | 2017 
Risk of bias tables 
Table A-9: Risk of bias – study level (RCTs) 
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Kang, 2016 Unclear Unclear Low High8 Low Low Unclear 
Chen, 2013 Unclear Unclear Low Unclear9 Low Low Unclear 
Bakim, 2012 Low Unclear Low Unclear Low Low Unclear 
Blumberger, 2012 Low Low Low Unclear Low Low Low 
Fitzgerald, 2012 Unclear Unclear Low Unclear High10 Low High 
George, 2010 Low Unclear Low Low Low Low Low 
Triggs, 2010 Unclear Unclear Low Low Low Low Unclear 
Mogg, 2008 Low Low Low High11 Low Low Unclear 
Bretlau, 2008 Unclear Unclear Low Low Low High12 High 
O’Reardon, 2007 Unclear Unclear High13 Low Low Low High 
Loo, 2007 Unclear Unclear Low Unclear Low Low Unclear 
Stern, 2007 Unclear Unclear Unclear Unclear Low Low Unclear 
Avery, 2006 Low Unclear Low Unclear Low Low Low 
Su, 2005 Unclear Unclear Low Unclear Low Low Unclear 
Holtzheimer, 2004 Unclear Unclear Low Unclear Low Low Unclear 
Mosimann, 2004 Unclear Unclear Unclear Unclear Low Low Unclear 
Fitzgerald, 2003 Low Low Low High14 Low Low Unclear 
Hoppner, 2003 Low Unclear Unclear Unclear Low Low Unclear 
Boutros, 2002 Low Unclear Low High15 Low Low Unclear 
Garcia-Toro, 2001 Unclear Unclear Low Unclear Low Low Unclear 
Berman, 2000 Unclear Unclear Low Unclear Unclear Low Unclear 
Padberg, 2002 Low Unclear Unclear Unclear Low Low Unclear 
Loo, 1999 Low Unclear Low Unclear Low Low Unclear 
Avery, 1999 Low Unclear Low Unclear Low Low Unclear 
Solvason, 2014 Unclear Unclear High13 Low Low Low High 
Keshtkar, 2011 Low Unclear High16 High16 Low High5 High 
Eranti, 2007 Low Low High16 High16 Low Low High 
                                                             
  8 Randomised rater blind study 
  9 The sham coil was placed at 90 degrees to the subject’s scalp, while the active coil was placed flat on the scalp. 
10 Adverse events not reported. 
11 Only research physicians knew the type of treatment.  
12 Blinding of outcome assessor unclear. 
13 Patients were instructed not to disclose any treatment details to study raters and they all received the first treat-
ment with the active coil. Therefore the patients might have been able to sport the difference later if they had been 
allocated to the sham group.  
14 It is stated that the physician administering the treatment was aware of the treatment group. 
15 It is stated in the study that an unblended psychiatrist administered TMS and had minimal interaction  
with the patients. 
16 Blinding is not possible either for patients or medical staff due to the nature of the intervention. 
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Rosa, 2006 Low Unclear High16 High16 High17 Low High 
Grunhaus, 2003 Low Unclear High16 High16 Low Low High 
Pridmore, 2000  Unclear Unclear High16 High16 Low Low High 
Grunhaus, 2000 
Dannon, 2002 
Low Unclear High16 High16 Low High18 High 
 
Applicability tables 
Table A-10: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The general characteristics of the enrolled patients were homogeneous including the mean age, sex, 
and depression score at baseline. There was heterogeneity in how the studies defined treatment-
resistance (ranging from failure of one antidepressant treatment to failure of two antidepressants or 
even failure of an ECT therapy). Some studies excluded patients who already had ECT treatment. 
Interpretation of the data is hindered by the non-unified TRD definitions. The number of failed 
treatments might have an effect on the effectiveness of the technology, therefore, it would be 
necessary to consider a uniform definition for TRD and apply it consistently in the clinical trials. 
Intervention The clinical studies conducted with rTMS do not always reflect the intended clinical use of the 
device. If it is intended to be used as monotherapy, the study protocol should allow only the use as 
monotherapy and not as add-on therapy and the treatment parameters should also be carefully 
defined and unified across studies.  
Comparators We considered sham and ECT as comparators in our assessment. As there is no standard treatment 
algorithm available, we chose the comparator based on what is currently the most effective treatment 
to achieve response for very severe depression that has not responded to any other treatment. Although, 
as it is suggested by CANMAT [11], rTMS response rates are poor in patients where ECT has failed, 
indicating that rTMS should rather be considered prior to ECT and patients who have not responded 
to ECT are unlikely to respond to rTMS. rTMS and ECT differ in their mechanisms, tolerability, and 
acceptability by patients and may be best considered as complementary rather than competing techniques. 
TMS may be an option in the early stages (stage 1 or 2) after one or two antidepressant therapies 
have failed. The place in the treatment hierarchy could precede more invasive interventions such as 
ECT, VNS and DBS, after failure to respond to 4 or more adequate antidepressant treatments [4, 24].  
Outcomes Change in depression scores, remission, and response rates were the primary outcomes assessed and 
also these were the ones most frequently reported on. The time period for reporting the data was 
typically for the duration of the study (2-6 weeks), with some follow-up studies of 3-6 months. 
Ideally, outcomes such as quality of life and function would be primary outcomes that determine the 
impact of the intervention, but this was not reported in the included studies, except for one. A major 
limitation in the outcomes is that they are not measuring directly the improvement in the patients’ 
quality of life and that there is short-term data available. Due to the lack of long-term data, it is not 
possible to draw conclusion about the long-term effect and safety of the intervention. Some studies 
reported relapse, but we have no information how the treatment impacted patients’ lives in terms of 
daily functioning, returning to work etc.  
Setting The majority of the included studies were conducted in the USA, Australia, Canada, and Israel; some 
in Germany, Iran, UK, Taiwan, Spain, Denmark, and Turkey. There is no reason to suspect that the 
etiology of MDD and TRD are substantially different in other European countries. The clinical setting 
used in the studies reflects the setting in which the intervention will be typically used. 
Abbreviations: CANMAT Canadian Network for Mood and Anxiety Treatments, DBS deep brain stimulation, ECT 
electroconvulsive therapy, MDD major depressive disorder, rTMS repetitive transcranial magnetic stimulation, UK United 
Kingdom, TRD treatment-resistant depression, VNS vagus nerve stimulation 
Sources: Health Quality Ontario [13], CANMAT [11], RAZCP [24], CME [4] 
                                                             
17 HDRS scores at T1 and T2 were not reported, only stated that there was a significant difference.  
18 Outcome assessors‘ blinding unclear. 
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Appendix 2: 
Regulatory and reimbursement status 
Table A-11: Regulatory status 
Country 
Institution 
issuing 
approval 
Authorisation 
status 
yes/no/ 
ongoing 
Verbatim wording  
of the (anticipated) indication(s) Specified contra-indications 
Date of approval 
(include expiry 
date for country 
of assessment) 
Launched 
yes/no; If no 
include date 
of launch 
Approval 
number  
(if 
available) 
Neurostar TMS Therapy® System 
Europe Notified 
Body 
Yes NeuroStar TMS Therapy is indicated for the 
treatment of Major Depressive Disorder in 
adult patients who have failed to receive 
satisfactory improvement from prior anti-
depressant medication in the current episode 
NeuroStar TMS Therapy should not be used with 
patients who have non-removable conductive metal 
in or near the head. NeuroStar TMS Therapy has not 
been studied in patients who have not received prior 
antidepressant treatment. 
2012 Yes N/A 
USA FDA Yes NeuroStar TMS Therapy is indicated for the 
treatment of Major Depressive Disorder in 
adult patients who have failed to receive 
satisfactory improvement from prior anti-
depressant medication in the current episode 
NeuroStar TMS Therapy should not be used with 
patients who have non-removable conductive metal 
in or near the head. NeuroStar TMS Therapy has not 
been studied in patients who have not received prior 
antidepressant treatment. 
2008 Yes K083538 
Australia TGA Yes NeuroStar TMS Therapy is indicated for the 
treatment of Major Depressive Disorder in 
adult patients who have failed to receive 
satisfactory improvement from prior anti-
depressant medication in the current episode 
N/A 2015 Yes N/A 
Mag&More: PowerMAG 
Europe Notified 
Body 
Yes Treatment of Major Depressive Disorder 
in adult patients who have failed to 
achieve satisfactory improvement from 
prior antidepressant medication in the 
current episode 
 patients with metal implants in the head area, e.g. 
shunts, clips (for patients with metallic implants 
or similar objects in the vicinity of the point of 
treatment, the user must weigh the potential risk 
against the utility of the treatment), 
 patients with implanted medical devices (cochlear 
implant, medication pump, pacemaker, etc.), 
 during pregnancy (in this case the magnetic nerve 
root stimulation is of critical importance; the 
transcranial stimulation is less critical on the basis 
of the greater distance to the foetus), 
 patients with increased intracranial pressure  
(e.g. after trauma or infection), 
 patients with a history of epileptic seizures  
(only applies for the cortical use; if necessary a 
risk/benefit analysis should be performed), 
 increased cerebral susceptibility to epileptic seizures 
through medication (e.g. wellbutrin, zoloft, adderall, 
fluoxetine, aripiprazole, lithium carbonate, clonazepam) 
N/A Yes  N/A 
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Country 
Institution 
issuing 
approval 
Authorisation 
status 
yes/no/ 
ongoing 
Verbatim wording  
of the (anticipated) indication(s) Specified contra-indications 
Date of approval 
(include expiry 
date for country 
of assessment) 
Launched 
yes/no; If no 
include date 
of launch 
Approval 
number  
(if 
available) 
USA FDA No N/A N/A N/A N/A N/A 
Magstim: Rapid2 Therapy System, Super Rapid2 
Europe Notified 
Body 
Yes  rTMS is indicated for patients that have 
not responded to pharmaceutical 
solutions – it is estimated that up to 40% 
of patients do not benefit from, or cannot 
tolerate, antidepressant medications – 
even after repeated attempts. 
N/A N/A Yes  N/A 
USA FDA Yes  The Rapid2 and Super Rapid2 Therapy 
Systems are indicated for the treatment  
of Major Depressive Disorder in adult 
patients who have failed to achieve 
satisfactory improvement from prior 
antidepressant medication in the current 
episode. 
N/A 2015 Yes  K143531 
Neurosoft: Neuro-MS 
Europe Notified 
Body 0535 
Yes  N/A N/A 2013 Yes CE577342 
USA FDA No N/A N/A N/A N/A N/A 
Magventure: MagVita TMS Therapy System 
Europe Notified 
Body 
Yes  MagVita TMS Therapy™ is approved for 
the treatment of MDD in adult patients 
who have failed to achieve satisfactory 
improvement from two prior 
antidepressant medications, at or above 
the minimal effective dose and duration  
in the current episode. 
N/A N/A Yes  N/A 
USA FDA Yes  The MagVita TMS Therapy System is 
indicated for the treatment of Major 
Depressive Disorder in adult patients  
who have failed to receive satisfactory 
improvement from prior antidepressant 
medication in the current episode. 
N/A 2015 Yes  K150641 
Abbreviations: CE Conformité Européene, FDA Food and Drug Administration, MDD major depressive disorder, N/A not available, TGA Therapeutic Goods Administration,  
TMS transcranial magnetic stimulation 
Sources: [33, 35, 39, 96-101] 
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Table A-12: Summary of reimbursement recommendations in European countries for the technology 
Country and issuing 
organisation  
e.g. G-BA, NICE 
Summary of reimbursement  
recommendations and restrictions 
Summary of reasons for recommendations, 
rejections and restrictions 
Germany, G-BA In Germany, no HTA report, guidance 
document, or reimbursement decision on 
rTMS for depression has been published so 
far. In ambulatory care, rTMS is not 
reimbursed by statutory sickness funds. 
However, some private insurance companies 
pay for rTMS in treatment-resistant 
depression. 
In 2015, the German Association for Psychiatry, 
Psychotherapy, and Psychosomatics (DGPPN) 
issued multi-disciplinary, evidence-based 
guidelines on the treatment of depression [21]. 
According to these guidelines, rTMS should be 
considered only as a therapeutic option. This 
statement is limited to high-frequency rTMS 
of the left dorsolateral prefrontal cortex in 
patients with symptoms despite drug therapy. 
UK, NICE Recommended as an option within normal 
arrangements for audit, the device used with 
the procedure is a local decision.  
The evidence on repetitive transcranial 
magnetic stimulation for depression shows  
no major safety concerns. The evidence on  
its efficacy in the short‑term is adequate, 
although the clinical response is variable [22]. 
France, HAS The Department for the Evaluation of Medical 
Procedures at HAS has not evaluated this 
technique; however a request had previously 
been submitted by a professional organisation. 
It is not currently reimbursed if done outside 
of the hospital. The technique is reimbursed/ 
covered if carried out in the course of a 
hospitalization (a patient hospitalized for 
depression). 
Poland, AOTMiT The technology is not reimbursed in Poland. 
No HTA assessment has been conducted.  
It may be used and financed by DRG groups. 
Portugal, 
INFARMED 
The technology is not reimbursed in Portugal. 
No HTA assessment has been conducted. 
It is possible for each hospital to proceed with 
its direct acquisition. 
Slovenia, NIJZ The technology is not reimbursed in Slovenia. 
No HTA assessment has been conducted. 
The technology is used for other indications 
in Slovenia.  
Spain, RedAETS This technology is not explicitly included  
in the Spanish Portfolio of the National 
Health Service.  
There is a low degree of adoption by some 
private health institutions in the country. 
Hungary, OGYEI The technology is not reimbursed in Hungary.  No HTA assessment has been conducted. 
Netherlands The technology is not reimbursed. No HTA assessment has been conducted. 
Croatia, CHIF Mapping, initial assessment and examination, 
and max. 30 therapy sessions are reimbursed 
for use in health institutions only. 
Indication: Depression – moderate and  
severe episodes 
Stimulation of left DLPFC (20 Hz; 2 sec train, 
40 pulses, pause 28sec;  
40 repetitions = 1600 pulses). Stimulation  
of right DLPFC (1 Hz – excitation; 1600 sec;  
1 repetition). 20-30 min per treatment,  
2-4 weeks (10-20 treatments) are 
recommended, can be delivered in 
combination with psychotherapy.  
Exacerbations – maintenance therapy. 
Guidelines for therapy are cited in:  
Perera et al. The Clinical TMS Society 
Consensus Review and Treatment 
Recommendations for TMS Therapy for  
Major Depressive Disorder [41]. 
Italy, Reg.  
Emilia-Romagna 
The technology is not reimbursed. No HTA assessment has been conducted. 
Belgium, KCE The technology is not reimbursed. No HTA assessment has been conducted. 
Abbreviations: G-BA Gemeinsamer Bundesausschuss, NICE National Institute for Health and Care Excellence,  
AOTMiT Agencja Oceny Technologii Medycznych i Taryfikacji/Agency for Health Technology Assessment and pricing,  
NIJZ National Institute of Public Health Slovenia, INFARMED National Authority of Medicines and Health Products, 
HAS French National Authority for Health, DRG diagnosis-related group, CHIF Croatian Health Insurance Fund,  
OGYEI Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet/National Institute of Pharmacy and Health Products, 
RedAETS Red Española de Agencias de Evaluación de Tecnologías Sanitarias, rTMS repetitive transcranial magnetic stimulation, 
DGPPN Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde/German Association 
for Psychiatry, Psychotherapy, and Psychosomatics, DLPFC dorsolateral prefrontal cortex, HTA health technology assessment 
Sources: [21, 22, 41] 
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Table A-13: Summary of recommendations in European countries for the technology in the indication under assessment 
Country Organisation 
Summary of recommendations  
and restrictions 
Summary of reasons  
for recommendations and restrictions 
UK NICE Recommended as an option within 
normal arrangements for audit, the 
device used with the procedure is a 
local decision. 
The evidence on repetitive transcranial magnetic 
stimulation for depression shows no major safety 
concerns. The evidence on its efficacy in the 
short‑term is adequate, although the clinical 
response is variable. 
Germany DGPPN rTMS should be considered only  
as a therapeutic option.  
The level of recommendation for the use of  
HF-rTMS to the left DLPFC is A.  
Spain AVALIA-t rTMS as an add-on therapy is 
currently not recommended. 
There is uncertainty in its clinical efficacy.  
Spain SESCS rTMS is recommended for TRD 
when there are no other alternatives 
of proven therapeutic value.  
The decision to apply rTMS or ECT should be 
discussed with the patient in a shared decision 
making framework in which the risk-benefit 
balance of the options are discussed. Regarding 
the effectiveness of rTMS, statistically significant 
effects were obtained. However, except for the 
overall effect of the technique on the short-term 
reduction of depressive symptoms, the evidence is 
insufficient to establish its efficacy in the treat-
ment of TRD because it comes from studies with 
small samples that yield imprecise estimations. 
Abbreviations: AVALIA-t Galician Agency for Health Technology Assessment, NICE National Institute for Health and Care 
Excellence, DGPPN Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde/German 
Association for Psychiatry, Psychotherapy, and Psychosomatics, DLPFC dorsolateral prefrontal cortex, rTMS repetitive 
transcranial magnetic stimulation, HF high-frequency, SESCS Evaluation Unit of the Canary Islands Health Service 
Sources: [21, 22, 73, 102] 
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Appendix 3: 
Checklist for potential ethical, organizational 
and legal aspects 
1 Ethical  
1.1 Does the introduction of the new technology and its potential use/non-use instead of 
the defined, existing comparator(s) give rise to any new ethical issues? 
Yes/No 
rTMS is indicated for those patients with major depressive disorder who remain disabled despite the use of 
antidepressants or because of their inability to tolerate medication side effects. By definition, the TRD does not 
include non-willingness to undergo ECT treatment or non-tolerance of ECT. Nevertheless, if rTMS could not be 
used, those who are unable to tolerate or refuse ECT would be left without any treatment option.  
1.2 Does comparing the new technology to the defined, existing comparators point to any 
differences that may be ethically relevant? 
Yes/No 
There is little knowledge about the exact patient group that could benefit the most from the new technology, 
but there might be a group where the efficacy and safety undoubtedly favours rTMS. Special populations like 
the elderly or adolescent patients could benefit from the use of the technology and would opt for the technology 
rather than ECT in the treatment algorithm. Treatment resistance is more frequent in the elderly and the risk 
of drug interactions is especially high. rTMS is free of the side effects of antidepressant drugs, it is physically less 
demanding than ECT, and it is not subject to drug interactions. However, these patient populations were out of 
scope of this assessment and currently, there is little research on the efficacy and safety of rTMS in them [103].  
2 Organisational  
2.1 Does the introduction of the new technology and its potential use/non-use instead  
of the defined, existing comparator(s) require organisational changes? 
Yes/No 
rTMS requires a physician with specialised knowledge, a silent room where the patient can lie down and  
the stimulator can be applied. Personnel skilled in the management of syncope and seizure are required.  
The technology is relatively staff intensive. 
2.2 Does comparing the new technology to the defined, existing comparator(s) point  
to any differences that may be organisationally relevant? 
Yes/No 
The new technology does not require anaesthesia. Nevertheless, the patients need to go to the hospital  
5 times a week for at least 2 weeks and get the treatment, which requires free capacities at the hospital in 
terms of personnel and space. 
3 Social  
3.1 Does the introduction of the new technology and its potential use/non-use instead  
of the defined, existing comparator(s) give rise to any new social issues? 
Yes/No 
The use of the comparator technology, ECT, may lead to stigmatisation.  
3.2 Does comparing the new technology to the defined, existing comparator(s) point  
to any differences that may be socially relevant? 
Yes/No 
The comparator, ECT, is associated with stigmatization. Repetitive TMS does not have this property.  
4 Legal  
4.1 Does the introduction of the new technology and its potential use/non-use instead  
of the defined, existing comparator(s) give rise to any legal issues? 
Yes/No 
 
4.2 Does comparing the new technology to the defined, existing comparator(s) point  
to any differences that may be legally relevant? 
Yes/No 
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Appendix 4: 
Diagnostic criteria according to DSM-IV-TR 
 
Source: APA [104] 
 
 
Repetitive transcranial magnetic stimulation for treatment-resistant major depression 
128 LBI-HTA | 2017 
Appendix 5: 
Safety guidelines 
 
Source: HQO [13] 
 

  
 
